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ABSTRACT?
Neurodegenerative diseases are characterized by progressive loss of distinct neuronal 
populations. In Parkinson’s disease (PD) the most prominent cell loss is seen in the 
dopamine (DA) neuron population in the substantia nigra pars compacta (SNpc). The 
resulting decrease in striatal DA levels causes dysregulation of neuronal circuits controlling 
movement  and  leads  to  motor  symptoms  typical  to  the  disease.  As  for  other  
neurodegenerative diseases, there are no available treatments that would interfere with 
the  degenerative  process  in  PD.  The  purpose  of  this  work  was  therefore  to  test  the  
therapeutic potential of long-term delivery of the neurotrophic factor (NTF) cerebral 
dopamine neurotrophic factor (CDNF) in the rat partial 6-hydroxydopamine (6-OHDA) 
lesion model of PD. 
 
When injected unilaterally in the striatum, 6-OHDA causes progressive dose-dependent 
loss of DA neurons in the SNpc accompanied by asymmetrical motor impairment. The 6-
OHDA model used in our NTF studies (2x10 µg 6-OHDA) showed a stable lesion progression 
with  a  cell  loss  at  two  weeks  post-lesion  corresponding  to  that  seen  in  PD  at  symptom  
onset. In the 6-OHDA model, the DAergic system is traditionally evaluated using 
immunodetection methods or measurements of tissue neurotransmitter levels. Imaging 
methods, such as single-photon emission computed tomography (SPECT), allows in vivo 
detection of neuronal circuits, and together with the DA transporter (DAT) radioligand 2?-
carbomethoxy-3?-(4-[123I]iodophenyl)tropane ([123I]?-CIT), SPECT/CT provided reliable 
estimations of the DA cell degeneration showing high correlation to immunohistochemical 
findings. The method is sensitive and selective and provides substantial benefits in pre-
clinical research allowing longitudinal studies in living animals. 
 
The neuroprotective effect of CDNF was studied by applying the NTF intrastriatally as two-
week protein infusion with osmotic pumps, or as gene therapy with a recombinant adeno-
associated viral vector in 6-OHDA-lesioned rats. Both CDNF delivery methods normalized 
the amphetamine-induced rotational asymmetry and provided partial protection of the 
tyrosine hydroxylase (TH) –reactive DAergic cells in the SNpc and DA fibers in the striatum. 
As for GDNF, there were indications of retrograde transport of CDNF, but contrary to what 
has been reported for GDNF, CDNF did not affect the intact rat DAergic system. In addition, 
there were differences between the treatments in the capacity to induce sprouting of TH-
reactive fibers. Our results confirm that CDNF can be considered as a potential therapy in 
PD, and that the neuroprotective mechanism of CDNF differs from that of GDNF. 
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ABBREVIATIONS?
AADC  aromatic amino acid decarboxylase 
AAV  adeno-associated virus 
??  ?-amyloid peptide 
ACh  acetylcholine 
AChE  acetylcholine esterase 
AD  Alzheimer’s disease 
ALS  amyotrophic lateral sclerosis 
ANOVA  analysis of variances 
APP  amyloid precursor protein  
ASO  antisense oligonucleotide 
?-syn  ?-synuclein  
?-CIT  ??-carbomethoxy-3?-(4-iodophenyl)tropane 
BBB  blood-brain barrier 
BDNF  brain-derived neurotrophic factor 
BH4  tetrahydrobiopterin 
CDNF  cerebral dopamine neurotrophic factor 
ChAT  choline acetyl transferase 
CNTF  ciliary neurotrophic factor 
CSF  cerebrospinal fluid 
COMT  catechol-O-methyltransferase 
CNS  central nervous system 
DA  dopamine 
DAT  dopamine transporter 
DOPAC  dihydroxyphenylacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ER  endoplasmic reticulum 
ESC  embryonic stem cells 
FDG  fluorodeoxyglucose 
FG  FluoroGold 
FMT  6-fluoro-L-m-tyrosine 
FUS  fusion in sarcoma 
GABA  gamma aminobutyric acid 
GAD  glutamic acid decarboxylase 
GDNF  glial cell line-derived neurotrophic factor 
GFL  GDNF family ligand 
GFP  green fluorescent protein 
GP  globus pallidus 
GPe  globus pallidus externa 
GPi  globus pallidus interna 
GCH  GTP cyclohydrolase 
HD  Huntington’s disease 
5-HIAA  5-hydroxyindoleacetic acid 
HSV  herpes simplex virus 
5-HT  serotonin 
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1. INTRODUCTION?
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), are characterized by 
progressive loss of neuronal function and cell death in certain neuronal pathways (Fahn, 
2003; Querfurth and LaFerla, 2010; Kiernan et al., 2011; Ross and Tabrizi, 2011). The 
incidence of these diseases increases with age, suggesting that the continuous rise in life 
expectancy will further increase the number of afflicted people. Moreover, the prognosis of 
neurodegenerative diseases is today very grim, and they are not only among the top ten 
causes of death, but also one of the leading causes of disability and dependency of other 
people. Present treatments used in these disorders only relieve symptoms and no disease-
modifying treatments have yet been discovered. 
 
Because of lack of curative treatments, there is an urgent need for new therapeutic 
approaches. Neurotrophic factors (NTF) regulate the life of neurons during development, 
but they also affect plasticity and regeneration in the adult organism (Airaksinen and 
Saarma, 2002; Lindholm and Saarma, 2010). Therefore, the NTFs constitute an interesting 
therapeutic opportunity. Indeed, the two NTFs glial cell line-derived neurotrophic factor 
(GDNF) and neurturin (NTN) have both been effective in pre-clinical in vivo models of PD. 
Nervertheless, results from clinical studies have this far been controversial (reviewed by 
Barker,  2009).  Novel  NTFs  that  have  received  attention  for  their  potential  as  
neuroprotective agents are mesencephalic astrocyte-derived neurotrophic factor (MANF) 
and cerebral dopamine neurotrophic factor (CDNF) (Lindholm and Saarma, 2010). MANF 
promotes survival of dopamine (DA) neurons in vitro (Petrova  et  al.,  2003),  and  the  
invertebrate analogue DmMANF has been shown to be crucial for maturation and 
maintenance of the fruit fly (Drosophila melanogaster) nervous system (Palgi et al., 2009). 
Both MANF and CDNF have also been neuroprotective in rodent models of PD when given 
as single intrastriatal injections (Lindholm et al., 2007; Voutilainen et al., 2009; Airavaara et 
al., 2012). 
 
Since the neurodegenerative diseases are chronic progressive diseases, long-term delivery 
of therapeutic agents is probably a requisite. This can be achieved, e.g., by continuous 
protein infusions or by gene therapy. In animal models of neurodegenerative diseases, 
several approaches using gene therapy have proven to be beneficial. In these studies, 
researches have tried to alter neuronal networks by modulating the synthesis of 
neurotransmitters (Björklund and Kordower, 2010), or aimed at neuroprotection by 
removing pathogenic proteins (San Sebastian et al., 2013), or by supplying the diseased 
tissue with neurotrophic support (Allen et al., 2013). Even though many of these 
therapeutic interventions have shown great potential in pre-clinical in vivo studies, the 
results from clinical trials have been rather disappointing. 
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2. REVIEW?OF?THE?LITERATURE?
2.1 NEURODEGENERATION? AND? NEURODEGENERATIVE?
DISEASES?
In neurodegeneration the structure and function of neurons or neuronal populations are 
progressively lost. In this chapter I will review four neurodegenerative diseases: PD, AD, 
HD, and ALS (Table 1). I chose these four diseases since even though they are characterized 
by vulnerability of distinct neuronal populations giving rise to symptoms typical to each 
disease, the underlying proposed pathological mechanisms show a great deal of 
similarities. 
 
Age is considered to be the greatest risk factor for neurodegenerative diseases and many 
of  them  show  a  steep  increase  in  incidence  with  age  (Hirtz  et  al.,  2007).  Age  itself  is  
thought to contribute to changes in neuronal systems, but it is still debated whether the 
loss of neuronal structure and function can be attributed purely to processes due to aging, 
or whether what is considered to be “normal” age-dependent decline in cognition and 
neuronal function is a result from underlying disease (discussed by Jagust, 2013). Even if 
age itself is most likely not the cause of neurodegenerative diseases, age seems to be a 
contributing factor predisposing to certain pathological events and clinical manifestations. 
Most of the cases of neurodegenerative diseases are classified as sporadic late-onset with 
unknown etiology. However, the impact of genetic factors is becoming more clear and has 
lately  received  a  growing  amount  of  interest  (Hardy  and  Orr,  2006;  Harvey  et  al.,  2011;  
Cookson, 2012). Mutations in seemingly unrelated genes have been found to modify the 
risk of getting a certain neurodegenerative disorder, and have provided new insights into 
the pathology of the diseases. In addition to age and genes, environmental factors 
(exposure to toxins, developmental events etc.) have been implicated in the etiology of 
these diseases (Whalley et al., 2006; Kiernan et al., 2011; Wirdefeldt et al., 2011). For most 
neurodegenerative diseases (sporadic forms), the disease is most likely multifactorial in 
which age, genes and environment together modify the risk of getting the disease. The 
exception is HD which is a monogenic disorder caused by an abnormally long CAG triplet 
repeat in the huntingtin (HTT) gene (Ross and Tabrizi, 2011). 
 
The pathogenesis in AD, PD, HD, and ALS shows many similarities. In all diseases there are 
misfolding and aggregation of certain proteins typical to each disorder (Table 1) (Ross and 
Poirier, 2004). The role of these abnormal protein inclusions is still debated, and their 
contribution to the pathogenesis is unclear. Other proposed molecular pathological 
mechanisms common for the diseases discussed below are mitochondrial dysfunction, 
oxidative stress, dysfunction of the ubiquitin-proteasome system (UPS), chronic 
inflammation and excitotoxicity (Bossy-Wetzel et al., 2004). All these complex mechanisms 
are interrelated and may all contribute to the progressive neurodegeneration. 
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Table 1. Late-onset neurodegenerative diseases and some of their characteristics. 
Disease Etiology; Incidence 
Main neuron 
population affected 
Characteristic 
pathology Symptoms 
Alzheimer’s 
disease 
Sporadic 95%  
Familial ?5%  
(including APP, 
PSEN1/2); 
 
1275/100 000 
 (>65 years) 
Acetylcholinergic 
neurons; degeneration 
in the entorhinal 
cortex, spreading to 
the temporal lobe and 
frontal cortex 
Extracellular ?-
amyloid plaques, 
intracellular 
neurofibrillary 
tangles 
Cognitive 
dysfunction with 
memory loss 
Parkinson’s 
disease 
Sporadic 90-95% 
Familial 5-10% 
(including ?-syn, 
parkin, PINK, DJ-1, 
LRKK2); 
 
160/100 000 
(>65 years) 
Dopamine neurons in 
the substantia nigra 
pars compacta 
Lewy bodies 
containing 
aggregated ?-syn 
Resting tremor, 
postural instability, 
rigidity, akinesia/ 
bradykinesia 
Huntington’s 
disease 
 
Monogenic 
(huntingtin); 
 
0.3-0.8/100 000 
(all ages) 
GABAergic medium 
spiny neurons in the 
striatum 
Aggregated 
huntingtin 
Chorea, psychiatric 
disturbances, 
cognitive 
impairment 
Amyotrophic 
lateral 
sclerosis 
Sporadic 90-95% 
Familial 5-10% 
(including SOD1, 
C9orf72; TDP-43, 
FUS, UBQLN2); 
 
1.6/100 000 
(all ages) 
Lower motor neurons 
in the spinal cord, 
upper motor neurons 
in the cortex 
Cytoplasmic 
ubiquitinated 
aggregates of 
SOD1, FUS or 
TDP-43 
Progressive muscle 
weakness, muscular 
atrophy, spasticity  
APP, amyloid precursor protein; ?-syn, ?-synuclein; FUS, fusion in sarcoma; GABA, gamma aminobutyric 
acid; PSEN1/2, presenilin1 and presenilin 2; SOD1, superoxide dismutase-1; TDP-43, TAR DNA-binding 
protein; UBQLN2, ubiquitin-like protein-2. Incidences in Europe and North America from Hirtz et al., 2007 
and Pringsheim et al., 2012.  
2.1.1 PARKINSON’S?DISEASE?
With  a  prevalence  of  9.5  per  1000  in  the  population  aged  over  65  years  in  the  Western  
world  (Hirtz  et  al.,  2007),  PD  is  considered  to  be  the  second  most  common  
neurodegenerative disorder. PD is mainly characterized as a progressive 
neurodegenerative movement disorder with cardinal symptoms consisting of resting 
tremor, rigidity, akinesia/bradykinesia, and postural instability (Fahn, 2003). The motor 
symptoms in PD result from an imbalance in the basal ganglia signaling (Parent et al., 
2000). The basal ganglia consist of the striatum (caudate nucleus and putamen), globus 
pallidus interna (GPi), and externa (GPe), subthalamic nucleus (STN), substantia nigra pars 
reticulata (SNpr) and pars compacta (SNpc), and the intralaminar nuclei of the thalamus 
(Figure 1). DAergic neurons in the SNpc innervate the striatum. DA released at the striatal 
level generally facilitates signaling through the direct pathway (striatum-GPi, action 
through D1 receptors), while the indirect pathway is inhibited (striatum-GPe, action 
through D2 receptors). In PD, degeneration of the neuromelanin-containing DA neurons in 
Review of the literature 
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the SNpc causes a decrease in DA concentration in the striatum. As the DA concentration 
decreases, both DAergic and non-DAergic compensatory mechanisms (e.g., increase in DA 
synthesis and release, loss of DA reuptake sites, supersensitivity of receptors, reduction in 
activity in the indirect pathway etc.) set in to counteract the loss of DA signaling (Brotchie 
and Fitzer-Attas, 2009). Because of these compensatory actions, it is estimated that, as the 
motor  symptoms  appear,  30-60%  of  the  nigral  DAergic  cell  bodies  are  lost  (Fahn,  2003;  
Cheng  et  al.,  2010)  and  the  striatum  is  subjected  to  an  up  to  80%  decrease  in  DA  
concentration (Fahn, 2003). Despite compensatory mechanisms, further loss of DA 
eventually results in lost control over the striatopallidal neurons causing an imbalance in 
the signaling through the direct and indirect pathway, and giving rise to the classical 
symptoms of PD (Figure 1). 
 
Figure 1. Simplified schematic figure of basal ganglia circuitry in normal (A) and PD brain (B). Decrease in 
striatal dopamine (DA) concentration leads to loss of control of the glutamatergic stimulation of the 
striatopallidal GABAergic neurons, causing an imbalance in the signaling equilibrium through the direct 
and indirect pathways (according to Parent et al., 2000). ENK, encephalin; GABA, gamma-aminobutyric 
acid; GPe, globus pallidus externa; GPi, globus pallidus interna; SNpc, substantia nigra pars compacta; 
SNpr, substantia nigra pars reticulate; SP, substance P; STN, subthalamic nucleus. 
 
In addition to the classical motor symptoms, many PD patients suffer from a range of non-
motor symptoms, such as fatigue and sleep disturbances, depression, cognitive deficits, 
and autonomic dysfunction (Wolters, 2009). These symptoms are attributed to 
dysfunctions in other extranigral neuronal networks, and many of them seem to precede 
the motor symptoms. This suggests that the disease does not actually start in the SN, but is 
anticipated by dysfunction in other networks. Braak and co-workers have indeed suggested 
spreading of PD pathology, and according to their theory, the pathologic changes could be 
initiated  in  the  autonomic  nervous  system  (Braak  et  al.,  2003b;  Kaufmann  et  al.,  2004).  
From the autonomic nervous system, the pathology would then spread to the brain starting 
from the lower brain stem and olfactory bulb (stage 1-2), to the basal midbrain and 
  Review of the literature 
 
5 
 
forebrain (including SN) (stage 3-4), and eventually to the neocortex (stage 5-6) (Braak et 
al., 2003a). The suggested pattern of PD pathology spreading coincides with many of the 
symptoms observed in PD patients, going from anosmia, constipation, depression and 
sleep disturbances, to motor symptoms, and eventually, in the later stages, cognitive 
dysfunction. 
 
Braak and co-workers based their theory of spreading of PD pathology on results from 
immunohistochemical staining of ?-synuclein (?-syn) (Braak et al., 2003a). ?-Syn is the 
major constituent of Lewy bodies, which are eosinophilic inclusion bodies found in the 
cytoplasm of surviving neurons and considered to be a pathological hallmark of PD. The 
Braak hypothesis of ?-syn pathology spread is supported by the findings that human 
embryonic DA nerve cells implanted into the putamen of PD patients develop PD 
pathology, including Lewy bodies (Kordower et al., 2008; Li et al., 2008). Furthermore, 
central spreading of ?-syn has also been observed in in vitro and in vivo studies following 
exposure  to  ?-syn  (injections  or  transgenic  mice)  (Desplats  et  al.,  2009;  Luk  et  al.,  2012;  
Masuda-Suzukake et al., 2013). However, although the data looks convincing, the ?-syn 
seeding theory has lately been heavily debated and the role of ?-syn spreading for the PD 
pathology is still unclear.  
 
Figure  2. The complex network of pathological mechanisms that may underlay neurodegeneration in 
Parkinson’s disease and other late-onset neurodegenerative diseases. A combination of age, genetic 
factors, and environment is thought to mediate changes that eventually result in injury, dysfunction and 
loss of neurons (Bossy-Wetzel et al., 2004; Wirdefeldt et al., 2011; Dehay et al., 2013; Kalia et al., 2013). 
 
The normal function of ?-syn is not completely understood, but the protein is known to be 
involved in vesicular trafficking and release (Burre et al., 2010; Nemani et al., 2010). ?-Syn 
is characterized by a high degree of plasticity, and whereas the protein is natively 
unstructured, it has the capability to undergo conformational changes leading to 
aggregation of the protein monomers (Kalia et al., 2013). Aggregation of ?-syn is thought to 
contribute to the pathogenesis in PD and especially the intermediate oligomeric aggregates 
of ?-syn are considered to be toxic, whereas sequestration of the protein in Lewy bodies 
could even serve as a protective mechanism. The pathway of ?-syn-mediated toxicity is not 
known, but abnormal aggregation of the protein could induce neuronal death by causing 
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disturbances in axonal transport and neuronal function, impairment in mitochondrial 
activity, UPS, and lysosomal and autophagy function, oxidative stress, and activation of 
inflammation processes (Figure 2) (Bossy-Wetzel et al., 2004; Dehay et al., 2013; Kalia et 
al., 2013). 
 
Table 2. Selection of genes associated with Parkinson’s disease (according to Houlden and Singleton, 
2012).  
Loci/Gene Protein Function; type of mutation Characteristics  
PARK1/SNCA ?-synuclein 
Synaptic protein, vesicular 
trafficking and release; 
gain-of-function 
Autosomal dominant; severe 
parkinsonism with early onset; 
dementia common; Lewy bodies 
PARK2 Parkin Ubiquitin-protein ligase;  loss-of-function 
Autosomal recessive; heterogeneity 
in age of onset and 
neuropathological features but often 
early onset without Lewy bodies 
PARK4/SNCA Multiplication of SNCA Excess of ?-synuclein 
Autosomal dominant; onset (early-
to-late) and symptoms depending on 
number of copies of SNCA (gene 
dosage) 
PARK6/PINK1 
PTEN-induced 
kinase 1 
(PINK1) 
Mitochondrial protein, 
provides protection against 
several stress factors;  
loss-of-function 
Autosomal recessive; onset in the 
40s-50s; slow progression; atypical 
features (dystonia, sleep benefit, 
pyramidal symptoms); heterogenic 
neuropathology 
PARK7 DJ-1 
Mediates oxidative stress 
response;  
loss-of-function 
Autosomal recessive; early onset; 
neuropathology not known 
PARK8/LRRK2 
Leucine-rich 
repeat kinase 2 
(LRRK2) 
Cytoplasmic kinase involved 
in endocytosis and vesicle 
function;  
gain-of-function 
Autosomal dominant; most common 
cause of familial PD; age of onset and 
neuropathological features 
depending on type of mutation 
 
Besides the fact that ?-syn is the major constituent of Lewy bodies, additional clues to the 
importance of ?-syn in the PD pathology come from the observations that mutations 
(A53T, A30P, E46K) in the ?-syn gene (PARK1, SNCA) causes autosomal dominant forms of 
PD (Table 2) (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004; Kalia et 
al.,  2013).  These mutations  seem to mediate  a  gain-of-function promoting aggregation of  
?-syn.  Also  multiplication  of  the  ?-syn  gene  has  been  linked  to  familial  PD  (PARK  4) 
(Singleton et al., 2003; Chartier-Harlin et al., 2004). Other genes associated with heredity of 
PD are PARK 2 (parkin), PARK 6 (PTEN-induced kinase 1, PINK1), PARK 7 (DJ-1), and PARK 8 
(leucine-rich repeat kinase 2, LRRK2) (Table 2) (reviewed by Houlden and Singleton, 2012). 
The normal functions of the corresponding proteins indicate association between PD 
pathology and mitochondrial function, oxidative stress, UPS, vesicular trafficking, and 
lysosomal dysfunction. These processes, together with inflammation and lysosomal 
impairment, are also thought to contribute to the pathogenesis in sporadic PD (Figure 2). 
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Why certain neuron populations (e.g., the DA neurons in the SNpc) are especially 
vulnerable to these changes in PD is still a puzzle. Features that could promote neuron-
specific toxicity are type of neurotransmitter and possible reactive metabolites, the 
morphology of neurons, and pattern of current flow and excitability (discussed by Sulzer 
and Surmeier, 2013). 
 
The etiology in sporadic PD is still unknown, but the combined sum of age, genes, and 
environment (exposure to chemicals and life-style factors) is thought to be behind the 
development of PD (Figure 2) (Wirdefeldt et al., 2011). There is still no treatment available 
that would slow down the neurodegenerative process in PD. The keystone in the 
symptomatic treatment of PD is L-DOPA (levodopa, 3,4-dihydroksy-L-phenylalanine), the 
precursor to DA, which is generally given in combination with inhibitors of peripheral 
aromatic amino acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT), to 
increase the levels of L-DOPA in the brain (Fahn, 2003). The treatment aims to reinforce the 
impaired DA signaling, and is usually effective in earlier stages of PD when the treatment is 
initiated. In a long-term use, as the disease progresses, the L-DOPA treatment is, however, 
accompanied by motor disturbances, such as dyskinesias and motor fluctuation (Obeso et 
al., 2000). Other treatments used in PD to increase the central DA signaling are DA agonists, 
inhibitors of monoamine oxidase-B (MAO-B, an enzyme participating in the DA 
metabolism), and amantadine. 
2.1.2 ALZHEIMER’S?DISEASE?
Alzheimer’s disease (AD) is the most common form of dementia and shows a prevalence of 
48  per  1000  in  the  population  over  65  years  (Hirtz  et  al.,  2007).  The  most  striking  
neuropathological change in AD is loss of neurons and projections in the neocortex, 
hippocampus, amygdala and basal nucleus of Meynert together with a robust reduction in 
cholinergic activity, which clinically results in progressive memory loss and impairment in 
cognitive functions (loss of attention, changes in personality, speech difficulties, etc.) 
(Wenk, 2003). The main symptomatic treatment consists of acetylcholine-esterase (AChE) 
inhibitors, which can provide temporary improvement of neurotransmission and cognitive 
functions (Bond et al., 2012). 
 
The common view today is that accumulation of misfolded proteins (?-amyloid (A?) 
peptides, hyperphosphorylated tau) leads to failure in neuronal energy production and 
synaptic dysfunction and contributes to the pathological changes in the AD brain (Figure 3) 
(reviewed by Querfurth and LaFerla, 2010). Amyloid precursor protein (APP) is a 
membrane-bound protein that can undergo cleavage by secretases into soluble non-
amyloidogenic  APP  or  A? peptides  of  different  lengths  (reviewed  by  Selkoe,  2001).  
Sequential cleavage of APP with ?-secretase (mainly beta-amyloid convertase enzyme, 
BACE  1)  and  ?-secretase  (a  complex  of  four  integral  membrane  proteins,  among  them  
presenilin (PSEN)) renders primarily A? peptides consisting of 40 or 42 amino acids (Figure 
3) (reviewed by Vassar and Citron, 2000). These A? peptides can self-aggregate to form 
soluble oligomers, intermediate filaments or insoluble fibrils (plaques), of which the soluble 
oligomers and intermediate filaments are considered to have the greatest neurotoxic 
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potential (discussed by Walsh and Selkoe, 2007). A? peptides are formed under normal 
circumstances (Shoji et al., 1992), but are cleared away by enzymes, such as neprilysin and 
insulin-degrading enzyme (Miners et al., 2011), by microglial phagocytosis (Rogers and Lue, 
2001), perivascular drainage (Weller et al., 2000) or transportation into blood vessels 
through the blood-brain barrier (BBB) (Deane et al., 2009). The neurotoxic aggregation of 
?? peptides is thus thought to be mediated either by an increase in production, by 
dysfunction in clearance, or both. There are now clear indications that in late-onset 
sporadic AD the A? peptides are produced at normal levels, but the clearance is impaired 
(Mawuenyega et al., 2010). Indeed, the most influential gene risk factor for sporadic, late-
onset  AD  is  polymorphism  in  the  apolipoprotein  E  (ApoE)  gene  (Corder  et  al.,  1993;  
Bertram and Tanzi, 2005), a protein thought to be involved in the clearance of A? (Fagan et 
al., 2002; DeMattos et al., 2004). In genetically inherited AD, the production of A? peptides 
is instead often altered, and mutations in APP, or PSEN1 or PSEN2 (subcomponents of ?-
secretase), have been linked to the disease (reviewed by Bettens et al., 2013). 
 
Figure 3 The protein aggregation hypothesis of Alzheimer’s disease. Favoring of amyloid precursor protein 
(APP) cleavage with ??? -secretases results in the formation of ? amyloid peptides (A?). A? peptides 
40/42 amino acids in length are prone to aggregate into oligomers and finally into amyloid plaques. The 
?? aggregates are thought to contribute to neurotoxicity and cell death. In parallel with A? aggregation, 
formation of intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein is 
characteristic to AD. The relationship between A?/plaque formation and tau/tangle pathology is still 
unclear. The most established theory, fuelled by the finding of mutations in APP, PSEN1, or PSEN2 in 
familial early-onset AD, is that abnormal A? aggregation is the primary event in AD pathology (Hardy and 
Selkoe, 2002). Accumulation of extracellular A? would then drive the hyperphosphorylation of tau and be 
the main cause of the pathologic cellular changes in AD. Another alternative theory states that 
aggregation of A? and hyperphosphorylated tau constitutes two different pathways contributing to the 
pathology of the disease (discussed by Small and Duff, 2008). 
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Tau is in normal conditions found in axons where the soluble protein promotes stability 
and assembly of microtubules and is therefore important for vesicle transport along axons 
(for  reviews,  see  Iqbal  et  al.,  2005;  Himmelstein  et  al.,  2012).   When  tau  is  
hyperphosphorylated, the protein becomes insoluble and can no longer interact with 
microtubules. Instead it aggregates into paired helical filament structures and further into 
intermediate aggregates, and finally neurofibrillary tangles (Figure 3). The aggregation of 
abnormal hyperphosphorylated tau is cytotoxic to neurons (Khlistunova et al., 2006), and 
has been shown to induce cell loss and behavioral deficits in vivo (Lewis et al., 2000; 
Santacruz et al., 2005). Furthermore, in vitro and in vivo results indicate that A? toxicity 
requires the presence of tau (Rapoport et al., 2002; Roberson et al., 2007). Even though 
mutations in TAU have been detected in frontotemporal dementia (for review, see Goedert 
and Jakes, 2005), no link between these mutations and AD has been found. 
2.1.3 HUNTINGTON’S?DISEASE?
Unlike AD and PD, HD has a clear genetic background. It is a monogenic, fully penetrant 
disorder caused by abnormal CAG triplet repeats in the 5´ end of the HTT gene (The 
Huntington's Disease Collaborative Research Group, 1993). The length of the polyglutamine 
stretch in HTT is indicative of disease burden (?40 repeats cause nearly full penetrance) and 
age of onset (longer repeats generally cause earlier onset) (Langbehn et al., 2004). It is still 
unclear why mutated HTT causes HD, and there are different views on whether the 
abnormally long polyglutamine stretch mediates a gain of toxic function or if the disease is 
a  result  of  reduction in  the normal  HTT activity  (discussed by Cattaneo et  al.,  2005;  Ross  
and Tabrizi, 2011). The normal function of HTT is still not completely understood, but the 
protein has the ability to interact with several proteins indicating that it functions as a 
scaffold  to  control  and  coordinate  other  proteins  (Cattaneo  et  al.,  2005).  Moreover,  HTT 
knock-out  mice  die  in  early  embryonic  stage  (Duyao  et  al.,  1995;  Nasir  et  al.,  1995),  and  
reduced  levels  of  HTT  (<50  %)  in  mice  result  in  impaired  neurogenesis  and  CNS  
malformation (White et al., 1997), implying that the protein is crucial during the 
development. 
 
The N-terminal portion of normal HTT is flexible and can adopt different conformations 
(Kim et al.,  2009). In mutant HTT, the expanded polyglutamine stretch seems to force the 
N-terminal portion of the protein into a compact conformation consisting of short ? strands 
causing aggregation of the protein (Poirier et al., 2005). In HD, large neuronal inclusion 
bodies of misfolded HTT can be seen mainly in the nucleus, but also in the cytoplasm, 
dendrites, and axon terminals in the affected areas (Ross and Tabrizi, 2011; Arrasate and 
Finkbeiner, 2012). There are some discrepancies between the presence and amount of 
inclusion bodies and extent of neuronal cell death, which indicates that the inclusion 
bodies might not, themselves, be toxic. Instead, as for A? and ?-syn, it is hypothesized that 
oligomeric intermediate aggregates mediate the toxic activity of HTT, while the formation 
of inclusion bodies may be a protective mechanism that serves to sequester toxic forms of 
the protein (Sanchez et al., 2003; Ross and Tabrizi, 2011; Arrasate and Finkbeiner, 2012). 
The most affected cell population in HD is striatal neurons with massive loss of the basal 
ganglia GABAergic medium spiny projection neurons projecting from the striatum to the GP 
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and  the  SN  (Figure  1)  (Reiner  et  al.,  1988;  Vonsattel,  2008;  Ross  and  Tabrizi,  2011).  In  
addition to the extensive loss of striatal neurons, there are also more global changes in the 
CNS including atrophy of the cerebral cortex, subcortical white matter, thalamus, and 
specific hypothalamic nuclei in the later stages of the disease (reviewed by Vonsattel, 
2008). The mechanisms behind the pathogenicity due to misfolded HTT and vulnerability of 
striatal GABAergic neurons are summarized in Figure 4. 
 
 
Figure 4 Proposed pathologic mechanisms in HD. Misfolded HTT is thought to mediate toxicity by altering 
the regulation of transcription, axonal trafficking and synaptic transmission, and by mediating 
mitochondrial dysfunction (Cattaneo et al., 2005; Ross and Tabrizi, 2011). The reason for the striatal 
vulnerability in HD is still unclear but it is possibly due to reduced neurotrophic support (reduction in 
transcription and axonal trafficking of the NTF brain-derived neurotrophic factor (BDNF)) (Ferrer et al., 
2000; Gauthier et al., 2004; Cattaneo et al., 2005), and excitotoxicity triggered by glutamatergic 
projections from the cortex (Roze et al., 2011). 
 
As for the other neurodegenerative diseases already discussed, no disease-modifying 
therapy for HD exists and the disease usually results in death within 10-15 years after 
symptom  onset  (Ross  and  Tabrizi,  2011).  The  treatments  used  are  aimed  at  relieving  the  
symptoms, which consist of progressive motor dysfunction (chorea, bradykinesia, 
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dystonia), psychiatric disturbances (depression, anxiety, aggression, irritability), and 
cognitive decline (reviewed by Videnovic, 2013). Genetic testing can identify individuals 
predisposed to the disease before clinical onset which gives a time window that allow the 
testing of novel treatments that can modify the disease. 
2.1.4 AMYOTROPHIC?LATERAL?SCLEROSIS?
Amyotrophic lateral sclerosis (ALS) is a fatal disease characterized by progressive motor 
weakness caused by degeneration of lower motor neurons in the lateral horn of the spinal 
cord and upper motor neurons of the cerebral cortex (Kiernan et al., 2011). The peak onset 
for ALS happens in late midlife and the incidence in the population in their 60’s is estimated 
to be 5 per 100 000 with a slightly higher incidence in men than in women (male/female 
ratio approximately 1.3) (Hirtz et al., 2007). 
 
ALS is a heterogenic disease showing high variability in phenotype and clinical presentation, 
but despite these variations, the disease generally progresses to paralysis, respiratory 
failure and death within 3-5 years of symptom onset (Hardiman et al., 2011; Kiernan et al., 
2011). The most common form of ALS constitutes a combination of both lower and upper 
motor neuron degeneration with symptoms starting in the limbs (limb-onset ALS). Loss of 
lower motor neurons cause symptoms that typically consist of fasciculation and wasting 
weakness, while upper motor neuron symptoms include spasticity, weakness, and brisk 
deep tendon reflexes. 
 
As for the above discussed neurodegenerative diseases, the degeneration of motor 
neurons in ALS is also thought to be a process involving multiple interrelated pathways 
including excitotoxicity, ion channel dysfunction, oxidative stress, mitochondrial 
dysfunction, inflammation, and disrupted axonal transport (Figure 2) (Kiernan et al., 2011). 
In most cases, the diagnosed ALS is labeled as sporadic, while 5-10% of the ALS patients 
have familial forms of the disease. Many genes have been associated with familial ALS, 
among them those encoding superoxide dismutase-1 (SOD1), TAR DNA binding protein 
(TDP-43, or TARDBP), fusion in sarcoma (FUS), ubiquilin 2 (UBQLN2, ubiquitin-like protein), 
and angiogenin (ANG) (Al-Chalabi et al., 2012). Until recently, mutations in SOD1, mediating 
excitotoxicity, mitochondrial dysfunction, and oxidative stress, were thought to be the 
most common genetic risk factor for ALS, accounting for approximately 20% of familial ALS 
(Kiernan  et  al.  2011,  Al-Chalabi  et  al.,  2012).  However,  in  2011  a  hexanucleotide  repeat  
expansion in the first intron of the yet unknown gene C9orf72 was identified and reported 
to  underly  almost  40%  of  familial  ALS  in  European  and  US  patients  (Renton  et  al.,  2011;  
Majounie et al., 2012). The function of this gene is not yet known, but binding to RNA 
seems to be involved. Also TDP-43, FUS, and ANG are involved in regulating RNA processing 
and gene expression, while UBQLN2 has a role in autophagy and protein degradation (Al-
Chalabi et al., 2012). The pathogenic mutations in the different ALS-associated genes are 
manifested as variations in the ALS neuropathology, age of onset, and clinical presentation. 
 
The neuropathology of ALS is generally characterized by abnormal protein inclusions, but 
the presence and content of these show great variation depending on the type of ALS 
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(Kiernan et al., 2011; Turner et al., 2013). Cytoplasmic ubiquitinated inclusions containing 
TDP-43 are found in the lower motor neurons in nearly all cases of sporadic ALS (Mackenzie 
et al., 2007). However, these inclusions are generally not found in ALS patients carrying 
pathogenic mutations in SOD1 or FUS. In these cases, the inclusions may instead contain 
aggregated SOD1 or FUS, respectively (Turner et al., 2013). In addition to the ubiquitinated 
protein aggregates, ALS is associated with the presence of Bunina bodies, which are small 
eosinophilic intracellular inclusions found in motor neurons in the spinal cord and 
brainstem (Okamoto et al.,  2008). The specific role of the abnormal protein aggregates in 
ALS is not known, and it is unclear if the protein aggregates themselves mediate toxicity, or 
whether the cell is merely trying to protect itself by promoting sequestration of pathogenic 
proteins. 
 
Effort to provide symptomatic relief and preservation of quality of life is the main focus in 
the  treatment  of  ALS  (Hardiman  et  al.,  2011;  Kiernan  et  al.,  2011).  Despite  numerous  
clinical studies on potentially neuroprotective agents, the only treatment available for ALS 
today is the glutamate release inhibitor riluzole, which improves the survival time by three 
to six months. 
2.2 EXPERIMENTALLY?INDUCED?NEURODEGENERATION?
Animal models of human diseases are important tools in pharmacological research on the 
nature of diseases, in the search for novel treatment strategies, and in the pre-clinical 
evaluation of new therapeutic interventions. Ideally, an animal model should show 
comparative symptomatology, etiology, and physiological basis (face validity and construct 
validity), as well as drug effects (predictive validity) to the human condition. Traditionally 
animal models of neurodegeneration have been developed using specific or non-specific 
toxins, or surgical procedures (e.g., axotomy). With increasing knowledge about genes that 
predispose to certain diseases, models based on these genetic alterations have been 
designed. These so called etiologic models are important tools for studying the pathological 
basis of diseases, and the rapid growth in this field has been fueled by the enormous 
progress in our ability to produce genetically modified animals. 
2.2.1 TOXIN-INDUCED?ANIMAL?MODELS?
Parkinson’s disease 
With the help of specific toxins, researchers have tried to model the PD-associated loss of 
midbrain DA neurons and projections in animals. The most widely used toxin-induced PD 
models are the 6-hydroxydopamine (6-OHDA) -treated rat and the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) -treated mouse and primate. When intracerebrally (i.c.) 
injected, 6-OHDA is taken up by monoamine transporters (DA and noradrenaline 
transporters (DAT and NET)) and damage the cells mainly by induction of oxidative stress 
and mitochondrial dysfunction (Figure 5) (Schwarting and Huston, 1996; Duty and Jenner, 
2011). MPTP is used in both mice (mainly C57BL/6) and primates and is converted to the 
toxic moiety 1-methyl-4-phenylpyridinium (MPP+) in the brain by the sequential action of 
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MAO-B and spontaneous oxidation (Duty and Jenner, 2011; Bove and Perier, 2012). MPP+ 
is  taken  up  into  DA  neurons  via  DAT,  and  once  inside  the  cell  it  accumulates  in  
mitochondria where it inhibits the complex I of the electron transport chain, leading to a 
decrease in ATP production and induction of oxidative stress. Another complex I inhibitor 
that has been used to model PD is rotenone, a pesticide that induces cell death mainly by 
an  increase  in  reactive  oxygen  species  (ROS)  (Duty  and  Jenner,  2011;  Bove  and  Perier,  
2012). Imitation of several PD features has also been done with lactacystin, an inhibitor of 
the UPS (Zhu et al., 2007b; Xie et al., 2010), and with induction of inflammatory processes 
using lipopolysaccharide (LPS) (Castano et al., 1998; Choi et al., 2009). Figure 5 summarizes 
the actions of the different toxins. A review of the toxin-induced PD-like properties can be 
found in Table 3. 
 
Figure  5 Simplified drawing of the proposed mechanisms of toxins used for induction of 
neurodegeneration of dopaminergic neurons in animal models of Parkinson’s disease (according to Duty 
and Jenner, 2011; Bove and Perier, 2012). DAT, dopamine transporter; MAOB, monoamine oxidase B; 
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP, 1-methyl-4-phenylpyridinium; 6-OHDA, 6-
hydroxydopamine; ROS, reactive oxygen species. 
 
Huntington’s disease 
Toxin models of HD have been developed using substances that induce neuronal cell death 
by triggering excitotoxicity or mitochondrial dysfunction, two mechanisms that have been 
implied  in  the  pathogenesis  of  HD  (reviewed  by  Ramaswamy  et  al.,  2007b).  The  most  
frequent toxins used in both rats, mice, and non-human primates are quinolinic acid (QA) 
and 3-nitropropionic acid (3-NP). 
 
QA binds  to  N-methyl-D-aspartate  (NMDA) receptors  and causes  excitotoxic  cell  death of  
the striatal neurons when injected intrastriatally (Schwarcz et al., 1983; Brouillet et al., 
1999; Ramaswamy et al., 2007b). Rats treated with QA acid show striatal 
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neurodegeneration accompanied with a decrease in GABA concentration. In addition, the 
model is associated with cognitive deficits (Furtado and Mazurek, 1996), and motor 
dysfunction that can be monitored as asymmetrical behavior in unilaterally QA-lesioned 
animals (Borlongan et al.,  1995; Vazey et al.,  2006). The mitochondrial toxin 3-NP inhibits 
succinate dehydrogenase causing impairment in the energy metabolism, reduction of ATP 
production, and oxidative stress (Brouillet et al., 1999; Ramaswamy et al., 2007b). 3-NP 
causes rather selective degeneration of GABAergic neurons in the striatum when given as 
systemic injections or infusions, indicating that the striatal neurons are especially 
vulnerable to mitochondrial damage and dysfunction in the energy metabolism. The extent 
of the lesion and range of behavioral dysfunction varies depending on the injection 
schedule (e.g., dose of 3-NP and number of repeated injections). In rats there is also a clear 
strain-dependent difference in toxin sensitivity (Ouary et al., 2000). 
 
Table 3 Overview of the induced phenotypes in toxin and AAV-?-synuclein animal models of Parkinson’s 
disease (Schwarting and Huston, 1996; Castano et al., 1998; Zhu et al., 2007b; Choi et al., 2009; Xie et al., 
2010; Duty and Jenner, 2011; Bove and Perier, 2012; Lindgren and Dunnett, 2012; Lindgren et al., 2012). 
Model characteristics 6-OHDA MPTP Rotenone Lactacystin LPS AAV-?-synuclein 
 
Species 
 
Rat 
(mouse, 
primate) 
 
Mouse, 
primate 
 
Mouse, 
rat 
 
Mouse, 
rat 
 
Mouse, 
rat 
 
Rat 
 
Administration of 
substance 
 
i.c.  
 
i.p., s.c. 
 
i.v., s.c., i.p. 
 
i.c. 
 
i.c. 
 
i.c. 
 
Striatal dopamine 
loss/dysfunction 
 
 
+ 
 
+ 
 
+a 
 
+a 
 
+a 
 
+ 
Nigral dopamine cell loss 
 
+ + +a +a +a + 
Progressive cell loss 
 
5d-4wka no +/- 4-12 wk no 8-16 wk 
Extra-nigral dysfunction 
 
+ + + n.k. - n.k. 
Protein inclusions 
 
- +/- +/- +/- +/- + 
Motor deficits 
 
+ + +/- +/- +/- + 
Non-motor deficits 
 
+b +/-  +/- n.k. n.k. n.k. 
Responsiveness to L-DOPA + + + + + n.k. 
+, detected in the model; -, not detected in the model; +/-, high variability between studies; n.k., not 
known; a depending on dose and/or injection site; b generally requires bilateral lesion; AAV, adeno-
associated virus; i.c., intracerebral; i.p., intraperitoneal; LPS, lipopolysaccharide; MPTP, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; s.c. subcutaneous, i.v., intravenous.  
 
Alzheimer’s disease 
The cholinergic aspect of AD has been simulated in rodents using different specific and 
non-specific toxins (Hanin, 1992). Excitotoxins (excitatory amino acids such as kainic acid) 
are not specific to cholinergic neurons, but by injection into areas with cholinergic nerve 
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cell bodies in rats, e.g., the basal nucleus of Meynert, loss of cholinergic cells and 
projections, accompanied by cognitive changes, can be achieved. Ethylcholine aziridinium, 
AF64A,  is  a  more  specific  cholinergic  toxin.  It  is  a  choline  analog  that  is  taken  up  by  the  
high-affinity choline transport system into cholinergic neurons (Fan and Hanin, 1999). At 
least part of its toxic actions is thought to be due to alteration in choline acetyl transferase 
(ChAT) mRNA expression and enzyme activity. Administration of activated AF64A 
(intracerebroventricularly (i.c.v.) or into the hippocampus) causes reduction in cholinergic 
markers and decrease in the release of acetylcholine (ACh), and induces cognitive 
impairments including memory and learning deficits in rats (Gower et al., 1989; Hanin, 
1992; Fan and Hanin, 1999). The importance of the AD toxin models have diminished as the 
transgenic models have been developed, but they are still used to some extent for 
modeling AD in rats.  
2.2.2 TRANSGENIC?ANIMAL?MODELS?
Parkinson’s disease 
As gene defects underlying familial PD are being identified (for a list of selected genes, see 
Table 2), transgenic animal models trying to mimic these changes have been created. This 
far, ?-syn has been the main target and ?-syn knock-out, over-expressing and transgenic 
mice have been developed (Harvey et al., 2011; Crabtree and Zhang, 2012). Overexpression 
of wild type human ?-syn in mice results in accumulation of ?-syn into neuronal inclusion 
bodies and the protein aggregation is generally increased in transgenic mice expressing ?-
syn  with  PD-associated  mutations  (e.g.,  A30P,  A53T).  The  aggregation  of  ?-syn  in  mice  
shows some correlation with age-related loss of striatal DAergic terminals, reduced striatal 
levels of DA and motor impairment, but consistent reports of specific loss of midbrain 
DAergic neurons are lacking. Although not a subject of this thesis, it could be mentioned 
that expression of mutated ?-syn in Drosophila mimics several features of PD, including 
motor dysfunction, Lewy-body formation, and age-dependent loss of DA neurons (Feany 
and Bender, 2000). 
 
Loss of function mutations or knockout/knockdown of PARK2, PARK6, or PARK7 (parkin, 
PINK1,  or  DJ-1)  also  show  variable  phenotype  and  although  there  are  reports  of  motor  
impairments, DAergic dysfunction and mitochondrial alterations in these models, the 
nigrostriatal pathology typical to PD is absent (Duty and Jenner, 2011; Harvey et al., 2011; 
Crabtree and Zhang, 2012). The same holds true for LRRK2 models in which overexpression 
of mutant LRRK2 has been reported to cause progressive motor dysfunction and alterations 
in DA signaling, albeit no degeneration of nigral DAergic neurons has been observed. The 
lack of clear cell pathology does not support the use of these models in pre-clinical animal 
studies, but they may be used to shed light on the pathogenesis in neurodegenerative 
diseases. 
 
To imitate the loss of DA signaling in PD, animals with alterations in DA homeostasis 
(synthesis, metabolism, transport) have been developed (reviewed by Crabtree and Zhang, 
2012).  In  a  short  summary,  mice  with  reduced  expression  of  the  D2 receptor, tyrosine 
hydroxylase (TH; catecholamine synthesis enzyme), and vesicular monoamine transporter 2 
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(VMAT2; pre-synaptic transporter responsible for the uptake of DA into vesicles), as well as 
increased expression of MAO-B all show PD-like phenotypes. Even though these genetic 
alterations are not directly associated with human PD, the models can be important in the 
development of novel DA replacement therapies. 
 
Another genetic model with non-PD-related genetic alterations is the MitoPark mouse 
(Ekstrand et al., 2007). Based on the idea that mitochondrial dysfunction would play a role 
in PD pathogenesis, Ekstrand and co-workers developed a conditional knock-out mouse 
that allowed disruption of the gene encoding mitochondrial transcription factor A (Tfam) 
specifically in adult DAergic neurons, causing impairment in mitochondrial DNA 
transcription and respiratory chain dysfunction. The mice showed progressive motor 
dysfunction that could partially be reversed with L-DOPA treatment. The model was also 
characterized by progressive loss of midbrain DA neurons and striatal DA neuron 
innervation that was in addition preceded by the presence of neuronal protein inclusion 
bodies. 
 
Alzheimer’s disease 
Transgenic models of AD focus on the aggregation of A? and include mutations in APP and 
PSEN (for review, see McGowan et al., 2006; Harvey et al., 2011). Most of the models show 
increase in insoluble A? and plaque formation with a further accelerated rate of amyloid 
deposition in animals with combined mutations in both APP and PSEN (Borchelt  et  al.,  
1997; Holcomb et al., 1998; Chishti et al., 2001). Even though some neuronal loss has been 
reported in a few models, the extensive neurodegeneration seen in AD is generally lacking 
(McGowan et al., 2006). Some models are featured by decline in cognitive functions, but no 
consistent correlation between A? levels and degree of memory loss has been found. 
 
Huntington’s disease 
Transgenic mouse models of HD have naturally been generated with focus on HTT 
(reviewed by Beal and Ferrante, 2004; Vonsattel, 2008; Crook and Housman, 2011). Three 
alternative strategies have been applied: 1) Random insertion of an N-terminal fragment of 
HTT (human or chimeric human/mouse gene); 2) Insertion of full-length human HTT with 
expanded CAG repeats; 3) Introduction of pathological CAG repeats into the mouse Htt. 
The resulting phenotype (formation of inclusions, degree of cell loss, motor performance, 
cognitive abnormalities, and survival) varies depending on the type of manipulation (for 
review, see Crook and Housman, 2011). 
 
Amyotrophic lateral sclerosis 
Mutations in SOD1 provided the first genetic linkage to ALS and allowed the development 
of the first transgenic animal models of ALS (Gurney et al., 1994). Today there are many 
different transgenic SOD1-based ALS models in use and they generally show similarities to 
the human disease (mitochondrial and axonal dysfunction, progressive motor neuron loss 
and reduced lifespan) (reviewed by Harvey et al., 2011; McGoldrick et al., 2013). However, 
the resulting symptoms vary depending on the type of mutation, level of transgene 
expression, genetic background, and sex. This has made the translation of results from 
mouse studies to human clinical trials inadequate and may have contributed to the 
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continuous failure in proving the effect of novel treatment interventions in ALS (Turner et 
al., 2013). In addition, TDP-43 inclusions that are found in nearly all ALS cases are absent in 
SOD1-related ALS, and this may also make the generalization of results from animal studies 
to the human situation unreliable. 
 
As the genetic background of ALS is revealed, new transgenic models are being developed. 
This far none of the models, including transgenic TDP-43 and FUS animals, have proven to 
reproduce the ALS phenotype to the same extent as transgenic SOD1 mutants (McGoldrick 
et  al.,  2013).  Even  though  several  of  these  models  show  deficits  in  motor  behavior,  
axonopathy, muscle atrophy and denervation, the extensive loss of spinal motor neurons is 
usually absent. 
2.2.3 DELIVERY?OF?PATHOGENIC?PROTEIN?
Parkinson’s disease 
The accumulation of ?-syn seen in PD has been replicated in adult rats (and mice) by 
intranigral injections of recombinant viral vectors carrying ?-syn. Delivery of ?-syn gives rise 
to intracellular overexpression of ?-syn and the formation of ?-syn-containing inclusions 
(not, however, identical with Lewy bodies) accompanied by a generally moderate loss (20-
50%)  of  DA  neurons  in  the  rat  SN  (Kirik  et  al.,  2002b;  Klein  et  al.,  2002;  Lo  Bianco  et  al.,  
2002). With the advance in viral vector design, Decressac and co-workers (Decressac et al., 
2012) reported the use of a more efficient adeno-associated viral (AAV) vector. With their 
AAV-?-syn vector, they achieved a progressive impairment in motor behavior in rats 
reaching  its  maximum  8-16  weeks  after  the  injection.  During  this  time  interval,  the  rats  
showed  a  progressive  approximately  70-80%  loss  of  DA  neurons  in  the  SN  as  well  as  
progressive loss of DAergic fibers and striatal DA levels (phenotype compared to toxin-
induced animal models of PD in Table 3). The morphologic changes were preceded by 
impairment in DA release and re-uptake (Lundblad et al., 2012), and reduced expression of 
proteins participating in DA synthesis, metabolism, and transmission (Decressac et al., 
2012). 
 
Alzheimer’s disease 
Small  A? oligomers  have  been  used  to  induce  AD-like  symptoms  in  rats  and  mice.  I.c.v.  
injection of A? oligomers proved to inhibit hippocampal long term potentiation (LTP) 
(Walsh et al., 2002), and caused disruption of learned behavior in rats (Cleary et al., 2005). 
Also hippocampal injections of A? peptides induced delayed cognitive deficits (Cleary et al., 
1995;  O'Hare et  al.,  1999)  and reduced cortical  levels  of  BDNF in  rats  (Christensen et  al.,  
2008).  AD-like  pathology  has  also  been  replicated  in  rats  by  viral  vector-mediated  
overexpression of A? peptides in the hippocampus of adult rats (Lawlor et al., 2007). These 
rats show increase in A? levels (but no plaque formation), accompanied by mild behavioral 
and cognitive deficits. 
 
Huntington’s disease 
Delivery of mutant HTT into the brain (mainly striatum) of rats, mice and non-human 
primates to model HD has been done using viral vectors (reviewed by Ruiz and Deglon, 
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2012). Overexpression of the mutant protein has been shown to induce formation of 
inclusions, neuronal dysfunction, neuronal loss, as well as motoric dysfunction. 
 
Amyotrophic lateral sclerosis 
Injection of a recombinant AAV vector carrying the gene for human wild-type TDP-43 into 
the cervical spinal cord of both rats and non-human primates was done by Uchida and co-
workers (2012). Overexpression of TDP-43 resulted in progressive muscle weakness and 
muscle atrophy in both rats and primates. However, whereas injection of AAV-TDP-43 was 
associated with cytoplasmic aggregates and motor neuron and axon degeneration in 
primates, no such changes were observed in rats, indicating species-specific differences in 
the TDP-43-associated pathology. 
2.3 GENE?TRANSFER?METHODS?
Gene transfer can generally be used to study the function of a specific gene, to provide a 
therapeutic gene, or to correct for a mutated malfunctioning endogenous gene (Vannucci 
et al., 2013). In therapeutic approaches, the advantage of gene therapy is continuous 
targeting of a specific region of interest while overcoming certain problems associated with 
administration, uptake and distribution. This can provide substantial benefits when trying 
to target chronic diseases in the brain (Björklund et al., 2000). Gene therapy can roughly be 
divided into in vivo and ex vivo gene therapy, and in this chapter I will review these gene 
delivery methods from the perspective of CNS disorders. 
2.3.1 IN?VIVO?GENE?DELIVERY?
In vivo gene  delivery  is  defined  as  the  direct  insertion  of  a  gene  into  the  patient’s  or  
animal’s own cells forcing the endogenous cells to produce the protein of interest (Feigin 
and Eidelberg, 2007). This can be achieved by the use of recombinant viral vectors, or with 
liposomes and nanoparticles carrying the transgene of interest. 
 
Viral vectors are created by rearrangement of the viruses’ own genome so that while 
maintaining the infectious properties, the replication and production of new viral particles 
are  prevented  (Vannucci  et  al.,  2013).  In  terms  of  CNS  disorders,  AAV,  lentivirus  (LV),  
adenovirus, and herpes simplex virus (HSV) have been the mostly studied vectors (Feigin 
and  Eidelberg,  2007;  Lim  et  al.,  2010;  Vannucci  et  al.,  2013).  These  all  show  different  
characteristics in terms of the nucleic acid they are carrying (DNA, RNA, single- or double-
stranded), the size of transgene that can be incorporated, infectiousness, tropism to certain 
cell types, as well as onset and duration of the induced expression (Table 4). AAV vectors 
have  been  the  main  viral  vectors  used  to  deliver  therapeutic  genes  in  clinical  trials  of  
neurodegenerative diseases (Lim et al., 2010), and I will continue to discuss the attributes 
of this vector. 
 
Wild-type AAV is a small, icosahedral non-enveloped virus containing single-stranded DNA 
coding for four rep genes (needed for virus replication) and three cap genes  (coding  for  
  Review of the literature 
 
19 
 
structural proteins), flanked by short inverted terminal repeats (ITRs) (Rose et al., 1971; 
Samulski  et  al.,  1983;  Mendelson  et  al.,  1986;  Vonsattel,  2008).  Following  infection,  the  
wild-type virus genome is integrated into the host genome, but AAV cannot complete its 
replicative  life  cycle  until  a  helper  virus  (e.g.,  adenovirus,  HSV)  has  activated  the  cell.  In  
recombinant AAV vectors, the rep and cap genes have been replaced with the transgene 
(containing promoter, cDNA, and poly-adenylation signal) (Figure 6) (Lim et al., 2010; 
Vannucci et al., 2013). To produce viral vector particles in vitro, the rep and cap genes will 
therefore need to be supplied by co-transfection of a rep- and cap-containing plasmid. In 
addition, the helper function is applied either by co-transduction with a helper virus (e.g., 
adenovirus) or, more commonly today, by co-transfection with plasmids containing the 
helper genes, or using cell lines expressing these genes. 
 
Table 4 The characteristics of viral vectors proposed for use in neurodegenerative disorders (according to 
Lim et al., 2010; Vannucci et al., 2013). 
Viral vector Genome Transgene max. size 
Cell tropism 
in CNS 
Excistence 
in host cell 
Onset/duration 
of expression 
Immuno-
genicity 
       
AAV, 
recombinant ssDNA 2-6kb 
Neurons 
(glia) Episomal 
Days-weeks/ 
Months-years Low 
       
Lentivirus, 
recombinant ssRNA 6-9kb Neurons, glia Integrated 
Week/ 
Months-years Low 
       
Adenovirus, 
wild-type or 
recombinant 
dsDNA  8-30 kb Glia (neurons) Episomal 
Days/ 
Weeks-year High 
       
HSV, 
recombinant 
or amplicon 
dsDNA 40-150kb Neurons Episomal Days/ Weeks-year High 
       
AAV, adeno-associated virus; HSV, herpes simplex virus; ss, single stranded; ds, double stranded 
 
AAV has the ability to transduce both dividing and non-dividing cells, and in the CNS AAV 
vectors  transduce  mainly  neurons,  but  also  glial  cells  (Lim  et  al.,  2010;  Chtarto  et  al.,  
2013b). The specific cell tropism of AAV is determined mainly by the cap genes, since the 
capsid structure mediates the interaction between host cell and viral vector particle, 
including binding to host cell membrane receptor, internalization, and genome delivery 
into the cell nucleus (Chtarto et al., 2013b). By selecting or modifying the rep/cap source 
(serotype) in the production of recombinant AAV particles, the resulting transduction and 
transgene  expression  in  a  certain  cell  type  (e.g.,  neurons  vs.  glial  cells  in  the  CNS),  or  
subpopulation of cells can be altered. This far, AAV serotype 2 has been most extensively 
applied in both clinical and pre-clinical settings. There are, however, indications that other 
serotypes or hybrid serotypes would provide better spread and more efficient transduction 
(Burger  et  al.,  2004;  Asokan  et  al.,  2012).  Selection  of  transgene  promoter  can  further  
affect the tropism and cell-specific expression of the transgene (Chtarto et al., 2013b).  
 
Since the AAV DNA genome consists of single-stranded DNA, production of double-
stranded DNA is required before the transgene expression can start. This makes the AAV 
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vectors somewhat slow and limits their use in certain in vivo applications. The development 
of AAV vectors containing double-stranded (Wang et al., 2003) or self-complementary DNA 
(McCarty  et  al.,  2003)  has  therefore  provided  an  important  improvement  to  the  AAV  
technology, allowing earlier onset of transgene expression following AAV transduction. 
However, a drawback with self-complementary AAV vectors is the lowering of transgene 
capacity by approximately half of the normal.  
 
Figure  6 Production of recombinant AAV vectors. Transfection of cells with a plasmid containing 
necessary rep and cap genes and the recombinant AAV vector plasmid together with a helper plasmid 
renders AAV particles containing the transgene of interest (Lim et al., 2010; Vannucci et al., 2013). 
2.3.2 EX?VIVO?GENE?THERAPY?
In ex vivo gene therapy, genetically modified cells expressing the protein of interest are 
implanted/transplanted into the host CNS. Cells used for this purpose are neural stem cells 
(NSC, from host or embryo), embryonic stem cells (ESC), re-programmed adult fibroblasts, 
or different cell lines that have been modified to ensure survival and continuous 
proliferation by fusion with tumor cells or insertion of transforming agent (Mejia-Toiber et 
al., 2011). The cells are then further modified in vitro to transgene-expressing cells. The 
transgene can be delivered into the cells by non-viral (e.g., with liposomes, plasmids, 
electroporation, “gene gun”) or viral vector methods, and once the transgene expression is 
ensured, the cells can be implanted / transplanted into the host, where they function as 
small protein pumps, delivering the therapeutic agent to the host tissue. 
 
The implanted / transplanted cells can elicit an immune response in the host, resulting in 
rejection  of  the  introduced  cells  (Deierborg  et  al.,  2008;  Mejia-Toiber  et  al.,  2011).  In  
addition, there is a risk for overgrowth of stem cells or immortalized cell lines with 
sequential tumor formation. Both of these concerns can be overcome by encapsulating the 
transplanted cell population with a semi-permeable material, allowing influx of nutrients 
and efflux of the therapeutic protein. The encapsulation has also the advantage of allowing 
retraction of the genetically modified cells in case of any safety concern or when only 
transient delivery of the therapeutic protein is needed. 
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2.3.3 RNA?INTERFERENCE?
In addition to introduction of transgenes into the host cells, the spectra of expressed 
proteins can also be modified by post-transcriptional sequence-specific silencing of genes 
by RNA interference (RNAi). 
 
Initiation of RNA interference happens as double-stranded homologues RNA molecules are 
cleaved by the double-stranded RNA-specific endonuclease Dicer into shorter fragments 
(around  20  nucleotides)  called  small  interfering  RNAs  (siRNA)  (Raoul  et  al.,  2006).  
Alternatively, siRNA can be synthetized by Dicer-mediated cleavage of single-stranded 
short hairpin RNA (shRNA), which in turn can be generated by transcription of a DNA 
template introduced in experimental settings into the host cell by viral or non-viral vector 
methods. After cleavage, the siRNA is unwound into single-stranded RNA and one of the 
strands (guide strand) is incorporated into the RNA-induced silencing complex (RISC) in 
which it functions as an antisense strand guiding the highly specific degradation of an 
mRNA. 
 
Another  way  to  target  mRNAs  is  to  use  specific  antisense  oligonucleotides  (ASO)  (Devos  
and  Miller,  2013).  ASOs  are  short  nucleic  acid  sequences  made  to  complement  a  target  
mRNA.  The  result  is  an  RNA:DNA  complex  that  can  prevent  splicing,  processing,  or  
translation of the targeted mRNA. In addition, ASOs can direct RNA cleavage through the 
action of RNAseH, an enzyme that targets RNA:DNA duplexes and cleaves the RNA strand 
to release the DNA (Devos and Miller, 2013). Delivery of ASOs to the CNS can be done by 
direct infusion into the cerebrospinal fluid (CSF), or, alternatively, packed into vectors for 
delivery. 
2.4 STRATEGIES? USING? GENE? THERAPY? IN?
NEURODEGENERATIVE?DISORDERS?
When examining the potential of gene therapy for the treatment of neurodegenerative 
diseases, three different strategies could be applied (Figure 7): 
 
1) Symptomatic gene therapy. The neurodegenerative diseases described above are 
characterized by vulnerability of specific neuronal populations (nigral DAergic neurons 
in PD, AChergic neurons in AD, striatal GABAergic medium spiny neurons in HD, and 
motoneurons in ALS) (Table 1) (Fahn, 2003; Wenk, 2003; Kiernan et al., 2011; Ross and 
Tabrizi, 2011). The loss of these neurons leads to the loss of specific neurotransmitters 
and decrease in signaling resulting in the symptoms typical to each disorder. To re-
establish the lost signaling, the production or availability of neurotransmitters should 
be increased. This could be done by addition of genes encoding enzymes needed for 
the synthesis of neurotransmitters, or other proteins important for the synaptic 
transmission (e.g., storage, re-uptake). 
 
2) Elimination of pathogenic protein. The four neurodegenerative diseases described are 
all  featured  by  deposition  of  protein  aggregates  (Ross  and  Poirier,  2004).  Even  if  the  
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role of these protein inclusions is not entirely known, they are thought to contribute to 
the pathogenesis. Mutations in the proteins forming the main constituents of the 
inclusions have also a strong connection to familial forms of the diseases (APP, PSEN1, 
PSEN2  in  AD;  ?-syn  in  PD;  HTT  in  HD;  TDP-43,  FUS,  and  SOD1  in  ALS)  (Kiernan  et  al.,  
2011;  Ross  and  Tabrizi,  2011;  Houlden  and  Singleton,  2012;  Bettens  et  al.,  2013).  To  
decrease the formation of inclusions, different approaches can be applied. The 
expression of the mutated protein can be silenced using siRNA. The clearance of the 
protein can be increased by adding metabolic enzymes, or by enhancing the function of 
chaperon-mediated protein refolding, UPS or autophagy-lysosome system. 
 
3) Addition of a therapeutic endogenous or exogenous gene. Of all the substances that 
could be considered to belong to this category (e.g., anti-apoptotic proteins, proteins 
that affect the division, migration or differentiation of neural progenitor cells), the NTFs 
are the most interesting. NTFs have received attention because of their survival-
promoting effects on neurons (Bespalov and Saarma, 2007), but also since dysfunction 
in NTF signaling has been reported in several neurodegenerative disorders (Connor et 
al., 1997; Strand et al., 2007). Gene therapy aiming to replenish NTFs, or increase their 
signaling through addition of specific signaling molecules, might therefore serve as a 
disease-modifying therapy with potential to halt, or even reverse, the degeneration of 
neurons. 
 
Figure  7 Different  approaches  that  can  be  exploited  in  the  search  for  novel  therapies  for  
neurodegenerative diseases. 
2.4.1 SYMPTOMATIC?GENE?THERAPY?
Symptomatic gene therapy aims at improving the clinical status of the patients without 
targeting the underlying pathology. This therapeutic approach is most straightforward in 
the treatment of PD, in which the characteristic motor symptoms originate from loss of DA 
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signaling in the nigrostriatal pathway (see paragraph 2.1.1). In addition, this strategy should 
be feasible in PD, since a relatively small (approximately 10%) increase in striatal DA levels 
is enough to mediate clinical improvement (Pavese et al., 2006). 
  
Parkinson’s disease: targeting the dopamine synthesis 
The  adverse  effects  of  oral  L-DOPA  treatment  in  PD  are  thought  to  be  partly  due  to  the  
continuous fluctuation in the L-DOPA level caused by oral drug administration (Obeso et al., 
2000). This could be improved with continuous supply of L-DOPA or DA, e.g., by addition of 
enzymes required for their synthesis. DA is synthetized from tyrosine by the sequential 
action  of  TH  and  AADC  (Figure  8)  (Elsworth  and  Roth,  1997).  For  effective  conversion  of  
tyrosine to L-DOPA, TH requires the presence of its cofactor tetrahydrobiopterin (BH4). The 
rate-limiting step in the BH4 synthesis is in turn the conversion of guanosin triphosphate 
(GTP) to dihydroneopterin triphosphate by the enzyme GTP cyclohydrolase 1 (GCH1). 
When scrutinizing the DA synthesis pathway (Figure 8), the possible gene therapy 
alternatives  for  enzyme  replacement  in  PD  could  therefore  aim  at  1)  increasing  only  TH  
levels (with or without addition of GCH1), 2) introduction of TH (and GCH1) together with 
AADC, 3) addition of AADC alone (Elsworth and Roth, 1997; Björklund and Kordower, 
2010). 
 
Figure 8 Dopamine (DA) synthesis and metabolism. DA is synthesized by the sequential action of tyrosine 
hydroxylase (TH; in combination with its cofactor tetrahydrobiopterin (BH4)), and L-amino acid 
decarboxylase (AADC). In the presynaptic terminal, DA is transported into storage vesicles by the vesicular 
monoamine transporter (VMAT). After release, DA undergoes re-uptake by the DA transporter (DAT) and 
is either recycled into storage vesicles, or metabolized by monoamine oxidase B (MAO-B). Alternatively, 
DA in the synaptic cleft can be internalized into other neurons or glia by an uptake 2 mechanism and 
undergo subsequent metabolization in these cell (Iversen et al., 2009). COMT, cathecol-O-
methyltransferase; DOPAC, 3,4-dihydroxyphenylacetic acid; GCH, GTP cyclohydrolase; GTP, guanosin 
triphosphate; HVA, homovanillic acid; 3-MT, 3-methoxytyramine. 
 
Tyrosine hydroxylase 
Introduction of human TH in the rat 6-OHDA model of PD using HSV (During et al., 1994) or 
AAV  vectors  (Kaplitt  et  al.,  1994;  Fan  et  al.,  1998)  has  resulted  in  partial,  although  
statistically significant, recovery of rotational asymmetry. Addition of only TH is however 
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generally considered as a rather ineffective treatment alternative due to the ongoing 
degeneration and loss of other enzymes and co-factors required for the DA synthesis 
(Björklund and Kordower, 2010). 
 
Tyrosine hydroxylase and GTP cyclohydrolase 1 
With the progressive degeneration of DA neurons, also the levels of BH4 are reduced, 
leading to a decrease in TH activity (Levine et al., 1981; Björklund et al., 2009; Cederfjäll et 
al., 2012). Indeed, in in vivo studies the production of L-DOPA following viral vector-
mediated TH gene delivery is substantially increased after administration of exogenous BH4 
in 6-OHDA-lesioned rats (Mandel et al., 1998; Corti et al., 1999). The BH4 levels can also be 
continuously increased by introduction of the GCH1 gene. Several studies have shown that 
co-transduction with recombinant AAV-TH and AAV-GCH1 vectors results in marked 
improvement in motor behavior tests, as well as in a reduction of L-DOPA-induced 
dyskinesias in 6-OHDA-lesioned rats (Kirik et al.,  2002a; Carlsson et al.,  2005; Björklund et 
al.,  2010).  Because of  the limited genome size  of  the AAV,  all  of  these studies  have used 
two  AAV  vectors  to  deliver  the  genes  separately.  This  may  affect  the  outcome  since  the  
same cells are not necessarily transduced by both vectors. Recently, Cederfjäll and co-
workers (2012) reported the use of a recombinant pseudotyped AAV2/5 vector containing 
both TH and GCH1 controlled as two different expression cassettes, ensuring the optimal 
TH:GCH1 expression  ratio  of  5:1  (Björklund  et  al.,  2009).  Again,  the  treatment  with  this  
vector  showed  robust  effect  in  the  rat  6-OHDA  model  and  resulted  in  recovery  of  motor  
function as well as increase in striatal DA levels (Cederfjäll et al., 2012). 
 
Tyrosine hydroxylase, GTP cyclohydrolase 1, and aromatic L-amino acid decarboxylase 
The introduction of only TH and GCH1 transgenes relies on further decarboxylation of L-
DOPA  into  DA  in  striatal  serotonergic  and  spared  DAergic  fibers  (Hökfelt  et  al.,  1973;  
Björklund  et  al.,  2010).  In  the  rat  dorsal  striatum,  90%  of  the  AADC  activity  seems  to  
originate from the DAergic terminals and the AADC activity level is substantially reduced in 
6-OHDA-lesioned rats (Cederfjäll et al., 2012). In addition, the effect of TH and GCH1 gene 
therapy  is  greatly  enhanced  in  rats  with  partial  DAergic  lesions,  as  compared  to  more  
complete lesions, indicating that remaining DAergic axons in the striatum provide 
important functions in the synthesis and controlled storage and release of DA (Kirik et al., 
2002a). Enzyme replacement aimed at increasing DA levels should therefore most likely 
also involve introduction of AADC. Indeed, triple transduction of striatal cells using 
recombinant AAV vectors containing AADC, TH, and GCH1 proved to efficiently increase DA 
synthesis and reduced drug-induced rotational asymmetry in 6-OHDA-lesioned rats (Shen 
et al., 2000). When the same treatment was applied in MPTP-treated monkeys, the animals 
showed marked and long-lasting motoric recovery (Muramatsu et al., 2002). 
 
In  the first  studies  of  triple  gene therapy,  the full-length TH was used.  TH is  known to be 
negatively regulated by catecholamines (Fujisawa and Okuno, 2005), and the accumulation 
of  DA  in  the  cytosol  following  co-transduction  of  the  cells  with  TH, GCH1, and AADC can 
cause suppression of the TH activity and decrease in DA synthesis. The negative feedback 
of catecholamines on TH activity is mediated through the N-terminal end of the enzyme, 
and  by  removing  this  fragment,  TH  can  be  rendered  constitutively  active  (Moffat  et  al.,  
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1997). Azzouz and co-workers (2002) designed a LV vector derived from the equine 
infectious  anemia  virus  (EIAV)  that  carried  the  gene  for  the  N-truncated  form  of  TH,  
together with GCH1 and AADC and tested this trisistronic vector in 6-OHDA-lesioned rats. 
The treatment resulted in partial recovery of drug-induced rotational behavior and striatal 
DA  levels.  Following  further  development  of  the  EIAV  vector,  a  similar  therapeutic  
approach  was  tested  in  MPTP-treated  macaques  (Jarraya  et  al.,  2009).  Treatment  of  the  
MPTP-lesioned primates with the modified EIAV-TH-AADC-GCH1 vector significantly 
improved the motor performance and reduced L-DOPA-induced dyskinesia as well as 
normalized the striatal DA levels and restored dysfunctions in the basal ganglia circuitry. 
With these encouraging results, the EIAV vector under the brand name ProSavin® entered 
clinical trials. The results from the phase I/II clinical trial in patients with mid-to-late-stage 
PD have not yet been published, but Oxford Biomedica states in their homepage that the 
treatment has proven to be safe and led to improvement in motor function at six months 
post-injection (Oxford Biomedica, 2013). 
 
Aromatic L-amino acid decarboxylase 
A third strategy to increase the DA levels in PD would be to deliver AADC alone (Björklund 
and Kordower, 2010). This approach aims at replenishing the striatal tissue with AADC to 
improve the conversion of  orally  administered L-DOPA into DA in  the striatum.  Thus,  the 
effect of the treatment is controlled by a peripherally given drug (L-DOPA) that, in case of 
safety considerations, can be removed. When recombinant AAV-AADC vectors were 
injected into the striatum of 6-OHDA-lesioned rats, an increase in striatal AADC activity and 
DA  levels  (after  peripheral  administration  of  L-DOPA)  were  reported  (Leff  et  al.,  1999;  
Sanchez-Pernaute et al., 2001). In addition, the L-DOPA-induced contralateral turning 
behavior was stronger in AAV-AADC-treated rats, also indicating a more efficient 
conversion  of  L-DOPA  into  DA  in  these  rats  (Sanchez-Pernaute  et  al.,  2001).  In  MPTP-
treated  monkeys  AAV-AADC  treatment  resulted  in  a  normalization  of  AADC  activity,  
measured as striatal uptake of 6-[18F]fluoro-L-m-tyrosine ([18F]FMT) detected with positron 
emission tomography (PET), and increase in striatal DA levels following administration of L-
DOPA (Bankiewicz  et  al.,  2000).  Some of  the monkeys  in  this  study have been monitored 
for up to eight years, showing consistent normalization in striatal [18F]FMT uptake and 
improvement in a Clinical Rating Scale after administration of L-DOPA (Bankiewicz et al., 
2006; Hadaczek et al., 2010). 
 
To this date, one phase I study of AAV-AADC treatment in ten PD patients has been 
completed. The first reports from the clinical trial showed an increase in the striatal 
[18F]FMT uptake and improvement in the Unified Parkinson’s Disease Rating Scale (UPDRS) 
in both “on” and “off” medication stages up to 6 months post-operation (Eberling et al., 
2008; Christine et al., 2009). In addition, the treatment was associated with a reduction in 
the “off” time, while the “on” time was correspondingly increased. In a follow-up study of 
the patients,  the uptake of  [18F]FMT was shown to remain elevated for up to four years, 
while  the  UPDRS  scores,  after  the  first  12  months  of  improvement,  showed  slow  
deterioration during the following three years (Mittermeyer et al., 2012). The authors 
concluded that the initial dramatic improvement in UPDRS scores could partly be due to a 
placebo effect which should be controlled in following studies. Moreover, they suggested 
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that the transduced area of the human striatum was too limited, and state that this issue 
will be addressed in a follow-up phase I clinical trial (Mittermeyer et al., 2012). 
 
Parkinson’s disease: modulating basal ganglia signaling with glutamic acid 
decarboxylase 
As described in paragraph 2.1.1 (Figure 1), loss of DA neurons in PD results in dysregulation 
of the basal ganglia circuitry. In addition to the DA replacement therapy presented above, 
the dysfunction in the basal ganglia could be targeted by alternative strategies (Björklund 
and Kordower, 2010). One such approach is the delivery of the gene for glutamic acid 
decarboxylase (GAD) into the STN of PD patients. This treatment aims at increasing GABA 
production and thereby suppressing the STN activity with subsequent improvement in 
clinical symptoms. 
 
Luo et al. (2002) showed that transduction of the excitatory glutamatergic neurons in the 
STN with a recombinant AAV-GAD vector resulted in inhibitory signaling and GABA release 
in the SNpr in rats. When the treatment was tested in 6-OHDA-lesioned rats, the 
overexpression of GAD was able to normalize motor abnormalities and partially protected 
DAergic neurons in the midbrain. When the same treatment was applied in unilaterally 
MPTP-lesioned macaques, improvements (although rather small) in the Clinical Rating Scale 
and increased activity in the ipsilateral motor cortex were observed (Emborg et al., 2007). 
The treatment also seemed to be safe, and on the basis of these results, 12 PD patients 
were enrolled in an open-label phase I clinical trial (Kaplitt et al., 2007). 
 
In the clinical trial the PD patients received unilateral injections of three different doses of 
AAV-GAD into the STN (Kaplitt et al., 2007). Three months post-injection, the patients 
showed significant improvement in both “on” and “off” medication UPDRS motor scores, 
with more substantial benefits in the limbs on the contralateral side. The metabolic activity 
detected with [¹?F]fluorodeoxyglucose ([¹?F]FDG) PET was decreased in the ipsilateral STN, 
while  an  increase  in  activity  was  observed  in  the  motor  cortex  (Kaplitt  et  al.,  2007).  The  
study of AAV-GAD continued as a phase II double-blind, sham surgery-controlled, 
randomized trial (LeWitt et al., 2011). The published results from this study cover the first 
six months post-operation, and show significant improvement in UPDRS “off” medication 
scores in AAV-GAD-treated patients, as compared to patients that underwent sham 
surgery. No serious adverse events that would have been attributed to the AAV-GAD 
treatment  were observed in  either  of  the clinical  trials  (Kaplitt  et  al.,  2007;  LeWitt  et  al.,  
2011). 
 
Alzheimer’s disease: targeting acetylcholine synthesis and metabolism 
In Alzheimer’s disease, dysfunction and degeneration of especially AChergic networks are 
thought to be the primary cause of the cognitive symptoms seen in the disease. In addition 
to targeting the ACh signaling using small molecular AChE inhibitors, the level of ACh can 
also be affected with gene therapy strategies. 
 
One strategy to increase the level of ACh would be to down-regulate the expression of 
AChE.  This  approach  was  used  by  Fu  and  co-workers  (Fu  et  al.,  2005),  who  injected  
  Review of the literature 
 
27 
 
liposomes carrying an AChE-ASO  i.c.v.  in  wild-type  and  AD  mice  (i.c.v.  injection  of  A? 11  
days  prior  to  treatment).  The  ASO  caused  a  decrease  in  cortical  AChE  activity  with  a  
corresponding increase in ACh levels. In AD mice, the AChE-ASO was able to normalize A?-
induced memory impairment. The observation time in the study was short, and it is unclear 
whether these effects would be maintained during longer periods of time. 
 
The level of ACh can also be raised by increasing the synthesis, e.g., by supplying the tissue 
with choline acetyl transferase (ChAT). To achieve this, Park and co-workers (Park et al., 
2012a; Park et al., 2012b) used ex vivo gene therapy and transferred an NSC line over-
expressing ChAT by i.c.v. injections in two different rat models of AD (kainic acid and AF64A 
models). Following injection, the NSCs were found to be diffusely distributed in different 
brain regions (hippocampus, thalamus, hypothalamus, cortex and septum) and nine weeks 
post-injection, differentiation of these NCSs into astrocytes and neurons was observed 
(Park et al., 2012b). In both models, the treatment with ChAT-expressing cells resulted in 
restoration of ACh levels in the cerebrospinal fluid and normalization of learning and 
memory functions in the rats (Park et al., 2012a; Park et al., 2012b). Gene therapy aiming at 
modulating the ACh levels have not yet been tested clinically. 
2.4.2 ELIMINATION?OF?PATHOGENIC?PROTEIN?
The idea that misfolded abnormal proteins would be a trigger of pathogenesis in 
neurodegenerative diseases would suggest that by removing these pathogenic proteins, 
neuroprotection could be achieved (for overview of aggregates typical to each disease, see 
Figure 9). The elimination or reduction of abnormal proteins can be done either by 
silencing the expression or by increasing the clearance of the proteins (San Sebastian et al., 
2013). 
 
 
Figure 9 Protein aggregation in late-onset neurodegenerative diseases. 
 
Silencing of pathogenic protein 
RNAi, the targeting of an mRNA for degradation with siRNAs or ASOs, can be used to 
silence the expression of specific proteins. The use of these techniques in 
neurodegenerative diseases has been most widely exploited in HD. 
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Silencing of huntingtin 
Several rodent studies show that silencing of HTT with  siRNAs  delivered  to  the  striatum  
with AAV vectors (Boudreau et al., 2009) or as cholesterol conjugates (DiFiglia et al., 2007) 
has a beneficial effect on both neuropathology and motor dysfunction in mouse models of 
HD. These studies used siRNAs for nonallele-specific silencing of HTT, affecting both wild-
type and mutated protein. Since wild-type HTT is thought to execute important functions in 
the  normal  brain,  it  would  be  beneficial  to  avoid  any  excessive  decrease  in  the  levels  of  
wild-type HTT. This can be achieved with siRNAs targeting specifically the mutated allele 
(Hu et al., 2009; Pfister et al., 2009). However, McBirde et al. (McBride et al., 2011) did not 
observe  any  toxicity  after  nonallele-specific  reduction  of  HTT  by  45%  in  the  striatum  of  
intact rhesus macaques. Also, infusion of ASOs designed to target human HTT were tested 
in three different transgenic mouse models of HD (Kordasiewicz et al., 2012). I.c.v. infusion 
of HTT-ASOs into these mice resulted in suppression of HTT levels accompanied with 
marked changes in the pathologic phenotype, including delayed disease progression, 
behavioral improvement, and an increased lifespan. Kordasiewicz and co-workers (2012) 
continued their work by infusing an ASO complementary to both human and rhesus 
monkey HTT into the CSF of rhesus macaques, showing widespread reduction in HTT levels 
in the brain, with highest levels of suppression in the cortex and spinal cord. 
 
Silencing of ?-synuclein 
There  are  a  few  reports  on  suppression  of  ?-syn  levels  using  RNAi  in  PD  animal  models.  
Sapru and collegues (Sapru et al., 2006) showed that LV-mediated delivery of an shRNA 
specific for human ?-syn was able to markedly reduce the levels of ?-syn in rats with LV-
induced striatal overexpression of ?-syn. In another study, the silencing of human ?-syn 
was tested in rats displaying motor dysfunctions and DAergic cell loss due to an intranigral 
injection of AAV-?-syn (Khodr et al., 2011). Although the silencing of human ?-syn in these 
rats resulted in normalization of forelimb use, no protection of the nigral DAergic neurons 
was observed. In fact, the AAV-mediated delivery of shRNA specific for human ?-syn to the 
nigra of healthy rats turned out to cause neuronal cell loss in the SNpc. Also injection of the 
control vectors caused reduction in TH-reactivity, although to a lesser extent than ?-syn-
shRNA vectors.  The authors speculate that the toxic effects of their shRNA could be caused 
by unspecific silencing of rat ?-syn or  be  a  result  of  toxic  shRNA  effects  caused  by  
saturation of  the RNAi  processing in  the cell  (Khodr  et  al.,  2011).  Also Gorbatyuk and co-
workers (2010) reported nigrostriatal neurodegeneration following silencing of rat 
endogenous ?-syn. However, they found that the neurotoxicity of AAV-delivered shRNA 
was attributed to ?-syn suppression, since none of the control vectors used in their study 
showed signs of neuronal cell loss. However, in a study in healthy squirrel monkeys, siRNA 
specific for ?-syn was continuously infused into the SN showing a significant reduction of ?-
syn  levels  with  no  signs  of  toxicity  (McCormack  et  al.,  2010).  These  controversial  results  
clearly point out the problems with silencing of the expression of proteins potentially 
important to the cells. We still do not know how big reduction in the normal protein 
expression can be tolerated in long-term, and using gene silencing as a therapeutic 
approach will still need to be thoroughly examined before the potential of this treatment 
alternative can be evaluated. 
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Silencing of SOD1 
The expression of SOD1 has been suppressed both in vivo and clinically in ALS patients. In 
SOD1 transgenic mice, both intramuscular (i.m.) (Ralph et al., 2005) and intraspinal (Raoul 
et al., 2005) injections of LV-shRNA vectors, mediating silencing of human SOD1, were 
shown to delay the onset of disease, improve motor function and motoneuron survival, 
and prolonged the lifespan of the mice. Infusion of an SOD1-ASO into the CSF of transgenic 
rats resulted in wide distribution of the ASO and suppression of the levels of human SOD1 
in  the  rats  (Smith  et  al.,  2006).  Furthermore,  the  treatment  was  associated  with  
significantly slower disease progression and pro-longed survival. Recently, a report of the 
first clinical trial using SOD1-ASO in SOD1 familial ALS patients was published (Miller et al., 
2013). This phase I randomized placebo-controlled trial was assigned to assess the safety of 
intrathecal infusions of the SOD1-ASO. The ASO was infused during 11.5 h, and the patients 
were followed up to 28 days post-infusion. The treatment was proven to be safe with some 
mild to moderate adverse events that were attributed to the infusion method and not to 
the treatment itself. The patients were also evaluated using an ALS functional rating scale, 
but SOD1-ASO treatment showed no clear benefit over placebo. When writing this text, no 
follow-up study has been announced. 
 
Targeting the clearance of pathogenic protein 
The clearance of pathogenic proteins can be targeted, e.g., by enhancing the protein-
specific metabolism, through the UPS or autophagy, or by immunization. This strategy to 
lower the levels of pathogenic protein has rendered special interest for the treatment of 
AD,  since  aggregation  of  A? in  sporadic  AD  is  thought  to  be  due  to  a  decrease  in  its  
clearance, and not an increase in production. 
 
Targeting protein metabolism 
The best example of increasing the expression or activity of metabolic enzymes to enhance 
the  clearance  of  pathogenic  protein  comes  from  AD  research.  As  already  mentioned,  A? 
can be enzymatically degraded by, e.g., neprilysin. Using transgenic mouse models 
expressing human mutated APP, injections of LV (Marr et al., 2003; Spencer et al., 2008) or 
AAV vectors (Iwata et al., 2004) encoding human neprilysin have been done into the frontal 
cortex and/or hippocampus. In these studies, overexpression of neprilysin has significantly 
reduced  the  levels  of  A? (Marr  et  al.,  2003;  Iwata  et  al.,  2004;  Spencer  et  al.,  2008)  and  
improved  the  performance  in  cognitive  tasks  (Spencer  et  al.,  2008).  Similar  results  have  
also been obtained with AAV-neprilysin treatment in APP + PSEN1 double-mutant mice 
(Carty  et  al.,  2013)  and  with  ex vivo gene therapy exploring the transplantation of 
neprilysin-expressing fibroblasts into the hippocampus of APP mice (Hemming et al., 2007). 
 
Following unilateral i.c. delivery of neprilysin, a reduction of A? levels was also observed in 
the contralateral side (Iwata et al., 2004; Carty et al., 2013). In addition, peripheral (into the 
hind limb) delivery of AAV-neprilysin to transgenic mice expressing mutant human APP, 
PSEN1 and tau, reduced the levels of soluble A? and plaque load in the mouse brain (Liu et 
al., 2009). The same results were also achieved with intravenous (i.v.) transplantation of 
neprilysin-expressing leukocytes (Guan et al., 2009). Looking from a clinical perspective, the 
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peripheral route of administration has many advantages and further studies will show if 
this therapeutic alternative would be feasible in reducing the plaque load in AD patients. 
 
Enhancing the ubiquitin-proteasome system and autophagy 
Cells have mainly two different defense lines to cope with misfolded proteins: the UPS and 
autophagy-lysosome system (Ebrahimi-Fakhari et al., 2012). The degradation of soluble 
intracellular misfolded proteins is handled by the UPS and proceeds by several sequential 
steps. First, chains of small globular proteins, chaperons, are bound to the misfolded 
protein by the action of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes 
(E2) and ubiquitin ligases (E3). The chaperon chain targets the protein for degradation by 
the proteasome, which cleaves the proteins into smaller peptides that can further be 
degraded into amino acids by intracellular peptidases. The autophagy-lysosome system 
degrades cellular components in three different ways. 1) Expression of autophagy-related 
genes can induce de novo synthesis of double membrane vesicles that sequester part of the 
cytosol (macroautophagy). This autophagosome has no proteolytic activity, but needs to 
fuse with a lysosome before degradation of the sequestered material can take place. 2) 
Proteins can also be targeted for degradation in lysosomes by a ubiquitin-mediated 
pathway, or 3) simply by a process in which the lysosome ‘swallows’ the cytosol close to its 
surface by invagination of the its membrane. All of these autophagic pathways are 
constitutively active in the cells, but they can be further enhanced in situations of cellular 
stress. 
 
The strategy to enhance protein degradation could be applied in all diseases with 
pathogenic protein misfolding and aggregation. In addition, dysfunction in the UPS has 
been implicated in neurodegenerative diseases, further supporting this approach as a 
therapeutic possibility. One way of enhancing the UPS and chaperon-mediated refolding of 
abnormal proteins would be to up-regulate the expression or activity of chaperons. Dong et 
al. (2005) induced expression of the chaperon heat shock protein 70 (Hsp70) with an AAV 
vector five weeks before the mice were treated with MPTP. Nigral overexpression of Hsp70 
turned out to protect the DAergic cells from MPTP-induced toxicity and restored the DA 
levels in the striatum. However, in transgenic Hsp70-overexpressing mice there was no 
observed neuroprotection against MPTP (Gao et al., 2011), making this approach 
controversial. In addition, the enhancement of chaperon-mediated refolding and UPS may 
be  a  poor  strategy  to  control  proteins  that  are  prone  to  aggregate.  Instead,  autophagy  
could be targeted by, e.g., expression or activation of autophagy-inducing pathways. 
Recently, the link between aggregation of ?-syn and glucocerebrosidase (GBA) activity has 
received attention (Dehay et al.,  2013). GBA activity is linked to lysosomal function, and a 
decrease in the enzyme activity seems to promote aggregation of ?-syn. Aggregation of ?-
syn  is  in  turn  thought  to  interfere  with  the  transport  of  GBA  from  ER  to  the  lysosomes,  
leading to a further decrease in lysosomal GBA activity still excacerbating ?-syn aggregation 
and neurotoxicity. There is a reduction in GBA activity in the SN of PD patients (Gegg et al., 
2012) and mutations in the GBA gene have been linked to PD (Sidransky et al., 2009). One 
possible therapeutic approach could therefore be to increase the GBA activity by applying 
the enzyme using gene therapy. Indeed, delivery of the GBA gene with an AAV vector 
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reduced the levels of soluble ?-syn in the A53T ?-syn transgenic mouse (Sardi et al., 2013) 
suggesting therapeutic potential for this strategy.  
 
Immunization against pathogenic protein 
Proteins can be targeted for destruction by the immune system by immunization against 
the protein in question. Using gene therapy, transduced cells can be forced to continuously 
produce protein-specific antibodies, and this approach has been applied in AD research. 
AAV-mediated i.c.v. delivery of an anti-A? single-chain variable fragment (scFv) into 
neonatal APP transgenic mice resulted in reduced A? levels and plaque load (Levites et al., 
2006). Also intrahippocampal injection of an AAV-A?-scFv into three month old transgenic 
AD  mice  led  to  a  decrease  in  the  levels  of  insoluble  A? and  was  accompanied  by  
improvement in cognitive function (Ryan et al., 2010). Furthermore, in a recent study also 
i.m. injection of an AAV encoding a monoclonal anti-A? antibody was shown to reduce the 
amount of A? as well as number and size of plaques in APP transgenic mice (Shimada et al., 
2013). 
 
Vector-mediated delivery of antibodies or antibody fragments offers several advantages as 
compared to more conventional methods. A clinical trial of active immunization, in which 
AD patients were treated with aggregated A? peptides in combination with an adjuvant, 
was stopped when part of the patients developed meningoencephalitis (Orgogozo et al., 
2003). Passive immunization by infusion of monoclonal anti-A? antibodies can be a safer 
alternative, but requires repeated infusions of the antibody. Here, gene therapy is clearly 
beneficial in providing long-term and wide-spread expression of the antibody. 
 
Since related to the neuronal defense system, it could also be mentioned that gene therapy 
with anti-inflammatory cytokines (IL-4 or IL-10) delivered with AAV vectors into the 
hippocampus has been shown to be beneficial in APP + PSEN1 double-mutant mice (Kiyota 
et  al.,  2010;  Kiyota  et  al.,  2012).  When  treated  with  these  vectors,  the  mice  show  
significant reduction in A? levels and neuroinflammation, together with enhanced 
neurogenesis and improvement in cognitive functions. 
2.4.3 ADDITION?OF?THERAPEUTIC?GENE?
NTFs are important for the survival and maintenance of neurons and synapses (Bespalov 
and Saarma, 2007; Lindholm and Saarma, 2010). In the developing nervous system they 
control the number of neurons, and regulate migration, differentiation, and neurite 
outgrowth. They also promote neuronal survival, as well as regulate plasticity and 
regeneration of mature neurons. Strategies that aim to supply target areas with 
endogenous NTFs, or NTF mimetics, are therefore considered to be of importance in the 
search for disease-modifying therapies in neurodegenerative diseases. Several of the 
traditional NTFs have indeed been extensively studied in pre-clinical settings of 
neurodegenerative disorders, and some have even entered clinical trials (for summary of 
clinical trials with NTFs, see Table 5). 
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Table 5. Clinical trials with neurotrophic factors in neurodegenerative diseases. 
NTF Disease Administration Status Results; number of patients Reference/ 
Company 
NGF AD 
Infusion,  
i.c.v. Completed 
Increase in nicotine binding, 
no cognitive improvement, 
adverse effects; n=3. 
Eriksdotter-
Jönhagen et al., 
1998 
Ex vivo,  
basal forebrain Completed 
Decrease in cognitive decline 
rate, increase in cortical FDG 
uptake, treatment safe; n=8 
Tuszynski et al., 
2005 
Ex vivo,  
basal forebrain Completed 
Cognitive improvement and 
increase in nicotine binding in 
subset of patients, treatment 
safe and well tolerated; n=6 
Eriksdotter-
Jönhagen et al., 
2012 
AAV2,  
basal forebrain Ongoing 
Phase I: completed but no 
results published; n=10 
Phase II: ongoing; n~50 
Ceregen Inc., San 
Diego, USA 
 
BDNF 
 
ALS 
Infusion, 
 s.c. Completed 
Phase I/II: slower decline in 
respiratory function and 
walking speed; n=283 
Phase III: positive results not 
repeated, increase in survival 
in subset of patients; n=1135. 
Bradley, 1995 
The BDNF Study 
Group, 1999 
Infusion, 
intrathecal 
Completed 
 
No clinical benefits, dose-
related adverse effects, n=25 
Ochs et al., 2000; 
Beck et al., 2005 
GDNF PD 
Infusion,  
i.c.v. Completed 
PhaseI/II: No clinical benefits, 
adverse effects; n=50 Nutt et al., 2003 
Infusion, 
putamen Completed 
Phase I: treatment safe, 
clinical improvement and 
increased FDOPA uptake; n=5 
Phase I/II: No clinical benefits, 
antibodies detected; n=34 
Gill et al., 2003; 
Lang et al., 2006 
AAV2,  
putamen Ongoing No results published; n~100 
NINDS, 
Bethesda, USA 
NTN PD 
AAV2, 
putamen Completed 
Phase I: treatment safe, some 
clinical improvement, n=12 
Phase II: small improvement 
only in secondary 
measurements, limited 
distribution of NTN; n=58 
Marks et al., 
2008, 2010; 
Huddleston et 
al., 2011 
AAV2,  
putamen and SN Ongoing No results published; n~60 Ceregen Inc. 
CNTF 
HD Ex vivo, i.c.v. Completed 
Phase I: safe, no clinical 
benefits; n=6 Bloch et al., 2004 
ALS 
Infusion, 
s.c. Completed 
Phase II/III: no clinical 
benefits, adverse effects 
(cough, anorexia, asthenia); 
n=730 
ALS CNTF 
Treatment Study 
Group, 1996 
Ex vivo, 
intrathecal Completed Phase I: treatment safe; n=6 
Aebischer et al., 
1996 
IGF-1 ALS Infusion,  s.c. Completed 
Phase III: three studies with 
variable results, generally no 
significant clinical benefit; 
n=266/183/330 
Lai et al., 1997; 
Borasio et al., 
1998; Sorenson 
et al., 2008 
VEGF ALS Infusion, i.c.v. Ongoing No results published; n=18 
NeuroNova, 
Stockholm, 
Sweden 
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AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; BDNF, brain-derived neurotrophic factor; 
CNTF, ciliary neurotrophic factor; FDG, fluorodeoxyglucose; GDNF, glial cell line-derived neurotrophic 
factor; i.c.v., intracerebroventricular; IGF-1, insulin-like growth factor-1; NGF, nerve growth factor; NINDS, 
National Institute of Neurological Disorders and Stroke; NTF, neurotrophic factor; NTN, neurturin; s.c., 
subcutaneous; SN, substantia nigra; VEGF, vascular endothelial growth factor. 
 
Neurotrophic factor families  
The classical NTFs can be divided into three families: neurotrophins, GDNF family ligands 
(GFL), and neurokines (Bespalov and Saarma, 2007). These proteins provide survival signals 
through receptor tyrosine kinases or via other intracellular kinases that interact with the 
NTF  receptor  (Bespalov  and  Saarma,  2007).  In  addition,  CDNF  and  MANF  have  been  
suggested to constitute a novel evolutionary conserved family of NTFs based on their NTF-
like properties (secretion, neuroprotection, neurorestoration, neurodevelopmental effect) 
(Lindholm and Saarma, 2010).  
 
The first studies on NTFs were done on the neurotrophin nerve growth factor (NGF). 
According to the classical NTF hypothesis postulated by Rita Levi-Montalcini and co-
workers, small amounts of NTFs are secreted from the target tissue of developing neural 
processes (Levi-Montalcini, 1987). Only a few of the neurons trying to innervate the target 
tissue will receive the NTF support needed for further outgrowth and establishment of 
synapses. Neurons that are devoid of the NTF signal will fail to form connections and are 
destined to undergo apoptosis. Even though still valid, this theory has later been proven to 
be a truth with modifications as additional functions and secretion patterns for the NTFs 
have been revealed.  
 
Neurotrophins 
The neurotrophins, NGF, BDNF, neurotrophin 3 (NT3) and neurotrophin 4 (NT4), are 
synthesized as pro-forms, which are processed intra- or extracellularly into mature proteins 
(Park and Poo, 2013). The mature neurotrophins bind to their specific tropomyosin-related 
tyrosine kinase receptor: NGF to TrkA, BDNF and NT4 to TrkB, and NT3 to TrkC. The binding 
of the homodimeric ligand initiates homodimerisation of two tyrosine kinase receptors, 
mediating trans-phosphorylation of intracellular tyrosine residues with subsequent 
activation of signal cascades resulting in neuronal differentiation, survival, and gene 
expression. In addition, all neurotrophins (both pro-forms and mature protein) have affinity 
to p75NTR, a member of the tumor necrosis factor (TNF) receptor superfamily. While p75 
assists in the binding of neurotrophins to the respective tyrosine kinase receptor, binding 
of the pro-neurotrophins and subsequent activation of p75 can mediate cell death. 
 
In accordance with the classical NTF hypothesis, NGF is produced and secreted by the 
target tissue of sympathetic and sensory neurons, and thereby stimulate the survival and 
maintenance of these neurons. In the brain, NGF is expressed in the cortex and 
hippocampus where it seems to be important for the maintenance and survival of, e.g., the 
basal forebrain cholinergic cells and projections (Hefti, 1986; Fischer et al., 1987; Koliatsos 
et al., 1990; Tuszynski et al., 1990). NGF has therefore been suggested to have therapeutic 
potential in AD. In a small clinical study, NGF was infused i.c.v. in three AD patients (Table 
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5) (Eriksdotter-Jönhagen et al., 1998). Although the patients showed an increase in 
[11C]nicotine binding in several brain areas together with a reduction of slow-wave cortical 
activity, no clear cognitive improvements were observed. The NGF treatment was 
associated with weight loss and back pain, and the trial was stopped. 
 
BDNF signaling is important for many neuron subpopulations and neuronal circuits, 
including sensory neurons, retinal ganglia, some cholinergic and DAergic neurons, and 
spinal motor neurons. BDNF can be secreted both in constitutive and regulated manners, 
and the production of BDNF in neurons is affected by neuronal activity and plays an 
important role in synaptic transmission, plasticity and growth (Nagahara et al., 2009; 
Nagahara and Tuszynski, 2011; Park and Poo, 2013). As showed in Figure 4, reduced levels 
and dysfunctional axonal transport of BDNF are thought to partly mediate the vulnerability 
and  damage  of  striatal  GABAergic  medium  spiny  neurons  in  HD  (Gauthier  et  al.,  2004;  
Strand  et  al.,  2007).  Reduced  levels  of  BDNF  have  also  been  reported  in  the  AD  brain  
(Connor  et  al.,  1997),  and  this  loss  can  experimentally  be  triggered  with  A?42  oligomers  
(Garzon and Fahnestock, 2007). In addition, the density of neurotrophin receptors in 
cholinergic neurons is reduced in the basal forebrain in AD. Due to its broad effects on 
different neuron populations, BDNF has been applied with various results in animal models 
of  PD,  AD,  HD,  and  ALS  (reviewed  by  Nagahara  and  Tuszynski,  2011),  as  well  as  tested  
clinically in ALS (Table 5) (The BDNF Study Group, 1999; Ochs et al., 2000; Beck et al., 2005).  
 
GDNF family ligands 
The GFLs belong to the transforming growth factor-? (TGF-?) superfamily that consists of 
four members: GDNF, neurturin (NTN), artemin, and persephin (Airaksinen and Saarma, 
2002; Bespalov and Saarma, 2007). They are all synthesized as precursor proteins, and 
undergo post-translational glycosylation and N-terminal cleavage to render active proteins. 
The GFLs signal through the receptor tyrosine kinase Ret, a receptor that requires 
association with a glycosylphosphatidyl inositol (GPI)-anchored receptor complex called 
GDNF family receptor ? (GFR?) before activation. There are four known GFR?s, and each of 
them  binds  preferentially  one  of  the  GFLs:  GDNF  to  GFR?1,  NTN  to  GFR?2,  artemin  to  
GFR?3, and persephin to GFR?4. The order in which the GFL-GFR?-Ret complex is 
assembled is still not completely understood, but the end product is thought to consist of a 
GFL homodimer bound to two GFR? molecules that bring two Ret molecules together 
causing transphosphorylation of tyrosine residues in the intracellular Ret tyrosine kinase 
domain. The tyrosine kinase activity can in turn activate multiple intracellular signaling 
cascades, including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-
kinase (PI3K) pathways, mediating survival and growth. 
 
GDNF has neurotrophic effect on a large variety of neurons, including, e.g., spinal and 
central motor neurons, and sympathetic, parasympathetic and enteric sensory neurons 
(reviewed by Airaksinen and Saarma, 2002). However, it is the strong survival-promoting 
effect of GDNF on DAergic neurons (Lin et al., 1993; Pascual et al., 2008) that has received 
most attention and led to numerous studies in animal models to elucidate its potential as a 
therapeutic agent for the treatment of PD. In a short summary, infusions of GDNF protein 
into the SN or striatum of 6-OHDA-lesioned rats have mediated neuroprotection, and in 
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some cases even neurorestoration, of the midbrain DAergic neurons (Hoffer et al., 1994; 
Kearns and Gash, 1995; Sauer et al., 1995; Kearns et al., 1997; Aoi et al., 2000; Kirik et al., 
2000a;  Kirik  et  al.,  2001).  The effect  of  GDNF depends on the infusion site  of  both GDNF 
and 6-OHDA, and the most impressive neuroprotection has been achieved in studies where 
GDNF and 6-OHDA have been injected into the same site (striatum) with only a short time 
interval between the injections (Sauer et al., 1995; Kearns et al., 1997; Kirik et al., 2000a). 
In addition to rodent PD models, in vivo studies of GDNF injections in non-human primates 
have also rendered promising results. In MPTP-treated monkeys, a clear improvement in 
motor function was observed after i.c.v., intranigral or intraputaminal GDNF delivery, and 
the improvement could be sustained by repeated injections of GDNF (Gash et al., 1996; 
Zhang et al., 1997; Grondin et al., 2002).  
 
The promising results from pre-clinical in vivo studies paved the way for clinical trials of 
GDNF protein delivery in PD patients (Table 5). A phase I trial of intraputaminal delivery of 
GDNF yielded positive behavioral results in PD patients (Gill et al., 2003; Patel et al., 2005), 
but these results were not replicated in the following phase I/II study (Lang et al., 2006). In 
addition, some patients developed antibodies against GDNF, and this, together with the 
failure  of  the  clinical  trials  to  show  sustained  improvement  in  the  patients,  led  to  
discontinuation of the trials. 
 
Also NTN supports the survival of midbrain DA neurons both in vitro and in vivo. Studies of 
intracerebral  infusions  of  NTN  in  rodents  (Horger  et  al.,  1998;  Akerud  et  al.,  1999;  
Rosenblad et al., 1999; Oiwa et al., 2002; Li et al., 2003) and non-human primates (Li et al., 
2003) have showed NTN-mediated protection of DAergic neurons in experimental PD 
models. Even though the protective effect of NTN on the DAergic neurons in the SN has 
been suggested to be similar to that of GDNF (Horger et al., 1998), unlike GDNF, neurturin 
does not seem to have the capability to induce axonal growth and hypertrophy (Akerud et 
al., 1999). 
 
Neuropoietic cytokines 
The cytokine family of NTFs includes ciliary neurotrophic factor (CNTF), leukemia inhibitory 
factor (LIF), and interleukin 6 (IL-6) (Ip and Yancopoulos, 1996; Gould and Oppenheim, 
2011). They bind to heterodimeric receptor complexes consisting of the tyrosine kinase LIF 
receptor-? (LIFR-?) and glycoprotein130 (gp130), and through the janus kinase/signal 
transducer and activator of transcription-3 (JAK/STAT) and PI-3K pathways they activate 
different intracellular signaling cascades. Of the neurokines, CNTF is the most interesting 
member from the neurodegeneration point of view and the first NTF to enter clinical trials 
in HD (summarized below) (Bachoud-Levi et al.,  2000; Bloch et al.,  2004). CNTF promotes 
survival and regulate transmission of a broad range of neuronal populations in both the 
peripheral and central nervous system, including GABAergic neurons in the basal forebrain 
as a four-day infusion of CNTF into the striatum of rats prevented QA-induced loss of 
striatal neurons (Anderson et al., 1996). In addition, CNTF’s trophic effect on motor 
neurons has also been of special interest in the ALS research (reviewed by Gould and 
Oppenheim, 2011). 
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CDNF/MANF family 
MANF and CDNF constitute a protein family with characteristics that differ from the 
traditional NTFs (Lindholm et al., 2007; Lindholm and Saarma, 2010). The MANF and CDNF 
proteins consist of two structural domains: an N-terminal saposin-like domain and an 
unstructured C-terminal domain containing a cysteine bridge (Mizobuchi et al., 2007; 
Parkash et al., 2009). According to their structure, it is hypothesized that MANF and CDNF 
could exert their action, e.g., by interacting with lipids (N-terminal domain), and/or by 
influencing protein folding during endoplasmic reticulum (ER) stress (Lindholm and Saarma, 
2010). Indeed, several studies have provided evidence for the function of MANF in ER 
stress and the unfolded protein response. Endogenous MANF is localized to ER and the 
expression of MANF is up-regulated in response to both cardiac and cerebral ischemia as 
well as ER stress (Mizobuchi et al., 2007; Apostolou et al., 2008; Tadimalla et al., 2008; Shen 
et al., 2012; Henderson et al., 2013). Furthermore, MANF deprivation seems to sensitize 
cells to ischemia- and ER stress-induced cell death (Apostolou et al., 2008; Tadimalla et al., 
2008). In line with this, addition of MANF promotes recovery and decreases tissue damage 
in  models  of  myocardial  infarction  and  ischemic  brain  injury  (Tadimalla  et  al.,  2008;  
Airavaara  et  al.,  2009;  Airavaara  et  al.,  2010;  Glembotski  et  al.,  2012).  In  a  recent  
publication, also CDNF was implied in the ER stress response since astrocytes over-
expressing CDNF were less sensitive to ER stress-induced cell damage and showed 
decreased expression and secretion of pro-inflammatory cytokines (Cheng et al., 2013). 
 
In addition to its intracellular actions, MANF is also secreted and its secretion is highly 
responsive to ER stress in several cell lines (Apostolou et al., 2008; Tadimalla et al., 2008; 
Glembotski  et  al.,  2012;  Henderson  et  al.,  2013).  Both  the  secretion  and  localization  of  
MANF to the ER seems to be dependent on the four amino acid (RTDL) C-terminal end, and 
there are indications that the RTDL sequence also may mediate cell surface binding after 
secretion  (Glembotski  et  al.,  2012;  Oh-Hashi  et  al.,  2012;  Henderson  et  al.,  2013).  How  
secreted or extracellularly applied MANF can affect target cells is, however, still not known, 
and no receptors or receptor-specific signaling pathways activated by MANF or CDNF have 
yet been clarified. 
 
Both MANF and CDNF show wide expression in both central and peripheral tissue 
(Lindholm  et  al.,  2007;  Lindholm  et  al.,  2008).  The  first  indication  that  the  MANF/CDNF  
family could serve as trophic factors for DAergic neurons came from a study showing that 
MANF mediates survival of DAergic neurons in vitro (Petrova  et  al.,  2003).  Later,  the  
invertebrate analog to MANF was suggested to be essential for the development of 
Drosophila flies, with important functions for both the development and maintenance of 
DA neurites  (Palgi  et  al.,  2009).  Importantly,  human full-length MANF was able  to  rescue 
the DmMANF knockout phenotype, providing evidence for evolutionary conserved 
functions for the MANF protein (Palgi et al., 2009; Lindström et al., 2013). Also knockdown 
of manf in the zebrafish resulted in decrease in DA levels and TH expression, as well as 
decrease in a subset of TH-positive neurons ? changes that could be partially reversed by 
delivery of manf mRNA to the zebrafish (Chen et al., 2012). Furthermore, intrastriatal 
infusions of CDNF and MANF have proved to provide protection and promote recovery of 
the  nigrostriatal  DAergic  pathway  in  the  rat  6-OHDA  and  the  mouse  MPTP  models  of  PD  
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(Lindholm et al.,  2007; Voutilainen et al.,  2009; II;  Airavaara et al.,  2012). Taken together, 
these results indicate that the MANF/CDNF family of NTFs has therapeutic potential in 
neurodegenerative disorders, such as PD. 
 
Neurotrophic factor gene therapy in Parkinson’s disease: GDNF and NTN 
Delivery of NTN or GDNF with  viral  vectors  into  the  SN  or  striatum,  or  both,  has  been  
effective in several animal models of PD (reviewed by Deierborg et al., 2008; Björklund and 
Kordower,  2010),  with  the  exception  of  the  ?-syn-overexpressing  rat  (Lo  Bianco  et  al.,  
2004;  Decressac  et  al.,  2011).  The  most  effective  injection  site  has  turned  out  to  be  the  
striatum, where induced overexpression of NTN or GDNF has resulted in protection of 
striatal fibers with a concurrent improvement in motor behavior, and protection of DA cell 
bodies  in  the  SN  (Bilang-Bleuel  et  al.,  1997;  Kirik  et  al.,  2000b;  Kordower  et  al.,  2000;  
Eslamboli et al., 2003; Kordower et al., 2006; Gasmi et al., 2007a; Eberling et al., 2009). The 
capacity to protect cell bodies in the SN even though expressed in the striatum is probably 
due to the fact that both NTN and GDNF can be retrogradely transported from the striatum 
to the SNpc (Tomac et al., 1995; Oiwa et al., 2002). In contrast, while GDNF delivery in the 
SN provide efficient protection of DA cell bodies (Choi-Lundberg et al., 1997; Mandel et al., 
1999b; Kirik et al., 2000b), no or very modest re-innervation of the striatal DAergic fibers is 
generally seen, partly explaining the lack of motor improvement in some of these studies. 
 
 
 
 
 
 
Intrastriatal delivery of a recombinant AAV2-NTN vector has recently undergone phase I 
and II  clinical trials (Figure 10; Table 5). The phase I clinical trial showed promising results 
(Marks et al., 2008), but in a double-blind randomized controlled phase II trial significant 
functional improvement in only a subset of patients was observed not until 18 months 
post-injections (Marks et al., 2010; Huddleston and Factor, 2011). Post-mortem analyses 
revealed very scarce amounts of NTN-positive cells in the SNpc without TH induction 
(Bartus et al., 2011). These results suggest that the lack of significant improvements could 
be due to the limited retrograde transport of NTN from the injection site to the SNpc. To 
overcome this, a new phase II study is ongoing using higher viral vector titers and multiple 
injection sites (striatum and SN) (Bartus et al., 2013), an approach supported by pre-clinical 
data in both non-human primates and rodents (Kordower et al., 2006; Herzog et al., 2013). 
Figure 10 Midbrain dopaminergic 
pathways in the human brain (according 
to Cooper, Bloom, and Roth, 2002b). In 
Parkinson’s disease (PD) dopaminergic 
cells in the substantia nigra (SN) are lost, 
causing dopamine depletion in the 
striatum. Clinical trials with glial cell-line 
derived neurotrophic factor and 
neurturin have aimed at rescuing and 
improving the function of the affected 
dopaminergic neurons applying the 
trophic therapy into the striatum alone 
or  into  both  the  striatum  and  the  SN  of  
PD patients. 
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In addition to clinical trials on AAV2-NTN, recruitment of PD patients to an open-label 
clinical study on intrastriatal delivery of an AAV2-GDNF vector is now in progress and aims 
at assessing the safety and tolerability using four escalating doses of AAV2-GDNF 
(NCT01621581; U.S. National Institutes of Health, 2013). 
 
Neurotrophic factor gene therapy in other neurodegenerative diseases 
Neurotrophic factor gene therapy in Alzheimer’s disease: NGF and BDNF  
Gene therapy with the neurotrophins NGF and BDNF has been most extensively explored in 
AD. Fibroblasts or NSCs genetically modified to express NGF have been transplanted into 
the basal forebrain of both rodents (Rosenberg et al., 1988; Kawaja et al., 1992; Martinez-
Serrano et al., 1996) and primates (Tuszynski et al., 1994; Smith et al., 1999). These studies 
show cholinergic re-innervation, axon regeneration and rescue of cholinergic neurons in 
response to NGF treatment following age-dependent or axotomy-induced cholinergic 
denervation. The ex vivo gene therapy approach has been translated into two phase I 
clinical trials in which AD patients received transplants of viral-vector transduced NGF-
expressing fibroblasts (Tuszynski et al., 2005) or encapsulated retinal pigment epithelial 
cells (Eriksdotter-Jönhagen et al., 2012; Wahlberg et al., 2012) into the basal forebrain 
(Figure 11). No serious adverse effects attributable to the treatments were observed in 
either of the trials. In a small subset of patients, positive effects on cognitive functions and 
increased cortical activity measured with PET-FDG were detected (Table 5). There is still no 
information about possible follow-up studies or phase II clinical trials regarding the NGF ex 
vivo gene therapy concept. 
 
Also  AAV-vector  mediated  delivery  of  NGF  has  been  processed  into  clinical  trials  by  
Ceregene  Inc.  (San  Diego,  CA,  USA).  A  phase  I  study  has  been  completed  and  a  phase  II  
randomized controlled trial is ongoing (NCT00087789 and NCT00876863; U.S. National 
Institutes of Health, 2010, 2012), but no results from these trials on AAV-NGF delivery into 
the basal forebrain have yet been published. In animal studies, AAV-NGF treatment has 
showed promising results. Injection of AAV-NGF into the medial septum of rats lead to an 
increase in both the survival and cell size of cholinergic neurons in a fibria-fornix lesion 
model of AD (Mandel et al., 1999a; Wu et al., 2003; Bishop et al., 2008). Similar outcomes 
were seen in aged rats when AAV-NGF was delivered into the basal nucleus of Meynert 
(Bishop et al., 2008). In intact young rodents (Bishop et al., 2008) and primates (Herzog et 
al., 2011), hypertrophy of cholinergic cells was observed after a single injection of AAV-NGF 
into the basal nucleus of Meynert, while no adverse effects could be detected in a two-year 
study (Herzog et al., 2011). 
 
The effects of BDNF gene therapy in AD models were reported in an extensive study done 
by Nagahara and co-workers (Nagahara et al., 2009). They assessed the protective 
potential of LV-mediated overexpression of BDNF targeted to the entorhinal cortex in APP 
transgenic mice, and lesioned or aged rats and primates. In APP transgenic mice, BDNF 
gene therapy lead to an improvement in memory and learning, an increase in synaptic 
markers and normalization of APP-related changes in gene expression. The amyloid plaque 
density load seen in the model was not affected by the treatment. Anterograde transport 
of BDNF from the injection site to the hippocampus was observed with a concurrent 
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increase in ERK phosphorylation in the hippocampus. In lesioned rats and non-human 
primates, delivery of LV-BDNF in the entorhinal cortex prevented lesion-induced neuron 
loss, while in aged non-human primates treatment-dependent improvement in cognitive 
performance as well as an increase in entorhinal neuron size was observed (Nagahara et 
al., 2009). BDNF has not yet been applied in AD clinical trials. 
 
 
 
Neurotrophic factor gene therapy in Huntington’s disease: CNTF, BDNF, GDNF, NTN 
The effect of CNTF gene therapy in HD has been studied in both pre-clinical and clinical 
settings. Encapsulated CNTF-overexpressing baby hamster kidney (BHK) fibroblasts 
transplanted into the striatum of QA-lesioned rats provided significant protection of striatal 
neurons  as  well  as  normalized  motor  behavior  (Emerich  et  al.,  1996).  Using  the  same  
method for CNTF delivery, the treatment was also tested in QA-lesioned monkeys, showing 
substantial reduction in lesion area, protection of striatal neurons and projections (GP and 
SNpr),  as  well  as  attenuation  of  QA-induced  retrograde  athropy  of  the  motor  cortex  
(Emerich  et  al.,  1997).  In  both  studies  performed  by  Emerich  and  co-workers,  the  CNTF-
expressing cells were transplanted before the excitotoxic lesion was induced. Instead, 
Mittoux and co-workers (2000) used the 3-NP model and transplanted encapsulated BHK-
CNTF cell into the striatum of monkeys two months after initiation of intoxication. Also in 
this model CNTF gene therapy protected the striatal neurons and restored the nigrostriatal 
function accompanied by improvements in cognitive and motor functions. Based on these 
promising results, ex vivo CNTF  gene  therapy  was  translated  into  clinical  trials  (Table  5)  
(Bachoud-Levi et al., 2000; Bloch et al., 2004). Encapsulated BHK-CNTF cells were implanted 
into the lateral ventricle of six HD patients and changed every sixth month over a two-year 
period. Even though the treatment turned out to be safe, no significant clinical benefits 
were observed. The authors speculate that this could be due to low CNTF release, since 
electrophysiological results were improved in a subset of patients that had received the 
highest amounts of CNTF (Bloch et al., 2004). 
 
In vivo CNTF gene therapy has been studied using adenoviral, LV and AAV vectors. Delivery 
of CNTF with an adenoviral vector into the striatum of rats prior to 3-NP intoxication turned 
out to protect neurons in the striatum and striatal target areas. In addition, CNTF mediated 
significant  improvement  in  motor  behavior  (Mittoux et  al.,  2002).  The same results  were 
achieved using recombinant LV vectors in the rat QA model of HD (Pereira de Almeida et 
al., 2001; Regulier et al., 2002). However, in vivo CNTF gene therapy using recombinant LV 
Figure 11 Main cholinergic innervations affected 
in Alzheimer’s disease, including cholinergic 
neurons in the medial septal nucleus (ms) and 
basal nucleus of Meynert (nb) (Cooper, Bloom, 
and Roth, 2002a). In clinical trials, neurotrophic 
factor therapies have been targeted to the basal 
forebrain in an attempt to increase the survival 
and function of the cholinergic cells and their 
projections. 
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or AAV vectors in HTT transgenic mice pointed out potential problems with long-term CNTF 
overexpression showing CNTF-dependent loss of striatal neurons, striatal down-regulation 
of several markers including DARPP-35 (marker of DA signaling in GABAergic medium spiny 
neurons), weight loss, motor impairment and abnormal behavior in both wild-type and 
transgenic mice (Zala et al., 2004; Denovan-Wright et al., 2008). 
 
The observations that dysfunction in the cortical expression and anterograde transport of 
BDNF is impaired in HD (Cattaneo et al., 2005) has laid the ground for the hypothesis that 
increasing the levels of BDNF in the cortico-striatal pathways may promote neuronal 
survival and slow down the disease progression. In QA-lesioned rats, delivery of BDNF into 
the striatum using recombinant adenoviral vectors (Bemelmans et al., 1999) or genetically 
engineered fibroblasts (Perez-Navarro et al., 2000b) protected the striatal neurons and 
reduced the lesion size. Also AAV vector-mediated BDNF gene therapy in the QA model 
provided striatal preservation and improvement in motor function (Kells et al., 2008). 
However, this study again demonstrated possible problems with uncontrolled long-term 
overexpression  of  NTFs  since  rats  that  had  received  high  titers  of  the  AAV-BDNF  vector  
developed seizure activity and experienced weight loss. These effects may have been 
caused by off-site delivery of BDNF to other brain regions due to anterograde and/or 
retrograde transport. 
 
In addition to CNTF and BDNF, also GDNF and NTN have showed neuroprotective potential 
in animal models of HD. Both ex vivo (Perez-Navarro et al., 1999; Pineda et al., 2007) and in 
vivo (McBride et al., 2003) GDNF gene therapy has proven to normalize behavior and 
protect  striatal  neurons  in  the  QA  and  3-NP  rat  models  of  HD.  In  transgenic  mice,  AAV-
GDNF delivery has resulted in inconsistent results. Whereas in one HTT transgenic mouse 
model (N171-82Q), AAV-GDNF was proven to be efficient in improving motor behavior as 
well as protecting striatal neurons and preventing neuronal atrophy (McBride et al., 2006), 
GDNF delivery with an LV vector showed no therapeutic benefits in the R6/2 transgenic 
mouse (Popovic et al., 2005). Regarding NTN, the same AAV vector used for clinical trials in 
PD patients has also been tested in rodent HD models. Intrastriatal delivery of this vector 
provided partial protection of striatal neurons and ameliorated behavioral deficits in both 
3-NP-treated rats (Ramaswamy et al., 2007a) and HTT transgenic mice (N171-82Q) 
(Ramaswamy et al., 2009). Interestingly, there are indications that the neuroprotective 
effect of intrastriatal GDNF and NTN in animal HD models may differ regarding specificity 
for neuronal circuits (Perez-Navarro et al., 1999; Perez-Navarro et al., 2000a). While ex vivo 
GDNF gene therapy was capable of protecting GABAergic neurons only in the direct circuit 
(projections to the SN) together with cholinergic interneurons, NTN preserved GABAergic 
projection neurons also in the indirect circuit, without effect on interneuron survival in the 
QA-lesion rat. 
 
Neurotrophic factor gene therapy in amyotrophic lateral sclerosis: GDNF, IGF-1, VEGF, 
CNTF, BDNF 
Several NTFs, including GDNF, BDNF, NT-3, and CNTF, affect the development and survival 
of motor neurons (reviewed by Gould and Oppenheim, 2011). Even though in vitro studies 
have provided evidence for strong positive effects of GDNF in models of motor neuron 
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degeneration (Henderson et al., 1994; Corse et al., 1999), in vivo benefits from GDNF 
treatment have been more inconsistent in animal SOD1 models of ALS. When administered 
centrally into the spinal cord, GDNF gene therapy generally protects the motor neurons, 
but does not affect the motor neuron innervation of the muscle, and, hence, no significant 
improvement of motor behavior has been observed (Suzuki et al., 2007). Since GDNF can 
be retrogradely transported, delivery of GDNF with viral vectors or GDNF overexpressing 
cells into muscles targeted by the degenerating motor neurons has been explored. 
Contrary to central administration, delivery of GDNF into the muscle mediates preservation 
of muscle innervation with concomitant improvement in motor function (Mohajeri et al., 
1999; Acsadi et al., 2002; Wang et al., 2002; Suzuki et al., 2008). In addition, the retrograde 
transport of GDNF also allows some protection of the motor neurons in the ventral horn of 
the spinal cord. However, GDNF gene therapy has generally resulted in rather modest 
changes in disease onset or survival time in the SOD1 rodent models of ALS. 
 
More robust changes in disease progression and survival parameters were obtained with 
i.m.  viral  vector-based  gene  delivery  of  insulin-like  growth  factor-1  (IGF-1)  (Kaspar  et  al.,  
2003) or vascular endothelial growth factor (VEGF) (Azzouz et al., 2004), two growth factors 
that in addition to their other effects on peripheral tissues and other neuronal populations, 
also provide motor neurons with direct trophic support and/or enhance neuronal survival 
through angiogenesis (Gould and Oppenheim, 2011). Despite the positive effects of IGF-1 in 
animal models of ALS, a phase III clinical trials of s.c. administration of IGF-1 in ALS patients 
showed no benefits regarding motor performance or overall survival (Table 5) (Sorenson et 
al.,  2008).  The  same  disappointing  results  were  obtained  in  a  phase  II-III  clinical  trial  of  
subcutaneous injections of CNTF (ALS CNTF Treatment Study Group, 1996), an NTF that is 
known for its motor neuron regenerative effect both in vitro (Sendtner et al., 1990) and in 
vivo (Mitsumoto et al., 1994). In addition, systemic treatment with CNTF was associated 
with adverse events, such as cough, anorexia and asthenia (ALS CNTF Treatment Study 
Group,  1996),  side  effects  that  were  overcome  in  a  phase  I  clinical  trial  applying  ex vivo 
CNTF gene therapy intrathecally in ALS patients (Aebischer et al., 1996). Also BDNF has 
been investigated in ALS clinical trials given as s.c. (Bradley, 1995; The BDNF Study Group, 
1999)  or  intrathecal  infusions  (Ochs  et  al.,  2000;  Beck et  al.,  2005),  but  again,  the results  
have been controversial. The status of clinical trials regarding BDNF, CNTF, or IGF-1 
treatments in ALS patients is not known. The Swedish company NeuroNova is currently 
evaluating the safety and tolerability of i.c.v. infusion of VEGF in ALS patients, but no 
results from the study are yet available (NCT01384162; U.S. National Institutes of Health, 
2011). 
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3 AIMS?OF?THE?STUDY?
Despite promising results in non-clinical study settings, the clinical trials conducted on NTFs 
in neurodegenerative diseases have this far failed to show robust clinical benefits. There is 
therefor still a need for testing novel neurotrophic agents with potentially better 
therapeutic characteristics together with improving techniques for delivery of the NTFs. 
The main purpose of this study was to examine the therapeutic potential of long-term i.c. 
delivery of the NTF CDNF in the rat partial lesion model of Parkinson’s disease. 
 
The specific aims of this study were: 
1) To  characterize  the  rat  partial  6-OHDA  PD  models  used  in  our  studies  and  to  
validate the use of in vivo single-photon emission computed 
tomography/computed tomography (SPECT/CT) in this model. 
2) To study whether a two-week infusion of CDNF or MANF is neuroprotective in the 
rat 6-OHDA model. 
3) To determine the AAV vector-induced expression of CDNF and examine the 
neuroprotective effect of intrastriatal CDNF gene therapy in the rat 6-OHDA model. 
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4 MATERIAL?AND?METHODS?
4.1 DRUGS,?TOXINS,?AND?NEUROTROPHIC?FACTORS?
The following drugs and toxins were used for the in vivo experiments: amphetamine 
hydrochloride (Faculty of Pharmacy, University of Helsinki, Helsinki, Finland), 2?-
carbomethoxy-3?-(4-[123I]iodophenyl)tropane ([123I]?-CIT, MAP Medical Technologies Oy, 
Tikkakoski, Finland), desipramine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA), 6-
OHDA hydrochloride (Sigma-Aldrich), pentobarbital (Mebunat®, Orion Oyj, Espoo, Finland), 
tramadol (Tramal®, Orion Oyj).  
 
In study II, the following NTF proteins were used: CDNF (Biovian, Turku, Finland) (Lindholm 
et  al.,  2007),  MANF (Lindholm et  al.,  2008),  GDNF (Amgen Inc.,  Thousand Oaks,  CA,  USA;  
ProSpec-Tany TechnoGene Ltd, Rehovot, Israel).  
 
For study III,  AAV2 vectors carrying the genes for human CDNF (hCDNF, for plasmid map, 
see study III), GDNF (Lonka-Nevalaita et al., 2010), and green fluorescent protein (GFP) 
were produced in the National Virus Vector Laboratory (University of Eastern Finland, 
Kuopio, Finland). The AAV2 vectors were made using the Stratagene AAV Helper-Free 
System according to the manufacturer’s instructions (Stratagene, La Jolla, CA, USA). The 
titers of the viral vectors were determined by quantitative PCR. 
4.2 ANIMALS?
Wistar male rats (Harlan, Netherlands) were used in all in vivo experiments. Rats were 
normally housed in groups of 3-4 individuals in 12h/12h light/dark cycle (light 6.00-18.00, 
dark 18.00-6.00). All behavioral experiments were conducted during the light period. Rats 
had access to conventional laboratory animal food (Harlan) and water ad libitum. All animal 
experiments were reviewed and approved by the National Animal Experiment Board (ESLH-
2007-06679/Ym-23, ESLH-2009-05234/Ym-23, ESAVI/4706/04.10.03/2011) and carried out 
in accordance with the European Communities Council Directive 86/609/EEC. 
4.3 STEREOTAXIS?
All i.c. injections were done under isoflurane anesthesia using a stereotaxic frame 
(Stoelting, Wood Dale, IL, USA), automatized injector (Stoelting) and 10 µl 26G syringes 
(Hamilton, Bonaduz, Switzerland). All coordinates were determined according to the rat 
brain atlas of Paxinos and Watson (1997). During the operation, rats received an injection 
of tramadol (1 mg/kg, s.c.) for post-operative pain. The animals were allowed to recover in 
single cages overnight. 
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4.3.1 RETROGRADE?LABELING?OF?DOPAMINE?NEURONS?WITH?FLUORO-
GOLD?
For labeling rat nigral DA neurons in vivo, the retrograde neuronal tracer FluoroGold (FG) 
(4% in sterile saline) (Fluorochrome, LLC, Denver, CO, USA) was injected bilaterally into the 
striatum (A/P +1.0; L/M ±2.7; D/V -5.0; 0.2 µl, 0.05 µl/min) 7-8 days before injection of 6-
OHDA (Schmued and Fallon, 1986; Divac and Mogensen, 1990).  
4.3.2 6-OHDA?INJECTIONS?
6-OHDA  was  diluted  in  0.02%  ascorbic  acid  solution  and  4  µl  were  injected  at  1  µl/min  
(Ungerstedt, 1968; Sauer and Oertel, 1994). Single injections (8 µg or 20 µg 6-OHDA) were 
done into A/P +1.0, L/M ±2.7, D/V -5.0, and two 6-OHDA injections (2x10 µg) into A/P +1.6, 
L/M ±2.2,  D/V -5.0  and A/P -0.4,  L/M ±4.0,  D/V -5.0.  For  protection of  the noradrenergic  
neurons, rats received an injection of desipramine (15 mg/kg, i.p.) at least 30 min before 
the 6-OHDA injection (Luthman et al., 1989). 
4.3.3 TREATMENT?WITH?NEUROTROPHIC?FACTORS?
Neurotrophic  factors  CDNF,  MANF,  or  GDNF  were  delivered  into  the  rat  brain  as  single  
protein injections, two-week infusions, or gene therapy with recombinant AAV serotype 2 
vectors (treatment groups and study design in Table 6 and Figure 12). 
 
Single protein injections were done into the rat striatum with the equipment described 
above. 
 
For two-week infusions of the neurotrophic factors, osmotic pumps were used (Alzet®, 
Durect Corporation, Cupertino, CA, USA). The pumps were filled with NTF solution under 
aseptic conditions, and allowed to reach the steady-state pumping rate by incubation in 
37°C over night. A brain cannula (Alzet® brain infusion kit) attached to the pump was 
inserted into the rat striatum in a stereotaxic operation, and the cannula was fixed to the 
scull with two screws and dental cement. The osmotic pump was placed under the skin on 
the rat’s neck, and the incision was closed by suturing. Infusion of phosphate-buffered 
saline (PBS, vehicle) was used as a negative control. 
 
Gene therapy with neurotrophic factors was accomplished using recombinant AAV2-CDNF, 
and AAV2-GDNF vectors. Viral vector stocks were, if necessary, diluted in PBS and injected 
into the rat striatum with the equipment described above. Controls used in the study 
consisted of PBS or AAV2-GFP injections. 
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Table 6. Study design and treatment groups for neurotrophic factor (NTF) studies (II, III). The proteins or 
recombinant viral vectors were infused into the coordinates A/P +1.0, L/M +2.7, D/V -5.0. The 6-OHDA 
dose was 2x10 µg in both studies. 
Study Design Delivery method Infusion Treatment groups 
 
II Neurorestoration: infusion of 
NTFs for two weeks starting 
two weeks post-lesion. 
Osmotic pump 
(Alzet®, model 
2002) 
0.5 µl/h, 
striatum 
CDNF 1.5 µg/24h 
CDNF 3.0 µg/24h 
CDNF 4.5 µg/24h 
MANF 1.5 µg/24h 
MANF 3.0 µg/24h 
MANF 4.5 µg/24h 
GDNF 3.0 µg/24h 
PBS (vehicle) 
Effect on intact brain: infusion 
of NTFs for two weeks. 
Osmotic pump 
(Alzet ®, model 
2002) 
0.5 µl/h, 
striatum 
CDNF 3.0 µg/24h 
MANF 3.0 µg/24h 
GDNF 3.0 µg/24h 
Diffusion of NTFs: infusion of 
NTFs for 3, 5, 7, or 14 days. 
Osmotic pump 
(Alzet ®, models 
2002 and 1007D) 
0.5 µl/h, 
striatum 
CDNF 3.0 µg/24h 
MANF 3.0 µg/24h 
GDNF 3.0 µg/24h 
NTF transportation: injection of 
125I-labeled NTFs. 
Protein injection 1 µl/min, 6 µl, 
striatum   
125I-CDNF 
125I-GDNF 
III Neuroprotection: injection of  
viral vectors two weeks before 
6-OHDA injections. 
 
Analysis of expression 1, 2, 4, 8, 
and 12 weeks post-injection. 
AAV2 vector 1 µl/min, 5 µl, 
striatum 
AAV2-CDNF 4x107 vg 
AAV2-CDNF 2x108 vg 
AAV2-CDNF 1x109 vg 
AAV2-GDNF 1x109 vg 
AAV2-GFP 2x108 vg 
PBS 
Effect of CDNF gene therapy on 
dopamine levels in lesioned and 
intact rat striatum 
AAV2 vector 1 µl/min, 5 µl, 
striatum 
AAV2-CDNF 1x109 vg 
AAV2-GFP 2x108 vg 
4.4 BEHAVIORAL?TESTS?
4.4.1 DRUG-INDUCED?ROTATIONAL?BEHAVIOR?
Asymmetric rotational behavior was induced in unilaterally 6-OHDA-lesioned rats with 
amphetamine 2.5 mg/kg i.p. (Ungerstedt and Arbuthnott, 1970). The amount of full 360° 
drug-induced turns was detected for 120 min using a rotometer (Rotorat, Med Associates, 
Inc., Georgia, VT, USA).  
4.4.2 FORELIMB?AKINESIA?TEST?
The forelimb akinesia test was done according to Olsson et al. (1995). The rats were tested 
for three consecutive days, with two tests each day. The first forelimb akinesia test was 
preceded by pre-training for three days to allow the rats to get used to the handling. All 
tests were made by the same person at the same time of the day (12.00-17.00).  
 
The rat was held firmly with both hindlimbs and one forelimb fixed. With one free forelimb 
touching the surface of the table, the rat was moved sidewise for a distance of 90 cm in 5 s. 
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All the rats were tested in the same sequence: first with the left forepaw in the forehand 
and backhand direction, and then with the right forepaw in the forehand and backhand 
direction. The rats were videotaped and the amount of correcting steps taken in each set of 
the test was counted. Results are given as the average of six measurements (two trials 
every day for three consecutive days). 
4.4.3 CYLINDER?TEST?
Limb use asymmetry of unilaterally lesioned rats was measured using the cylinder test 
(Schallert et al., 2000). Rats were put in a transparent cylinder (diameter 24 cm, height 30 
cm) and videotaped for 5 min. The amount of wall touches made with the ipsilateral and 
contralateral paw during a rear was detected. Results are given as ipsilateral paw use as 
percentage of total paw use (ipsi- and contralateral). 
 
 
Figure 12. Study design for the experiments presented in this thesis. Characterization of the partial 6-
OHDA lesion in  rats  (A;  study I),  evaluation of  a  two-week infusion of  NTFs  (B;  study II)  and delivery  of  
CDNF with a recombinant AAV2 vector (C; study III) in the rat partial 6-OHDA lesion model. AAV, adeno-
associated virus; CDNF, cerebral dopamine neurotrophic factor; DA, dopamine; IHC, 
immunohistochemistry; NTF, neurotrophic factor; 6-OHDA, 6-hydroxydopamine; SPECT/CT, single-photon 
emission computed tomography/computed tomography. 
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4.5 IMMUNOLOGICAL?DETECTION?
4.5.1 IMMUNOHISTOCHEMISTRY?
For immunohistochemical staining, rats were anesthetized with a lethal dose of 
pentobarbital and intracardially perfused with PBS and 4% paraformaldehyde. Following 
post-fixation in paraformaldehyde, the brains were stored in 20% sucrose in +4 °C until 
freezing. Frozen brains were cut on a microtome into 40 µm sections and stored in a 
cryoprotective solution in -20 °C. 
 
Immunohistochemical staining was done on free floating brain sections with primary and 
secondary antibody combinations shown in Table 7. Briefly, after washing the brain 
sections in buffer, immunoreactivity was improved by heat-treating the samples in 80 °C in 
citrate buffer, pH 6.0 (all immunohistochemical stainings except TH). For staining with 
biotinylated secondary antibodies, the sections were incubated in hydrogen peroxide to 
block endogenous peroxidases. To decrease the amount of background staining, the 
sections were blocked with appropriate serum, and then incubated in primary antibody. 
Following wash and incubation in biotinylated secondary antibody, the staining was 
reinforced using avidin-biotin complex (ABC-kit, Vector labs) and visualized with 
diaminobenzidine (DAB). When using secondary antibodies labeled with fluorescent 
marker, sections were washed after incubation in the secondary antibody and mounted on 
glass slides using Vectashield mounting medium (Vector labs). 
4.5.2 ENZYME-LINKED?IMMUNOSORBENT?ASSAY?
The CDNF sandwich enzyme-linked immunosorbent assay (ELISA) was done as described in 
III.  Briefly,  homogenized  and  acid-treated  samples  from  rat  striatum  and  SN  were  
incubated on a 96-well plate coated with an anti-CDNF antibody. Following incubation with 
a detection anti-CDNF antibody, a secondary horse-radish peroxidase (HRP)-conjugated 
antibody was applied and using 3,3',5,5'-tetramethylbenzidine (TMB) substrate 
(DuoSetELISA Development System, R&D Systems) the CDNF protein concentration in the 
samples was estimated. The CDNF-ELISA was performed in the Institute of Biotechnology, 
University of Helsinki. 
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4.6 MORPHOMETRIC?ANALYSES?
All morphometric analyses were done on every sixth brain section (40 µm sections).  
4.6.1 CELL?COUNTS?
TH-immunoreactive  (DAB  as  a  chromogen)  or  FG-positive  (fluorescent)  cells  in  rat  SNpc  
were estimated according to the optical fractionator method combined with the dissector 
principle with unbiased counting rules using the Stereo Investigator platform 
(MicroBrightField,  Williston,  VT,  USA)  (West  et  al.,  1991).  Cells  in  the SNpc were counted 
bilaterally in either three or six sections from each brain. Results are given as percentage of 
cells in the lesioned rat SNpc as compared to the intact SNpc. 
 
Estimation of the total number and number of activated microglia in the dorsal striatum 
was done in three Iba1-stained sections using the same stereological counting procedure as 
described above. Resting and activated microglia were separated based on their 
morphology (Kreutzberg, 1996). Resting microglia were identified as Iba1-reactive cells 
with a small cell body and fine processes extending from a few long thin prolongations. 
Round, intensely Iba1-stained cells with enlarged, ameobic-like cell bodies with or without 
short, thick processes were labeled as activated microglia.  
4.6.2 FIBER?DENSITY?MEASUREMENT?
For  estimation  of  the  TH-reactive  fiber  density  in  the  striatum,  pictures  of  
immunohistochemically stained coronal striatal sections were acquired with a digital 
camera (Nikon Corporation, Tokyo, Japan) attached to a stereomicroscope. The fiber 
density was assessed by measuring the density along a line drawn across the dorsal 
striatum  (II,  III),  or  by  encircling  the  dorsal  part  of  the  striatum  (I)  using  Image-Pro  Plus  
software (Media Cybernetics, Bethesda, MD, USA) (Deumens et al., 2002). All density 
values from the striatum were corrected for the background staining from corpus callosum, 
an  area  devoid  of  neuronal  somas.  Three  (II,  III)  or  five  (I)  coronal  sections  from  the  
striatum of each rat brain were analyzed and the results are given as percentage of the 
lesioned striatum as compared to the intact striatum. 
4.6.3 ESTIMATION?OF?BLOOD-BRAIN?BARRIER?INTEGRITY?
To evaluate the condition of the BBB, the rat endothelial barrier antigen (EBA) was used as 
a marker for the competent BBB. After immunohistochemical staining, digital pictures from 
three striatal sections were taken and the amount of EBA-reactive blood vessels (area ?300 
dpi) in the dorsal striatum was estimated with Image-Pro Plus software (Media 
Cybernetics) (Piltonen et al., 2011). 
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4.6.4 DIFFUSION?VOLUME?
The diffusion volume of CDNF, MANF, and GDNF was assessed using 
immunohistochemically NTF-stained brain sections (Voutilainen et al., 2009; II). The area 
showing immunoreactivity in each section was estimated and the diffusion volume was 
assessed from all analyzed sequential sections with the Cavalier Estimator function on the 
Stereo Investigator platform (MicroBrightField).  
4.6.5 SPROUTING?
Using microscopy, the presence of sprouting was defined as an accumulation of intensely 
TH-stained fibers in areas that in the negative controls were devoid of such changes, or in 
areas that normally display little or no dopaminergic innervation (Georgievska et al., 
2002a). 
4.7 BRAIN?DOPAMINE?AND?DOPAMINE?METABOLITES?
Estimation  of  DA  and  DA  metabolite  levels  in  the  rat  brain  tissue  was  done  according  to  
Airavaara et al. (2006). Briefly, rat brains were snap frozen in cold isopentane and stored in 
-80 °C until dissection. Frozen brains were dissected in a cryostat and tissue samples from 
the striatum (3 mm punch, approximately 2 mm in A/P direction) and SN (2 mm punch, 
approximately  1  mm  A/P)  were  collected  and  stored  in  -80°C.  Tissue  samples  were  
homogenized in 0.2 M HClO4-antioxidant solution (oxalic acid, acetic acid, L-cysteine) using 
a sonicator (Rinco Ultrasonics, Romanshorn, Swizerland). The homogenates were 
centrifuged (4°C, 14 000 rpm, 35 min) and the supernatant was moved into Vivaspin® 
sample concentrators (Vivascience AG, Hannover, Germany) and centrifuged at 9 000 rpm 
for 35 min, 4°C. The concentration of monoamines (DA, dihydroxyphenylacetic acid 
(DOPAC), homovanillic acid (HVA), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA)) in 
the filtered samples was analyzed with high performance liquid chromatography (HPLC) 
using electrochemical detection. Eighty microliters of the filtrates were injected into the 
HPLC system with an autosampler (Shimadzu, Kyoto, Japan). The column (Kinetex 2.6 µm, 
50x4.60 mm2;  Phenomenex,  Inc.,  Torrance,  CA,  USA)  was  heated  to  45°C  with  a  column  
heater (Croco-Cil, Bordeaux, France). The flow rate of the mobile phase was set to 1 ml/min 
with  a  pump  (ESA  Model  582  Solvent  Delivery  Module;  ESA,  Chelmsford,  MA,  USA).  
Monoamines in the samples were detected using ESA CoulArray Electrode Array Detector 
(ESA). Results are given as ng/mg wet weight of the tissue. 
4.8 TRANSPORTATION?OF?NEUROTROPHIC?FACTORS?
To trace i.c. injected CDNF and GDNF, the NTFs were labeled with 125I, and injections of 125I-
NTF (1-1.5ng/6 ?l)  alone or together with an excess (100x to 20 000x) of “cold” unlabeled 
NTF were done into the striatum of naïve rats (Tomac et al., 1995; Voutilainen et al., 2009; 
II). After perfusion and fixation of the rat brains (24 h post-injection), samples from the 
frontal cortex, striatum, hippocampus and nigra were gathered, and the activity in the 
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samples was analyzed using a gammacounter (Wizard 3”, 1480 Automatic Gamma Counter, 
Wallac, Finland). For autoradiography measurements, fixed coronal paraffin sections (7 
?m) were made from a different set of rats and put against an autoradiography film (Kodak 
Biomax MS) for four weeks. 
4.9 SPECT/CT?
Rat brains were scanned with a nanoSPECT/CT (Bioscan Inc., Washington, DC, USA) under 
isoflurane anesthesia four hours after an i.v. injection of [123I]?-CIT (Neumeyer et al., 1991; 
Scherfler et al., 2002; III). The mean striatal [123I]?-CIT activity was estimated, and corrected 
for by the activity measured in the cerebellum. 
4.10 STATISTICS?
All  results  are  given  as  the  mean  ±  standard  error  of  the  mean  (SEM)  for  the  treatment  
group.  The statistical analyses were done using Pasw Statistics 10 (SPSS, Inc., Chicago, IL, 
USA).  For  pair-wise  comparisons,  the  t-test  was  used.  In  the  case  of  group  numbers  ? 3,  
group-wise comparisons were done using one-way analysis of variances (ANOVA), or 
repeated measures ANOVA, followed by Tukey HSD post-hoc test for normally distributed 
data. If Levene’s test for homogenicity showed statistical significance, Games-Howell post-
hoc test was used for group-wise comparisons. For correlation analyses, the Pearson 
correlation test was applied. The results were considered statistically significant if P<0.05.   
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5 RESULTS   
5.1 CHARACTERIZATION? OF? THE? PARTIAL? 6-OHDA?
LESION?
The experimental setup for characterization of the rat partial 6-OHDA lesion can be found 
in Figure 12A. Briefly, one week after retrograde labeling of nigral DAergic neurons with an 
intrastriatal  injection  of  FG,  three  different  doses  of  6-OHDA  were  injected  into  the  rat  
striatum. The progression of the lesion was evaluated using behavioral tests (8 weeks post-
lesion), immunohistochemistry (1, 2, 4, and 8 weeks post-lesion), and SPECT/CT (2 and 4 
weeks post-lesion). 
5.1.1 MOTOR? IMPAIRMENT? INDUCED? BY? INTRASTRIATAL? 6-OHDA?
(UNPUBLISHED?RESULTS)?
The dose-dependent effect on motor behavior following unilateral intrastriatal injections of 
6-OHDA was estimated at eight weeks post-lesion using amphetamine-induced rotational 
test, cylinder test and forelimb akinesia test. 
 
Figure 13 Asymmetric motor performance in unilaterally 6-hydroxydopamine (6-OHDA) -lesioned rats. 
Eight weeks post-lesion, rats lesioned with intrastriatal injections of 8, 20, or 2x10 µg 6-OHDA were tested 
for amphetamine-induced rotational behavior (2.5 mg/kg amphetamine i.p.) (A), limb use asymmetry in 
the  cylinder  test  (B),  and  their  ability  to  make  adjusting  steps  when  moved  in  the  forward  (C)  and  
backward (D) side-wise direction. **P<0.01 as compared to the ipsilateral side (paired samples t-test), 
#P<0.05 as compared to 8 µg group (one-way ANOVA and Tukey post-hoc test) n=6/group. 
 
Rats lesioned with only 8 µg showed no turning preference (Figure 13A), limb use 
asymmetry  (Figure  13B)  or  forelimb  akinesia  (Figure  13C,  13D).  While  the  dysfunction  in  
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motor behavior was not significant following a single injection of 20 µg in any of the test, 
dividing the dose into two injection sites (2x10 µg) resulted in a trend towards imbalance 
between the contra- and ipsilateral paw use in the cylinder test (Figure 13B; P=0.077, one-
way  ANOVA  (P=0.091, F2,17=2.818) and Tukey post-hoc test). The 2x10 µg lesion group 
showed also significant impairment in the ability to make adjusting steps with the 
contralateral forepaw both as compared to the ipsilateral side (Figure 13C; P=0.001, paired-
samples  t-test),  as  well  as  compared  to  the  results  for  the  8  ?g  group  (P<0.05,  one-way  
ANOVA (P=0.024, F2,17=4.809) and Tukey post-hoc test).  No changes in the ability to make 
adjusting steps in the backward direction was observed in any of the groups (Figure 13D). 
5.1.2 6-OHDA-INDUCED? CHANGES? IN? THE? NIGROSTRIATAL? DOPAMINERGIC?
PATHWAY?
The degeneration of the midbrain DAergic neurons following intrastriatal administration of 
8, 20, or 2x10 µg 6-OHDA was assessed by counting TH-reactive and FG-positive neurons in 
the SNpc, by estimating densities of TH- and DAT-reactive fibers in striatal sections, and by 
evaluating striatal DAT function in vivo with  [123I]?-CIT  SPECT/CT  (I).  The  results  are  
presented in Figure 14 and in study I. 
 
As expected, the decrease in TH-reactive cells in the SNpc showed to some degree time- 
and dose-dependence (Figure 14A, unpublished results). One week after the 6-OHDA 
injection, there were 72 ± 6% and 71 ± 6% TH-reactive cells remaining in the lesioned SNpc 
in  the  20  µg  and  2x10  µg  6-OHDA  groups,  respectively.  In  these  groups,  the  most  
prominent loss of TH-reactive cells happened between weeks two and four, and at week 
four there was a statistical tendency towards a difference in the TH-reactive cell loss 
between  rats  treated  with  8  µg  versus  2x10  µg  6-OHDA  (73  ±  4%  and  45  ±5%  cells  
remaining, respectively; P=0.057,  one-way  ANOVA  (P=0.063, F2,17=3.336) and Tukey post-
hoc  test).  No  clear  progression  of  the  lesion  was  observed  in  the  8  µg  6-OHDA  group.  
Starting  from week two,  the cell  loss  in  the group treated with  2x10 µg was consistently  
more pronounced that in the group that had received one single 20 µg injection. At eight 
weeks post-lesion, the results from TH-reactive cell counts implied a dose-related cell loss 
with 65 ± 10%, 51 ± 11%, and 38 ± 6% cells remaining in the SNpc in the 8, 20, 2x10 µg 6-
OHDA groups, respectively (difference not significant, one-way ANOVA: P=0.140, 
F2,17=2.245). 
 
The expected dose-dependent 6-OHDA-induced degeneration of DA neurons was not 
obvious when analyzing the amount of FG-positive cells in the SNpc (Figure 14B, 
unpublished results). At four weeks post-lesion, the remaining cell numbers were 
estimated to  39 ±  6%,  24 ±  5%,  and 35 ±  8% as  compared to  the intact  side in  the 8,  20,  
2x10 µg 6-OHDA groups, respectively. After this time point, the cell loss progress appeared 
to  stop  in  the  8  µg  and  20  µg  lesion  groups,  whereas  the  loss  of  FG-positive  neurons  
continued until week eight in the 2x10 µg lesion group, with only 23 ± 6% of the FG-positive 
neurons remaining at this time point. There was no significant decrease in the amount of 
FG-positive cells in the contralateral side (Figure 14C, unpublished results). 
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The loss of TH-reactive fibers in the striatum had reached its maximum level in all groups 
already one week post-lesion (Figure 14D, unpublished results). At both one and four 
weeks post-lesion, the damage to the striatal DAergic fibers were significantly more 
pronounced in the 20 µg group as compared to the 8 µg group (week one: P<0.05, one-way 
ANOVA (P=0.016, F2,17=3.336), and week four: P<0.01,  one-way  ANOVA  (P=0.002, 
F2,17=9.964), followed by Tukey post-hoc test). The absence of progressive degeneration in 
the striatum was also observed when analyzing striatal DAT-reactive fiber densities (study I, 
Figure 2). 
 
Figure 14 Evaluation of the decrease in dopaminergic markers in 6-hydroxydopamine (6-OHDA) -treated 
rats. Rats were sacrificed 1, 2, 4, or 8 weeks after intrastriatal injections of 8, 20, or 2x10 µg 6-OHDA and 
their brains were processed for tyrosine hydroxylase (TH) immunohistochemistry. One week prior to the 
6-OHDA injections, the nigral dopaminergic neurons were retrogradely labeled with an intrastriatal 
injection of FluoroGold (FG). TH-reactive (A) and FG-positive (B) cells in the ipsilateral substantia nigra 
pars compacta (SNpc) were counted and compared to the contralateral side. TH-reactive cell numbers in 
the contralateral SNpc can be seen in (C). The 6-OHDA-dependent loss of TH-reactive fiber densities in the 
ipsilateral rat striatum are shown in (D). The dopamine transporter (DAT) density was estimated with in 
vivo [123I]?-CIT SPECT/CT two and four weeks post-lesion (E). Representative coronal sections from [123I]?-
CIT SPECT/CT can be seen in (F) with color code (blue-red-white) according to the measured activity. 
#P<0.05, ##P<0.01, ###P<0.001  as  compared  to  the  8  µg  6-OHDA  group,  ***P<0.001 as compared to 
intact rats (one-way ANOVA and Tukey post-hoc test), n=6 (A-D), n=4-5 (E). 
  Results 
 
55 
 
When comparing the results from morphologic assessment of TH-reactive striatal fibers 
and nigral cells to results from the behavioral test (Figure 15), we found that a decrease in 
TH-reactive cells in the SNpc >45% and striatal TH-reactive fiber loss >60% induced motor 
deficits in approximately 50% of the rats. However, a robust impairment in the forelimb 
akinesia and cylinder tests was observed only in the four rats that each showed a cell loss 
>70% and fiber loss ?80% (encircled individuals in Figure 15).    
 
 
Figure 15 Comparison of the degree of dopaminergic innervation and response in motor performance 
tests. The 6-OHDA-induced loss of tyrosine hydroxylase (TH) –reactive cells in the substantia nigra pars 
compacta (SNpc) and TH-reactive fiber density in the striatum was compared to results from the forelimb 
ainesia test (left y axis) and the cylinder test (right y axis) eight weeks post-lesion. Encircled individuals 
denote rats showing consistent response in all parameters measured. The line shows 50% use of the 
ipsilateral limb in the cylinder test, indicating the level for no limb use asymmetry. 
 
In line with the results from the striatal density measurements, no lesion progression was 
observed in estimates of striatal DAT density with [123I]?-CIT SPECT/CT (Figure 14E). 
However, there were statistically significant differences in striatal [123I]?-CIT binding 
between  intact  rats,  and  rats  lesioned  with  8  µg  and  2x10  µg  6-OHDA  (Figure  14E,  F).  In  
addition, individual results from [123I]?-CIT  SPECT/CT  and  TH  and  DAT  
immunohistochemistry showed a high degree of correlation at both two and four weeks 
post-lesion (for correlation coefficients and P-values, see study I, Figure 3 and Table 1). 
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5.1.3 THE?EFFECT?OF?6-OHDA?DOSE?ON?MICROGLIAL?ACTIVATION?AND?BLOOD-
BRAIN?BARRIER?INTEGRITY?(UNPUBLISHED?RESULTS)?
To study some aspects of the unspecific actions of 6-OHDA, fixed striatal sections were 
immunolabeled with antibodies against Iba1 (microglial marker) and EBA (rat-specific 
marker for competent BBB) to examine whether there are 6-OHDA dose-dependent 
influences on microglia activation and/or BBB permeability.  
 
One week after the 6-OHDA injections, a robust activation of striatal microglia was 
observed in the ipsilateral striatum. There was a tendency towards a difference between 
the 8 µg and 20 µg lesion groups in both the total number of Iba1-reactive microglial cells 
(one-way ANOVA P=0.051, F2,17=3.663) and microglia with activated morphology (one-way 
ANOVA P=0.047, F2,17=3.789, significance not detected with post-hoc test (P=0.51 between 
8 µg and 20 µg groups, Tukey post-hoc test)) (Figure 16A). Also in the contralateral side a 
clear microglial response could be seen around the FG injection tract, but the total amount 
of Iba1-reactive cells was significantly less pronounced in all lesion groups as compared to 
the contralateral side (8 µg: P=0.006, 20 µg: P=0.041, 2x10 µg: P=0.002, paired samples t-
test). There was also a significant difference in Iba1-reactive cells displaying activated 
morphology  in  the  8  µg  (P=0.014) and 2x10 µg (P<0.001) 6-OHDA groups, while only a 
trend was seen in rats lesioned with 20 µg 6-OHDA (P=0.064). 
 
 
Figure 16 The impact of striatal 6-OHDA injections on the amount of microglia and blood-brain barrier 
(BBB) competence. One week post-lesion, striatal sections from rat brains injected with 8, 20, or 2x10 µg 
6-OHDA were immunohistochemically stained for Iba1 and rat endothelial barrier antigen (EBA). The total 
amount of Iba1-reactive cells (white (complete) bars) and proportion of Iba1-reactive cells with activated 
morphology (black bars) were determined as stereologic estimates of the amount of cells counted from 
three striatal sections (A). L denotes left (ipsilateral) side and R right (contralateral) side. The contralateral 
side (R) had received an injection of FluoroGold two weeks prior to the analysis, and is thereby not intact. 
The number of EBA-reactive blood vessels in the striatum presented in (B) represents the average amount 
of EBA-reactive blood vessels estimated from three striatal sections. *P<0.05, **P<0.01, ***P<0.001 as 
compared to the ipsilaterlal (L) side (paired samples t-test), n=6.  
 
At one week post-lesion, the amount of EBA-stained blood vessels in the dorsal striatum 
did not significantly differ between the 6-OHDA doses 8, 20, and 2x10 µg (Figure 16B). As 
compared to the contralateral side (that had received an injection of FG one week before 
the lesion, and was, thus, exposed to mechanical damage), the percentage of EBA-reactive 
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blood vessels in the lesioned side was 101±3%, 103±6 %, and 93±4% in the 8, 20, and 2x10 
µg 6-OHDA groups, respectively (differences not statistically significant). 
5.2 DELIVERY? OF? NEUROTROPHIC? FACTOR? IN? INTACT?
RAT?BRAIN?
Long-term delivery of NTFs was carried out using osmotic pumps delivering the NTF into 
the striatum via a cannula, or by intrastriatal injections of recombinant AAV2 vectors 
carrying the NTF gene of interest.  
5.2.1 INFUSION?OF?NEUROTROPHIC?FACTORS?
Following a three-day infusion of NTFs (CDNF, MANF, GDNF) into the striatum of naïve rats, 
immunohistochemical analysis of the striatal diffusion volume of the infused proteins 
showed that MANF had spread to a statistically significantly larger area than GDNF (Figure 
17A). After two weeks of NTF infusion, no difference between the treatment groups could 
be seen. A two-week infusion of NTFs into the striatum of naïve rats did not cause any 
statistically significant changes in the nigral TH-reactive cell counts, although infusion of 
GDNF showed a trend for reducing the TH-reactive cells as compared to the CDNF group 
(P=0.068, one-way ANOVA (P=0.073, F2,13=3.353) and Tukey post-hoc test) (Figure 17B). 
 
5.2.2 NEUROTROPHIC?FACTOR?GENE?DELIVERY?
A single intrastriatal injection of AAV2-CDNF resulted in long-term overexpression of 
hCDNF in the rat striatum that had reached its maximum between four and eight weeks 
post-injection (Figure 18A). The total striatal amounts of hCDNF were 0.17 ± 0.07 ng, 0.54 ± 
Figure 17 The spreading of neurotrophic factors (NTFs) 
in the brain tissue after NTF infusion and the effect of 
NTFs  on  the  number  of  tyrosine  hydroxylase  (TH)  –
expressing cells in the substantia nigra pars compacta 
(SNpc)  of  intact  rats.  CDNF,  MANF,  or  GDNF  protein  
was infused into the rat striatum with osmotic pumps 
for three days or two weeks and the diffusion volumes 
of the NTFs were stereologically determined after 
immunohistochemical staining of respective protein in 
fixed brain sections (A). The proportion of TH-reactive 
cells in the ipsilateral SNpc as compared to the 
contralateral SNpc was estimated in 
immunohistochemically TH-stained nigral sections 
after  a  two-week  infusion  of  CDNF,  MANF,  or  GDNF  
(B). *P<0.05 as compared to the GDNF treatment (one-
way ANOVA and Tukey post-hoc test). 
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0.08 ng, 0.78 ± 0.12 ng, 1.85 ± 0.30 ng, and 1.35 ± 0.52 ng at 1, 2, 4, 8, and 12 weeks post-
injection, respectively. At later time points our CDNF-ELISA also detected hCDNF in the rat 
SN (Figure 18A).  
5.2.3 TRANSPORT?OF?125I-CDNF?AND?125I-GDNF?
The transport of striatally administered CDNF to the SN was further studied in naïve rats 
using 125I-labeled CDNF. The presence of 125I-CDNF  in  the  SN  24  h  after  an  intrastriatal  
injection (1-1.5 ng) was confirmed by autoradiography (study II, Figure 8) and gamma 
counter measurements (Figure 18B). Furthermore, the signal from 125I-CDNF in the SN 
could be blocked in a dose-dependent fashion by addition of increasing amounts of 
unlabeled “cold” CDNF. Intrastriatally injected 125I-labeled GDNF was detected in the rat SN, 
and the presence of 125I-GDNF in the nigra was almost completely blocked by simultaneous 
injection of a 100x molar excess of unlabeled GDNF (Figure 18B). 
 
 
Figure 18 Detection of CDNF in the substantia nigra (SN) following intrastriatal delivery of AAV2-CDNF and 
125I-CDNF. The level of CDNF protein in dissected tissue from the striatum and SN 1, 2, 4, 8, and 12 weeks 
after an intrastriatal injection of 1x109 vg AAV2-CDNF was determined with a CDNF-ELISA assay (A).  
Twenty-four hours after an intrastriatal injection of 125I-labeled CDNF or GDNF (1-1.5 ng protein) with or 
without an excess of unlabeled “cold” neurotrophic factor, brains were dissected and the proportion of 
radiolabeled NTF in the SN was estimated using gamma counter measurements (B).  
5.3 EFFECT? OF? LONG-TERM? DELIVERY? OF? CDNF? ON?
ROTATIONAL? ASYMMETRY? IN? 6-OHDA? LESIONED?
RATS?
To evaluate the progression of the lesion and estimate the efficacy of long-term delivery of 
NTFs in normalizing neural circuits controlling movement after 6-OHDA lesioning (2x10 ?g), 
rats were tested using amphetamine-induced rotational test. Treatment with CDNF, both 
as two-week continuous infusions (starting two weeks post-lesion) and as AAV-mediated 
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gene therapy (AAV2-CDNF injection two weeks pre-lesion), resulted in significant decrease 
in ipsilateral rotations (Figure 19). In the protein infusion study, infusion of CDNF 3 µg/24h 
for two weeks provided optimal effect, while either smaller or larger doses did not affect 
the turning asymmetry (Figure 19A). When delivering CDNF with an AAV2 vector, the larger 
titers (2x108 and 1x109 vg) were able to normalize the drug-induced turning behavior, while 
the smallest titer (4x107 vg)  showed no effect  (Figure 19B).  For  more exact  P-values, see 
study II and III. 
 
In the protein infusion study, neither GDNF nor MANF showed sufficient neurotrophic 
potential to significantly reverse the ipsilateral turning asymmetry (Figure 19A and study II, 
Figure 3C, 3D). However, when delivered with an AAV2 vector, GDNF proved to efficiently 
reduce the amount of amphetamine-induced turns as compared to rats that had received 
the control treatments (Figure 19B).    
 
Figure 19 The  effect  of  CDNF  treatment  on  amphetamine-induced  turning  asymmetry  in  6-
hydroxydopamine (6-OHDA) -lesioned rats (6-OHDA 2x10 ?g intrastriatally). CDNF or GDNF was 
administered intrastriatally as two-week protein infusions starting two weeks post-lesion (A), or as adeno-
associated virus (AAV) vector-mediated gene delivery with the AAV vector injection two weeks prior the 
the  lesion  (B).  Every  second  week,  rats  received  an  i.p.  injection  of  amphetamine  2.5  mg/kg,  and  the  
amount of full ipsi- and contralateral turns were detected for 120 min. Statistics presented in (A): 
*P<0.05, CDNF 3.0 µg/24h as compared to vehicle (repeated measures ANOVA followed by Tukey post-
hoc  test).  Statistics  presented  in  (B):  *P<0.05, **P<0.01,  AAV-CDNF  compared  to  control  (AAV2-CDNF  
2x108 vg at week two and four, AAV2-CDNF 1x109 vg at week six and ten); #P<0.05, ##P<0.01, AAV-GDNF 
compared to control (one-way ANOVA followed by Tukey post-hoc test).  
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5.4 EFFECTS?ON?THE?MIDBRAIN?DOPAMINERGIC?SYSTEM?
FOLLOWING? LONG-TERM? DELIVERY? OF? CDNF? IN? 6-
OHDA?LESIONED?RATS?
To study the degree of DAergic cell loss and NTF-induced protection and/or recovery of 
DAergic cells in 6-OHDA-lesioned rats, fixed rat brain sections were immunohistochemically 
stained with TH and number of TH-reactive cells in the SNpc and TH-reactive fiber densities 
in the striatum were estimated. 
 
Figure 20 The effect of CDNF treatment on dopaminergic cell survival in the rat partial 6-
hydroxydopamine (6-OHDA) (2x10 µg) lesion model. CDNF or GDNF was delivered as two-week protein 
infusions starting two weeks post-lesion (A and C), or as adeno-associated viral (AAV) vector-mediated 
gene therapy initiated two weeks before the 6-OHDA injections (B and D). Fourteen (protein infusion) or 
ten (gene therapy) weeks post-lesion, rat brains were fixed and stained for tyrosine hydroxylase (TH) -
immunoreactivity. The number of TH-reactive cells in the ipsilateral SNpc (A and B) and TH-reactive fiber 
density in the ipsilateral striatum (C and D) were determined and compared to the measures in the 
contralateral side.  *P<0.05, **P<0.01 as compared to the vehicle/control group (one-way ANOVA and 
Tukey post-hoc test). 
 
As compared to the control groups, a two-week delivery of CDNF protein as well as CDNF 
gene  therapy  in  the  striatum  resulted  in  partial  protection  of  TH-reactive  cells  in  the  rat  
SNpc (Figure 20 A, B). In agreement with the results from amphetamine-induced rotational 
behavior, the most effective protection was achieved with a protein infusion dose of 3 
µg/24h or with injection of AAV2-CDNF 2x108 to 1x109 virus  genomes  (vg).  The  CDNF-
mediated preservation of nigral TH-reactive cells was higher in the protein infusion study 
(approximately 67%) as compared to the gene therapy study (approximately 49%). The 
degree  of  cell  loss  in  the  vehicle-treated  groups  was  similar  in  both  studies  with  
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approximately 25% and 27% cells remaining in the protein infusion and gene therapy study, 
respectively.  
 
Note that the results in Figure 20B represent the survival of TH-reactive cells in three nigral 
sections,  ranging  from  approximately  5.0  to  5.5  mm  posterior  to  bregma,  while  
corresponding figure in the original study II presents results from six sections. The re-
analyzis was done to be able to compare the results from the two separate studies. When 
analyzing six sections, ranging from approximately 4.5 to 6.0 mm posterior to bregma, we 
found variation in the degree of TH-reactive cell protection in the AAV2-CDNF-treated 
groups depending on the level (rostral, central, caudal) of the SNpc, with the most 
pronounced protection in the two central brain sections (III). On the contrary, the amount 
of surviving TH-reactive cells following AAV2-GDNF treatment was more consistent 
throughout all three levels. 
 
Intrastriatal infusion of CDNF 3 µg/24h resulted in a significant restoration of TH-reactive 
fiber  density  (P<0.05,  one-way  ANOVA  (P=0.006, F4,31=4.551) and Tukey post-hoc test) 
(Figure 20C). This increase in density was accompanied by signs of a sprouting-like 
phenomenon (network of intensely TH-stained fibers) at the site of infusion (study III, 
Figure 6). However, no sprouting was observed in the lesioned striata treated with AAV2-
CDNF, even though the treatment showed a strong trend towards protection of the 
DAergic  fibers  (Figure  20D).  Despite  sprouting  of  TH-reactive  fibers  at  the  GDNF  protein  
infusion site, the density was not significantly increased by the GDNF treatment (Figure 
20C). However, in the gene therapy study, intrastriatal delivery of AAV2-GDNF did result in 
significant protection of the striatal TH-reactive fibers (Figure 20D). A two-week protein 
infusion  of  MANF  had  no  significant  effect  on  the  number  of  nigral  TH-reactive  cells  or  
striatal TH-reactive fiber density (II). Note that the results from fiber density measurements 
in the protein infusion study (Figure 20C) were re-analyzed according to the protocol used 
for density measurement in the gene therapy study (correction for background staining) 
and therefore differ from data presented in the original study II. This was done to allow 
comparison of the results from study II and III.  
 
To study the effect of CDNF gene therapy on midbrain DA levels, tissue samples from non-
lesioned  or  6-OHDA-lesioned  (2x10  µg  6-OHDA)  rats  injected  with  either  AAV2-GFP  or  
AAV2-CDNF 1x109 vg were collected four weeks after the AAV2 injection (two weeks after 
the  6-OHDA  injection  in  lesioned  rats)  (Figure  12C).  Analysis  of  the  levels  of  DA,  DOPAC,  
HVA, 5-HT, and 5-HIAA in the striatum of non-lesioned and lesioned animals revealed no 
statistically significant differences between AAV2-GFP and AAV2-CDNF treatment (Table 8, 
unpublished data). In 6-OHDA-lesioned rats, the striatal DA level was approximately 42% 
higher in the AAV2-CDNF-treated group as compared to the AAV2-GFP. group (19.4 ± 5.7% 
versus  12.9  ±  6.8%  of  the  right  intact  side  DA  levels),  but  this  difference   did  not  reach  
statistical significance. In the 6-OHDA-treated control group a 25.2 ± 8.6% loss of striatal 5-
HT  levels  was  observed,  while  the  corresponding  loss  was  only  1.3  ±  10.8%  in  the  AAV-
CDNF-treated striatum (difference not statistically significant). 
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Table 8 DA, DOPAC, HVA, 5-HT, and 5-HIAA concentrations (ng/mg wet weight of tissue) in the rat 
striatum four weeks after AAV2-GFP (control) or AAV2-CDNF injection in non-lesioned and lesioned 
animals (2x10 µg 6-OHDA two weeks after AAV injection; n=6/group). The virus vector and 6-OHDA 
injections were done in the left striatum while the right hemisphere was left intact. 
AAV, adeno-associated virus; CDNF, cerebral dopamine neurotrophic factor; DA, dopamine; DOPAC, 3,4-
dihydroxyphenylacetic acid; GDNF, glial cell line-derived neurotrophic factor; GFP, green fluorescet 
protein; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; HVA, homovanillic acid; 6-OHDA, 6-
hydroxydopamine 
 
 
 
 
 
 
 
 
  Non-lesioned  Lesioned 
 Treatment Left (AAV) Right (naive)  Left (AAV+6-OHDA) Right (naive) 
DA 
AAV2-GFP 13.79 ± 0.60 14.14 ± 0.60  1.75 ± 0.89 13.36 ± 0.52 
AAV2-CDNF 14.25 ± 0.57 13.18 ± 0.46  2.48 ± 0.69 13.21 ± 0.36 
DOPAC 
AAV2-GFP 0.95 ± 0.08 0.97 ± 0.06  0.16 ± 0.07 0.87 ± 0.09 
AAV2-CDNF 0.89 ± 0.06 0.83 ± 0.02  0.23 ± 0.05 0.83 ± 0.06 
HVA 
AAV2-GFP 0.35 ± 0.06 0.30 ± 0.05  0.06 ± 0.04  0.26 ± 0.05 
AAV2-CDNF 0.25 ± 0.04 0.22 ± 0.01  0.07 ± 0.02 0.25 ± 0.03 
5-HT 
AAV2-GFP 0.22 ± 0.04 0.20 ± 0.01  0.19 ± 0.02 0.26 ± 0.03 
AAV2-CDNF 0.19 ± 0.02 0.21 ± 0.02  0.25 ± 0.05 0.26 ± 0.04 
5-HIAA 
AAV2-GFP 0.11 ± 0.03 0.08 ± 0.01  0.11 ± 0.02 0.09 ± 0.02 
AAV2-CDNF 0.07 ± 0.02 0.07 ± 0.01  0.14 ± 0.03 0.09 ± 0.02 
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6 DISCUSSION?
The purpose of this work was to evaluate the neuroprotective potential of CDNF in the rat 
partial 6-OHDA model of PD. In addition, we wanted to study the partial 6-OHDA models 
used in our present and previous works to be able to better estimate treatment outcomes 
and more efficiently time the treatment initiation. Our main results show that CDNF, given 
as two-week protein infusions or delivered with a recombinant AAV vector, provides 
functional improvement seen as normalization of the amphetamine-induced ipsilateral 
turning bias. CDNF treatment was also accompanied by partial preservation of TH-reactive 
neurons in the SNpc together with a restoration of TH-reactive fiber density in the striatum 
that was dependent on the way CDNF was delivered. 
6.1 RAT? 6-OHDA? LESION? MODELS? OF? PARKINSON’S?
DISEASE??
The use of 6-OHDA to induce degeneration of DA neurons in rats was first described by Dr. 
Urban Ungerstedt in 1968 (Ungerstedt, 1968). Since then the model and its modifications 
has become a widely used tool in PD research. The mechanisms of 6-OHDA toxicity is still  
not completely understood, but induction of oxidative stress through auto-oxidation and 
the  generation  of  reactive  oxygen  species  (ROS)  is  believed  to  be  the  main  cause  of  the  
deleterious effects (Mazzio et al., 2004; Duty and Jenner, 2011). In addition, 6-OHDA has 
been shown to interact with and inhibit the mitochondrial respiratory chain, further 
exacerbating the oxidative stress (Glinka et al., 1996), as well as induce neuroinflammation 
through microglial activation (Cicchetti et al., 2002; Depino et al., 2003).  
 
The midbrain DAergic pathway can be targeted for degeneration by injection of 6-OHDA in 
the rat SN, in the medial forebrain bundle (MFB; tract in which the nigrostriatal DAergic 
fibers  ascend),  or  in  the  striatum  (Deumens  et  al.,  2002;  Duty  and  Jenner,  2011).  While  
infusion of 6-OHDA in the rat SN or MFB creates a rapid neuron degeneration that is almost 
complete  in  less  than  one  week  (Jeon  et  al.,  1995;  Zuch  et  al.,  2000),  a  more  slowly  
progressive degeneration can be achieved with intrastriatal injections of 6-OHDA (Berger et 
al., 1991; Ichitani et al., 1991; Sauer and Oertel, 1994; Przedborski et al., 1995). The 
progressive nature of this partial 6-OHDA lesion model makes it suitable for monitoring the 
efficacy of neuroprotective agents and has been used in our NTF studies. In these studies, 
we have generally applied three different partial lesions: single injections of 8 µg or 20 µg, 
or two injections á 10 µg 6-OHDA (Lindholm et al., 2007; Voutilainen et al., 2009; II; III). To 
be  able  to  time  the  initiation  of  treatment  and  predict  the  clinical  relevancy  of  the  
therapeutic interventions, we wanted to determine the degree and progression of the 
lesions induced by these three different 6-OHDA lesion paradigms.  
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6.1.1 PROGRESSION?OF?6-OHDA?LESION:?DOSE-DEPENDENCE?
The TH-reactive fiber loss in the striatum was complete already at one week post-lesion in 
all lesion groups. This conclusion is supported by published data showing that when 
intrastriatally administered, 6-OHDA causes rapid damage to the dopaminergic terminals at 
the injection site (Sauer and Oertel, 1994; Przedborski et al., 1995). The extent of fiber loss 
was dependent on the 6-OHDA dose. Logically, injection of 1x20 µg or 2x10 µg 6-OHDA 
created a larger striatal lesion than 8 µg 6-OHDA. The reason why 1x20 µg and 2x10 µg 6-
OHDA resulted in a similar decrease in TH-reactive fiber density may be due to the fact that 
only three coronal sections from the striatum were analyzed. In study I, the density was 
estimated from five striatal sections showing a decrease in fiber density of approximately 
90%  two  weeks  after  injection  of  2x10  µg  6-OHDA.  When  analyzed  from  three  striatal  
sections, the corresponding fiber density loss was estimated to approximately 78%. This 
was in line with the CDNF protein infusion (II) and gene therapy (III) studies in which also 
only three striatal sections were analyzed showing a TH-reactive fiber loss of approximately 
73% and 78% in the control groups, respectively. 
 
Intrastriatal 6-OHDA injections cause a progressive loss of DAergic cells in the SNpc (Sauer 
and  Oertel,  1994;  Przedborski  et  al.,  1995).  Stereologic  counting  of  FG-positive  (DAergic)  
neurons in the SNpc indicated that, even though all three lesion paradigms were associated 
with progressive cell loss, the progressiveness differed between the groups. The cell loss 
following injection of 8 µg was rapid until two weeks. After this, the progression seemed to 
stop and the amount of cells remained stable until the end of the study. A single injection 
of 20 µg 6-OHDA mediated a rapid progression of the lesion until  week four, where after 
the cell loss reached a plateau. Instead, the loss of cells in the group treated with 2x10 µg 
was characterized by a slower ongoing progressive cell loss that continued until the end of 
the experiment (eight weeks post-lesion). The observation that a single injection of 6-OHDA 
led  to  a  more  rapid  FG-positive  cell  loss  than  the  two-site  lesion  could  have  been  
influenced by the fact that in the single 6-OHDA injection groups the FG and 6-OHDA 
injections were made in the same site. This would allow the same cells with projections in a 
close proximity to the FG injection site to also be most influenced by the toxic effects of 6-
OHDA.  On  the  other  hand,  in  the  2x10  µg  6-OHDA  group,  the  injection  site  for  FG  was  
different from that of 6-OHDA. However, also when counting TH-reactive cell, this group 
showed a slightly more evenly progressive cell loss throughout the study. 
 
Initially,  the  loss  of  TH-reactive  cells  was  more  pronounced  than  the  loss  of  FG-positive  
cells. This has also been shown in previous studies, and is suggested to indicate an initial 6-
OHDA-induced loss of TH phenotype that precedes the actual cell degeneration (Sauer and 
Oertel, 1994; Bowenkamp et al., 1996; Cohen et al., 2011). Starting from two weeks post-
lesion, the loss of FG-positive cells exceeded the loss of TH-reactive cells. The explanation 
for this difference may be technical. Striatal injection of FG retrogradely labeled mainly 
cells located medially in the SNpc and constituted about 50-70% of the TH-reactive cells in 
the contralateral side. As mentioned above, the shared injection site could render the FG-
positive cells more susceptible to the 6-OHDA-induced damage. A more marked decrease 
in FG-positive cells could also be due to eventual toxicity of FG. However, FG has previously 
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been reported to have no toxic effects on its retrogradely labeled neurons (Schmued and 
Fallon, 1986; Divac and Mogensen, 1990). 
 
The FG-positive cells in the contralateral side showed generally DA neuron morphology 
(medium-sized with polygonal shape and/or at least one long dendrite) (Fallon and 
Loughlin, 1995). In addition, mainly in the ipsilateral, but also in the contralateral side, glia-
like cells (small, star-like cells with fine processes) were detected, probably due to ingestion 
of FG-containing debris. In the ipsilateral side, variable amounts of small intensely 
fluorescent shrunken remnants of DAergic cells were observed. These were not counted as 
DA neurons. Even though we observed a small continuous decrease in the number of FG-
reactive cells in the contralateral side of animals that had received a single injection of 20 
µg 6-OHDA, this decrease was not statistically significant. In earlier studies, a striatal 
injection  of  20  µg  (Sauer  and  Oertel,  1994)  or  40  µg  6-OHDA  (Berger  et  al.,  1991)  has  
caused a statistically significant, although rather mild, loss of contralateral nigral FG-
positive or [3H]mazindol-labeled DA neurons. 
 
Which lesion would serve the best purpose for pre-clinical research and at what time point 
should the experimental neuroprotective treatments be initiated? Parkinson’s disease is a 
slowly  progressive  disorder  and  it  is  estimated  that  the  motor  symptoms  start  to  appear  
when approximately 30% of the DAergic cells in the SNpc are lost (Fearnley and Lees, 1991; 
Cheng  et  al.,  2010).  This  limit  is  exceeded  in  all  6-OHDA  groups  (8,  20,  2x10  µg)  by  two  
weeks post-lesion, and therefore, if clinical relevance is the goal, experimental treatments 
should not be initiated before this time point. While the neurodegeneration in the rats 
lesioned with 8 µg 6-OHDA halted after two weeks post-lesion, a slowly progressive 
neurodegeneration that continued until the end of the study was seen especially in the 
2x10 µg group. Compared to clinical PD, this is a desirable characteristic. 
 
At  the time of  motor  symptom onset,  it  is  estimated that  there is  up to  a  50-70% loss  of  
striatal DAergic terminals together with a 68-82% age-dependent decrease in striatal DA 
levels (Cheng et al., 2010). Following striatal injection of 2x10 µg 6-OHDA, the striatal tissue 
DA level was decrease by approximately 87% at two weeks post-lesion, being slightly more 
pronounced than at symptom onset in clinical PD. At the same time point, there was a 
corresponding 88% loss of striatal TH-reactive fiber density. The loss of striatal DA 
terminals was also estimated with [123I]?-CIT SPECT/CT, showing a much milder, 
approximately 30% decrease in striatal DAT density. Since the results from DAT-reactive 
fiber density measurements (approximately 90% loss, I) was similar to the results obtained 
with TH immunohistochemistry, the discrepancy is most probably due to methodological 
issues, such as area analyzed and correction for background signal, and not dependent on 
the marker (DAT or TH). Finally, at eight weeks post-lesion, the DA cell loss in the 2x10 µg 
group  was  approximately  77%,  corresponding  to  the  situation  at  10  to  15  years  of  
symptomatic PD (Fearnley and Lees, 1991; Cheng et al., 2010). 
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6.1.2 SPECT/CT? PROVIDES? RELIABLE? ESTIMATE? OF? DOPAMINE? NEURON?
DEGENERATION?IN?THE?RAT?PARTIAL?6-OHDA?MODEL?
The DAergic system can be studied in vivo with,  e.g.,  SPECT  and  PET  detection  of  
radiotracers with affinity to structural components of the DAergic transmission system 
(DAT,  VMAT2,  DA  receptors)  (Nikolaus  et  al.,  2011).  These  types  of  imaging  studies  have  
mainly been conducted on rats that have received a 6-OHDA injection into the MFB or SN. 
For example, injections of 8 µg 6-OHDA into the rat MFB have produced a wide variety of 
unilateral decrease in striatal binding of DAT markers ([123I]?-CIT, [11C]CFT, [11C]PE2I), 
ranging  from  29%  to  85%  (Chen  et  al.,  1997;  Scherfler  et  al.,  2002;  Inaji  et  al.,  2005;  
Pellegrino et al., 2007; Zhu et al., 2007a). A few of these studies have tried to correlate the 
imaging  results  to  nigral  DAergic  cell  counts  (Scherfler  et  al.,  2002)  or  to  behavioral  data  
(Inaji et al., 2005; Pellegrino et al., 2007) and have found significant correlations between 
the measures.  
 
The intrastriatal partial 6-OHDA model is generally thought to be better suited for pre-
clinical studies of neuroprotective agents than the more complete SN or MFB lesion models 
(Duty and Jenner, 2011). However, the partial lesion model has been scarcely studied with 
in vivo imaging methods. A PET study with the DAT marker [11C]CFT (2-?-carbomethoxy-3?-
(4-fluorophenyl)tropane) estimated the decrease in ligand binding to 65% following 
intrastriatal injection of 4x6 ?g 6-OHDA (Cicchetti et al., 2002). This decrease was 
accompanied by loss of TH-reactive nigral neurons, but the correlation between these two 
measures  was  not  determined.  We  chose  the  DAT  ligand  [123I]?-CIT to evaluate the 
neurodegeneration in the partial 6-OHDA model with our small animal nano-SPECT/CT 
system. In addition to DAT, ?-CIT has also affinity to the serotonin transporter (SERT), and 
is,  thus,  not  as  specific  as  CFT  (Bergström  et  al.,  1997;  Booij  et  al.,  1998).  The  [123I]?-CIT 
binding to SERT can be a contributing factor for the seemingly small decrease in striatal 
activity (approximately 32% in 2x10 µg 6-OHDA group) as compared to the study done by 
Cicchetti and colleagues. Unspecific background activity is suggested to be further 
exacerbated in the 6-OHDA lesioned striatum (Sossi et al., 2012). The serotonergic system 
is known to be affected in PD (Jellinger, 1991). In 6-OHDA-lesioned rats, results have been 
inconsistent with reports showing both increases and decreases in serotonergic innervation 
and serotonin levels (Zhou et al. 1991; Ichitani et al., 1994; Maeda et al., 2003; Lindgren et 
al., 2010). We observed an approximately 25% decrease (not statistically significant) in the 
serotonin levels in the striatum of 6-OHDA-lesioned rats (treated with control vector AAV-
GFP). It is unclear whether this is due to a loss of serotonergic innervation or decrease in 
serotonin production. The proportional decrease in DAT density is, however, more 
extensive than a possible decrease in SERT density and this shift may affect the results. The 
background activity due to [123I]?-CIT binding to SERT could have been at least partly 
avoided by administration of a selective serotonin reuptake inhibitor (e.g., paroxetine) 
(Booij  et  al.,  2007)  prior  to  the  [123I]?-CIT injection. However, it is obvious that there is 
generally rather big variation in results from SPECT and PET studies which makes the 
numeric results from these studies difficult to compare. 
 
Our results show, that the striatal DAT binding detected with [123I]?-CIT SPECT/CT is highly 
correlated to both TH-reactive cell  loss in the SNpc, as well as TH- and DAT-reactive fiber 
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density  loss  in  the  striatum  both  two  and  four  weeks  post-lesion  (study  I,  Figure  3).  We  
therefore conclude that the method can reliably be used to estimate the degree of 
degeneration of the nigrostriatal DAergic pathway in the partially 6-OHDA-lesioned rat. 
With our [123I]?-CIT SPECT/CT protocol we were able to distinguish partial lesions induced 
by two different amounts of 6-OHDA (8 µg versus 2x10 µg). In addition, there was a highly 
significant decrease in [123I]?-CIT  binding  in  rats  that  had  received  8  µg  6-OHDA  as  
compared to the DAT binding in intact rats. This difference was also detected in 
measurements of striatal fiber densities, but not in TH-reactive cell counts. On the other 
hand, as for [123I]?-CIT  SPECT/CT,  there  was  a  significant  difference  in  the  loss  of  TH-
reactive cells between the two lesion groups, while this difference again was not detected 
with TH- or DAT-reactive fiber density measurements. Hence, when comparing these three 
methods ([123I]?-CIT SPECT/CT, TH-reactive nigral cell counts, and TH-reactive striatal fiber 
density measurement), [123I]?-CIT SPECT/CT seems to be the most sensitive and selective 
method, showing significant differences both between intact rats and rats with mild 
lesions, as well as between rats with different degree of lesion. Our results indicate that 
compared to more conventional methods, such as immunohistochemistry, in vivo imaging 
of partially 6-OHDA-lesioned rats with SPECT offers a considerable potential for reliable 
monitoring of changes in the midbrain DAergic pathway allowing non-invasive longitudinal 
studies in living animals. 
6.1.3 BEHAVIORAL?EVALUATION?OF?THE?6-OHDA?LESION 
Since bilateral injections of 6-OHDA result in severe aphagia, 6-OHDA is generally applied 
unilaterally (Ungerstedt, 1971; Duty and Jenner, 2011). The imbalance between the ipsi- 
and contralateral side is manifested as an asymmetry in motor performance that can be 
monitored with specific drug-induced or spontaneous behavioral tests that allow 
evaluation of the lesion (reviewed by Meredith and Kang, 2006).  
 
The most used behavioral test in unilaterally 6-OHDA-lesioned rats is the drug-induced 
rotational test originally described by Ungerstedt and Arbuthnott (Ungerstedt and 
Arbuthnott, 1970). The test is based on the observation that rats with an imbalance in DA 
concentration between the hemispheres show a characteristic turning behavior in 
response to drugs acting on the DAergic system. The use of amphetamine to induce 
rotations usually detects already a 40-50% decrease in the striatal DA level, and 30-50% 
loss of cell bodies in the SN (Przedborski et al., 1995; Lee et al., 1996; Kirik et al., 1998). In 
our study, 8 µg 6-OHDA, causing an approximately 35% loss of TH-reactive and 59% loss of 
FG-positive cells, did not cause an amphetamine-induced ipsilateral rotational response at 
eight weeks post-lesion. In our previous studies, on the other hand, the same dose has 
given rise to clear rotational asymmetry (Lindholm et al., 2007; Voutilainen et al., 2009). In 
these studies, the amphetamine-induced rotations were detected two and four weeks 
post-lesion. Especially mild partial lesions are associated with compensatory mechanisms in 
the lesion side, such as changes in DA re-uptake and turnover, and axonal sprouting 
(Zigmond et al., 1990; Schwarting and Huston, 1996). It could be that these compensatory 
mechanisms are not yet fully developed at earlier time points, while at eight weeks post-
lesion they are able to silence the rotational bias. In the two groups injected with a total of 
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20 µg 6-OHDA, there was a clear ipsilateral rotation bias, but due to big inter-individual 
variations, the amount of netipsilateral turns did not differ significantly from the 8 µg 6-
OHDA group. 
 
Even though the assumption is that the amount of amphetamine-induced rotations reflects 
the loss of DA innervation (i.e., loss of striatal DA and post-synaptic receptor 
hypersensitization), the correlation between the number of rotations and actual 
denervation has often proven to be rather poor and non-linear, showing same magnitude 
of rotations for a wide range of DA cell loss (Lee et al., 1996; Kirik et al., 1998; Chang et al., 
1999). In addition, statements that the test is not relevant to PD (the need for drug to 
provoke a behavior not related to clinical PD) have been raised, questioning the use of the 
test in pre-clinical PD research (Meredith and Kang, 2006). Two other tests that have been 
suggested to provide good measures of unilateral lesions are the cylinder test, measuring 
limb use asymmetry (Schallert et al., 2000), and forelimb akinesia test, measuring the rat’s 
ability to initiate movement (Olsson et al., 1995).  
 
The forelimb akinesia test has earlier been reported to show an all-or-nothing response to 
a  decrease  in  striatal  DA  (Chang  et  al.,  1999).  Hence,  an  80%  depletion  of  DA  induced  a  
reduction in forelimb adjusting steps with no additional impairment due to further 
decrease in DA. In our hands, positive responses in both the forelimb akinesia and cylinder 
tests were detected in approximately 50% of the animals with cell loss ranging between 
45% and 70%. However, a DA cell  loss of >70% and DA fiber loss >80% were required for 
robust response in both tests. Of the four rats that showed clear impairment in all analyses, 
two were from the 20 µg and two from the 2x10 µg 6-OHDA lesion group. The same rats 
showed variable response in the amphetamine-induced rotational test, with netipsilateral 
rotations ranging from 133 to 1647 (960 ± 312).  
 
All three behavioral tests used in the study show a response to L-DOPA (Olsson et al., 1995; 
Lundblad et al., 2002). However, while L-DOPA, like in the clinical situation, improves the 
performance in the forelimb akinesia and cylinder tests, it exacerbates the abnormal 
rotational asymmetry in rat with lesion-induced sensitized DA receptors. Yet another 
advantage of the forelimb akinesia and cylinder tests is that they are based on normal 
behavior without being dependent on drug administration, learning skills or motivation. 
However, drug-induced rotational test provides an easy and objective way of assessing DA 
system impairments in the unilateral 6-OHDA lesioned rat. In addition, the test is rather 
sensitive, while both forelimb akinesia and cylinder test require more robust changes in the 
nigrostriatal DAergic system to induced changes measured behavior (Table 9). A combined 
used of  all  three tests  is  therefore probably  the optimal  solution,  allowing detection of  a  
wider range of lesion degree together with assessment of both clinically relevant 
physiologic behavior as well as treatment-induced enhancement in function and/or density 
of striatal DAergic terminals. 
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Table 9 Estimation of the loss of nigral tyrosine hydroxylase (TH) -reactive cells and striatal TH-reactive 
fiber density needed to induce asymmetric motor behavior in the rats. The estimates are based on the 
results presented in 5.1.1 with average values for the 6-OHDA lesion groups that showed response in the 
tests. 
Test Drug-induced or spontaneous Loss of TH-reactive cells in the SNpc 
Loss of TH-reactive fiber 
density in the striatum 
 
Rotational 
asymmetry 
 
 
Amphetamine-induced 
 
 
>35-50% 
 
>61-67% 
Forelimb 
akinesia test 
 
Spontaneous >49-62% >67-72% 
Cylinder test 
 
Spontaneous >62% >72% 
6.1.4 ASPECTS?OF?NEUROINFLAMMATION?IN?THE?6-OHDA?MODEL?
When injected into the brain, 6-OHDA is taken up by monoamine transporters (DAT and 
NET), and its toxicity is therefore considered to be rather specific for DA and noradrenaline 
neurons (Duty and Jenner, 2011; Bove and Perier, 2012). However, it is now recognized 
that in addition to the specific effects on monoaminergic neurons, 6-OHDA treatment can 
also mediate unspecific cellular damage by extracellular actions (Blum et al., 2000; Hanrott 
et al., 2006). In addition, the 6-OHDA-induced degeneration of DA neurons seems to be 
accompanied by neuroinflammation and microglial activation (Cicchetti et al., 2002; Depino 
et al., 2003; Maia et al., 2012). The actual role of microglial activation in the 6-OHDA model 
is still debated. Some studies suggest that it constitutes an important mechanism of action 
along with the production of ROS and inhibition of mitochondrial function (Rodriguez-
Pallares et al., 2007; Marinova-Mutafchieva et al., 2009; Pabon et al., 2011). Our results 
show, that there was a trend towards a 6-OHDA dose-dependent increase in both the total 
amount  of  Iba1-stained  microglia  as  well  as  in  the  amount  of  microglia  with  morphology  
indicative of activation one week post-lesion. The dose-dependency would suggest that 6-
OHDA partly acts through microglial activation, but the result could also merely be due to 
the more extensive tissue damage caused by increasing amounts of 6-OHDA. 
 
Microglial activation and subsequent neuroinflammation has been shown to cause BBB 
disruption (Lynch et al., 2004), and 6-OHDA has earlier been reported to induce an increase 
in BBB permeability (Carvey et al., 2005). However, we found no significant differences in 
the amount of EBA-expressing blood vessels in the striatum between the lesion groups one 
week post-lesion. In addition, the amount of EBA-reactive blood vessels in the ipsilateral 
side did not differ from that measured in the contralateral hemisphere. In the contralateral 
side there was a loss of EBA-reactive blood vessel together with a clear microglial response 
surrounding the FG injection tract (injection made two weeks prior to staining) indicating 
that the mechanical damage and/or possible FG toxicity at the site of injection is enough to 
induce clearly visible and measurable changes in both parameters.    
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6.1.5 ANIMAL? MODELS? OF? PARKINSON’S? DISEASE:? PROBLEMS? AND?
ALTERNATIVES?
The  toxic  mechanisms  of  6-OHDA,  i.e.,  the  increase  in  oxidative  stress  due  to  increase  in  
ROS and mitochondrial dysfunction, as well as (primary or secondary) microglial activation 
(Duty and Jenner, 2011), are mechanisms also implicated in the pathogenesis of clinical PD 
(Figure 2) (Bossy-Wetzel et al., 2004). Moreover, the 6-OHDA-induced physiological 
changes, including DA cell loss, decrease in striatal DA and TH levels, dysfunction in the 
basal ganglia signaling, and alterations in levels of striatal transmitters other than DA 
(encephalin, substance P, dynorphin, ACh), are neurochemical features also present in PD 
(Schwarting and Huston, 1996). In addition, the rat 6-OHDA model has successfully been 
used in the search for novel symptomatic agents and shows responsiveness to L-DOPA, to a 
wide range of  DA agonists,  to  MAO-B inhibitors,  and to  some anticholinergic  drugs  (Duty  
and  Jenner,  2011).  Taken  together,  this  suggests  that  the  rat  6-OHDA  model  is  
characterized by construct validity, face validity, and predictive validity, which would 
support the use of this model in pre-clinical PD research. 
 
However,  the  6-OHDA  model  is  associated  with  some  concerns.  First,  toxin  models  of  
neurodegenerative diseases cause acute cell death. This is very different from the clinical 
situation in which the degeneration generally is an ongoing progress that takes years to 
develop with initial pathological processes suggested to start in some cases already early in 
life  (Braak  and  Del  Tredici,  2012).  Even  though  the  partial  6-OHDA  lesion  model  is  
characterized by some progressiveness, the same degree of cell loss that is seen only after 
more than a decade of PD symptoms was in our hands completed already eight weeks after 
the striatal 6-OHDA injection. Second, Lewy bodies, representing a pathological hallmark in 
PD, are absent in the 6-OHDA model (Duty and Jenner, 2011). In contrast to PD, there are 
also no pathological changes in other brain areas. One could therefore argue that the 
model  is  merely  a  model  of  DA  neuron  degeneration,  and  not  actually  a  model  of  PD.  
Finally, the unilaterality of the model may induce compensatory mechanisms in the 
contralateral side, affecting the outcome of the studies (Zigmond et al., 1990; Schwarting 
and Huston, 1996). 
 
In an attempt to overcome the problems associated with toxin-induced models, known 
familiar genetic mutations have been used to create transgenic animal models of 
neurodegenerative diseases. However, these models have generally been rather 
disappointing showing no or very mild histopathological and/or behavioral changes. How 
come a genetic alteration with clear connection to a certain neurodegenerative disease 
does not create disease-specific changes in the animal? The reasons could be many, 
including species-specific functions of the gene, age-dependent processes, and other, yet 
unidentified, genes or secondary mechanisms needed to initiate the neurodegenerative 
process. As for toxin models, there seems to be rather big variations in the model outcome 
between different laboratories reflecting differences in, e.g., level of transgene expression 
and type of promoter used (for transgenic PD models, see review by Crabtree and Zhang, 
2012). In addition, genetic alterations induced in the embryonic stage may be associated 
with  compensatory  mechanisms  that  serve  to  make  up  for  the  genetic  deficit.  To  tackle  
this, the genetic alterations could be induced in adult animals. For example, in the AAV-?-
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syn model, overexpression of ?-syn in the adult rat SN results in intracellular aggregates of 
?-syn combined with progressive loss of nigral DA neurons of slower magnitude than the 
partial 6-OHDA model. In addition to providing important information about ?-syn-induced 
DA neuron dysfunction in vivo, the PD-like features of the model may be of importance in 
drug discovery research.  
 
The usefulness of current animal models in the evaluation of neuroprotective and -
restorative agents still needs to be proved, since numerous disappointing clinical trials 
show that positive treatment effects in animal disease models do not necessarily translate 
into the clinical situation. In addition to species-specific characteristics that can affect the 
outcome, the pathways of neuron loss in neurodegenerative diseases are still not 
completely understood. Moreover, the high degree of heterogeneity, reflecting the 
multitude of underlying pathogenic genetic and molecular interactions (Figure 2), makes 
these  diseases  very  difficult  to  model.  Often  the  model  mimics  only  one  distinct  
characteristic of the disease (e.g., A? toxicity in transgenic AD models, SOD1 in transgenic 
ALS models) while overlooking other features. The evaluation of these models is also often 
challenging, and the question is whether we are looking at the appropriate features and if 
measurements used are actually relevant to the clinical disease. Still adding to the disease 
complexity, but also providing therapeutic opportunities, there seems to be an overlap 
between different neurodegenerative diseases (e.g., ALS and frontotemporal dementia, 
ataxia, and PD (Al-Chalabi et al., 2012), that suggests the existence of susceptibility genes 
and neurodegenerative mechanisms in common for the diseases. 
6.2 NEUROTROPHIC? POTENTIAL? OF? LONG-TERM?
DELIVERY?OF?CDNF?
6.2.1 CDNF? PROVIDES? PROTECTION? IN? THE? RAT? PARTIAL? 6-OHDA? LESION?
MODEL?
Earlier studies show, that MANF and CDNF provide protection of the nigrostriatal DAergic 
system when given as single protein injections in the rat partial 6-OHDA and mouse MPTP 
models of PD (Lindholm et al., 2007; Voutilainen et al., 2009; Airavaara et al., 2012). To 
evaluate the in vivo effect  of  long-term  delivery  of  NTFs  on  the  rat  midbrain  DAergic  
pathway, rats lesioned with 2x10 µg 6-OHDA were treated with NTFs given as protein 
infusions or gene therapy. While vehicle-treated rats showed a strong amphetamine-
induced ipsilateral turning behavior throughout the studies, CDNF was able to normalize 
the rotational bias. The significant decrease in rotations in the CDNF-treated groups was 
obviously  due to  the CDNF treatment,  since the lowest  CDNF dose (1.5  µg /  24h)  had no 
effect on the rotational behavior. Moreover, in agreement with the very low levels of 
striatal CDNF in rats injected with AAV2-CDNF 4x107 vg (III),  this titer did not affect the 6-
OHDA-induced rotational bias. In addition to the lowest infusion dose of CDNF, neither the 
highest  dose  (4.5  µg  /  24h)  altered  the  behavior.  Thus,  the  effect  of  CDNF  in  this  model  
seems to be characterized by a U-shaped dose-response curve. The same type of non-linear 
dose-response curve has previously also been reported for GDNF (Hou et al., 1996; Shults 
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et  al.,  1996)  and  MANF  (Voutilainen  et  al.,  2009).  The  U-shaped  dose-response  curve  for  
CDNF was further translated to the TH-reactive cells and fibers analyses where the CDNF 
dose 3.0 µg / 24h provided the strongest neuroprotection. 
 
In line with the reduction in ipsilateral rotations, there were signs of sprouting together 
with a significant increase in TH-reactive fiber density in the striatum following infusion of 
CDNF protein. Supported by earlier observations (Kirik et al., 2000b; Kordower et al., 2000; 
Georgievska et al., 2002a; Georgievska et al., 2002b), sprouting of TH-reactive fibers not 
only in the striatum, but also in the GPe and SNpr, was also detected following AAV-GDNF 
delivery. However, although treatment with AAV2-CDNF led to an almost significant 
increase in TH-fiber density together with behavioral improvement, no sign of sprouting 
around the injection site was observed. The increase in fiber density due to AAV2-CDNF 
treatment was accompanied with a minor increase in striatal DA level as measured two 
weeks post-lesion (four weeks after viral vector injection). Although this increase was very 
small (approximately 42% as compared to the negative control treatment and 5% of the DA 
levels in the intact striatum), this may still be the explanation for the observed reduction in 
amphetamine-induced turning asymmetry (Rioux et al., 1991). 
6.2.2 NEUROTROPHIC?MECHANISMS?OF?CDNF?
The function of CDNF is still not known, but based on structural analyses it is hypothesized 
that the protein may be bifunctional. Thus, both interaction with lipids (the N-terminal 
domain, mediating, e.g., interaction with transmembrane proteins) and reduction of ER 
stress and blocking apoptosis (the C-terminal domain) could be involved (Parkash et al., 
2009; Hellman et al., 2011; Cheng et al., 2013). If this holds true, it can be speculated that 
sprouting can be seen only after infusion of CDNF protein, reflecting N-terminal domain 
effect, while intracellular expression of CDNF after AAV2-CDNF reflects mainly C-terminal 
domain effect. The CDNF signal in immunohistochemically stained AAV2-CDNF-injected 
striata was mainly located intracellularly. When intrastriatally injected, AAV2 is known to 
transduce striatal GABAergic neurons that project to the SNpr (Paterna et al., 2004). These 
neurons are part of the extrapyramidal system controlling locomotor activity. It would be 
tempting to propose that expression of CDNF alters the function of GABAergic neurons 
normalizing the lesioned nigrostriatal circuitry without acting directly on the DA neurons. 
However, this suggested mechanism does not explain the restoration of the DA phenotype 
seen in the protein infusion study, in which the treatment was initated not until two weeks 
post-lesion. 
 
Alternatively, based on the results showing that MANF secretion is increased in response to 
ER stress (Apostolou et al., 2008; Tadimalla et al., 2008; Glembotski et al., 2012), could also 
6-OHDA induce a transient increase in CDNF secretion from AAV2-CDNF-transduced striatal 
neurons? And could this boost of secreted CDNF be responsible for the partial 
neuroprotection? In our study, the AAV2 vector was delivered two weeks pre-lesion. At the 
time of the 6-OHDA injection, the viral vector-induced CDNF expression had not yet 
reached its maximum level and the prevailing total amount of CDNF in the rat striatum was 
approximately  0.54  ng  (0.04  ng/mg  tissue  wet  weight).  Compared  to  the  earlier  studies,  
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showing that 10 µg CDNF gives optimal neuroprotection (Lindholm et al., 2007), the 20 000 
times smaller  dose at  the time of  the 6-OHDA injection could explain  the modest  results.  
However,  the  same  amount  of  GDNF  (0.04  ng/mg  tissue)  in  the  putamen  of  AAV-GDNF-
injected marmosets did provide significant protection (both behavioral and morphological) 
from  6-OHDA-induced  DAergic  degeneration  (Eslamboli  et  al.,  2005).  In  addition  to  a  
hypothetical direct effect on the DAergic neurons, CDNF was in a recent study suggested to 
act by suppressing neuroinflammation (Zhao et al., 2013). This theory still needs to be 
verified, but regarding the accompanying neuroinflammation in 6-OHDA-treated rats, this 
could be of importance for the neuroprotective effect of CDNF in this model.   
 
Further clues to the mechanisms of action of MANF and CDNF could be obtained from 
studying the intracerebral transportation profiles of the NTFs. While MANF has been shown 
to favor transportation to cortical areas (Voutilainen et al., 2009), we found that 24 h after 
a striatal injection of 125I-CDNF, the signal from 125I  was detected not only at the injection 
site, but also in the frontal cortex, hippocampus and SN. Importantly, the transport of 
CDNF to SN could be blocked in a dose-dependent fashion by adding increasing levels of 
unlabeled CDNF. However, compared to GDNF, many-fold higher excess of unlabeled CDNF 
was  needed  to  block  the  CDNF  signal  from  the  SN.  Reasons  for  this  could,  e.g.,  be  a  
substantially higher dissociation constant and/or higher abundance of a hypothetical 
pathway for CDNF transportation. In the studies of CDNF transportation using radiolabeled 
NTF, the whole SN was analyzed without separation of the SNpc and SNpr. The same is true 
for the CDNF-ELISA analysis that detected CDNF in the SN following striatal AAV2-CDNF 
injection. It is therefore impossible to say whether the nigral CDNF originated mainly from 
retrograde or anterograde transport. The presence of CDNF in the SNpc following 
intrastriatal delivery with our AAV2-CDNF vector was confirmed with 
immunohistochemistry, favoring a retrograde transportation mechanism. However, it is still 
unclear if the nigral CDNF-reactivity was due to retrograde transport of striatally expressed 
CDNF, or whether in fact the signal was due to transportation of the AAV2 vector (Paterna 
et al., 2004). 
6.2.3 CDNF?AND?MANF?VERSUS?GDNF?
Treatment with CDNF showed similar neuroprotective potential as GDNF in both the 
protein infusion and gene therapy studies. The most striking difference between the NTFs 
was seen in the gene therapy experiment, where GDNF caused aberrant sprouting of TH-
reactive fibers in the basal ganglia while this phenomenon was absent in the AAV2-CDNF-
treated animals. In addition, protein infusion of GDNF for two weeks into the intact rat 
striatum resulted in an approximately 21% decrease in TH-reactive neurons in the SN. 
Instead, CDNF protein infusion caused an approximately 12% increase in cell numbers. 
GDNF has previously been reported to induce TH down-regulation in intact rat brain 
(Rosenblad  et  al.,  2003;  Salvatore  et  al.,  2004;  Salvatore  et  al.,  2009)  and  our  results  
suggest  that  this  is  not  a  property  of  CDNF.  This  is  in  agreement  with  a  recent  study,  
showing that AAV vector-mediated striatal overexpression of CDNF did not alter the striatal 
TH levels (Ren et al., 2013). In addition, in our own gene therapy study we found no CDNF-
induced  differences  in  the  striatal  DA  levels  in  intact  rat  brain  four  weeks  after  an  AAV-
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CDNF injection. On the contrary, GDNF has been reported to cause an increase in tissue DA 
and DA turnover (Hudson et al., 1995; Beck et al., 1996; Salvatore et al., 2004). 
 
Protein infusion of MANF did not improve the rotation asymmetry nor did it increase the 
cell survival in the SN. This was surprising since single injections of MANF were earlier 
shown to promote recovery of 6-OHDA-lesioned rats both when given six hours before and 
two  weeks  after  the  6-OHDA  injection  (Voutilainen  et  al.,  2009).  In  the  previous  studies,  
MANF was given into the same site as 6-OHDA. This differs from the present study design 
in which the protein was infused between the 6-OHDA injection sites. One could speculate 
that this difference in setup was the reason for lack of effect. However, when the diffusion 
of the NTFs was measured after a three-day infusion, MANF showed extensive spreading 
throughout the striatal tissue with a significantly larger diffusion volume than GDNF. After a 
two-week infusion, no differences in diffusion volumes between MANF, CDNF, and GDNF 
were observed. It seems, though, that the spreading of MANF reaches its steady-state 
faster than GDNF. This may be due to differences in biochemical properties, such as 
isoelectric point and interactions with components of the extracellular matrix, e.g., GDNF 
binding to heparan sulphates (Piltonen et al., 2009). The difference between diffusion 
volumes could also merely be a technical issue and reflect properties of the antibodies 
used. Because of the seemingly effective spreading of MANF, it appears unlikely that the 
injection site would be the obstacle in our study. An alternative explanation for the lack of 
effect of MANF could simply be the obvious difference in lesion severity in the vehicle-
treated group between the two studies (MANF versus CDNF), which may mask the effect of 
MANF. 
 
GDNF did not provide statistically significant protection or restoration of nigral TH-reactive 
cells in neither the protein infusion nor the gene therapy study, even though there was an 
increase in surviving cells as compared to the vehicle-treated rats (56% versus 25% in the 
protein infusion study and 45% versus 27% in gene therapy study) (Table 10). Our results 
from the protein infusion study are in line with results from Kirik and colleagues (2001), 
who showed that a similar GDNF infusion gave very minor preservation of nigral cells and 
only transient functional improvement in the rat partial 6-OHDA model. The lack of 
significant effect of GDNF gene therapy is, however, in contrast to earlier studies, in which 
the treatment has generally led to significant neuroprotection (Bilang-Bleuel et al., 1997; 
Choi-Lundberg  et  al.,  1998;  Kirik  et  al.,  2000b;  Georgievska  et  al.,  2002b).  This  lack  of  
significant effect on the nigral DA cell level is probably attributed to the rather low 
expression levels after a single injection of our AAV2-GDNF vector. 
 
Overall, these results propose that the neuroprotective mechanism of CDNF is different 
from that of GDNF. However, the possible mechanisms discussed above are only 
speculations and no further conclusions can be made until the actions of CDNF and MANF 
on neuronal survival and neurotransmission have been studied in more detail. The neuron 
selectivity of the neurotrophic effect of CDNF and MANF is also still unsolved. We found a 
normalization of the striatal serotonin levels in 6-OHDA-lesioned rats after AAV-CDNF 
treatment, which would indicate that, in addition to the dopaminergic pathway, CDNF also 
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affects the serotonergic system. This could be of importance for the treatment of PD, since 
also the serotonergic neurons are subjected to degeneration in the disease.  
 
Table 10 Summary of the neuroprotective effects of GDNF and CDNF on nigrostriatal tyrosine hydroylase 
(TH) –reactive dopaminergic neurons in the rat partial 6-hydroxydopamine (6-OHDA) model. The 
neurotrophic factors were given as protein infusions or gene therapy and their effects were compared to 
the negative control (denoted vehicle (PBS) or control (AAV-GFP or PBS)). The results are for protein 
infusion  doses  of  3  µg/24  h  and  AAV2  vector  titers  of  1x109 vg  and  represent  the  mean  ±  SEM  for  
ipsilateral values as percentage of contralateral values.  
 Protein infusion  Gene therapy 
 VEHICLE GDNF CDNF  CONTROL AAV-GDNF AAV-CDNF 
        
TH-reactive cells 
(SNpc) 
25.1 ± 3.5 55.8±8.6 67.3 ± 5.4 
** 
 27.0 ± 3.9 45.0 ± 8.5 45.8 ± 6.9 
* 
        
TH-reactive fiber 
density (striatum) 
26.7 ± 3.6 51.7 ± 7.5 56.1 ± 6.9   22.4 ± 2.4 41.4 ± 5.1 
** 
36.5 ± 3.9 
P=0.054 
        
AAV, adeno-associated virus; CDNF, cerebral dopamine neurotrophic factor; GDNF, glial cell line-derived 
neurotrophic factor; GFP, green fluorescent protein; PBS, phosphate-buffered saline; SNpc, substantia 
nigra pars compacta. *P<0.05, **P<0.01, one-way ANOVA and Tukey post-hoc test. 
6.2.4 GENE?THERAPY?VERSUS?INFUSION?
When comparing the neuroprotective potential of the two different ways of 
administration, CDNF protein infusion seems to be superior to delivery of CDNF with an 
AAV2 vector  (67% versus  46% of  TH-reactive  cells  remaining,  and 56% versus  37% of  TH-
reactive fiber density preserved) (Table 10). This was surprising, since the gene therapy was 
initiated already two weeks before the 6-OHDA injections, while the protein infusion was 
not started until two weeks post-lesion. This could be explained by the rather limited 
transduction of the striatal neurons with subsequent low levels of CDNF together with the 
seemingly poor secretion of CDNF from the transduced cells. The spreading and 
transduction capacity of the AAV2 vector could be improved by increasing the titer, by 
doing multiple simultaneous injections (Kirik et al., 2000b) or by changing the AAV serotype 
(Burger et al., 2004; Asokan et al., 2012).  
 
In a recent study (Ren et al.,  2013), injection of AAV-CDNF into the rat striatum six weeks 
after a striatal injection of 18 µg 6-OHDA mediated substantial restoration of the 
nigrostriatal DAergic system, with significant increase in DA cell survival, TH and DAT 
expression, as well as striatal DAT binding of [11C]CFT. These changes were accompanied by 
an almost complete reduction of amphetamine-induced rotations up to 54 weeks post-
lesion (Ren et al.,  2013). In this study, the same AAV serotype (serotype 2) and promoter 
(CMV) as in our study was used. Compared to our study, the total titer injected per animal 
was  only  approximately  two  to  three  times  bigger  and  divided  into  two  injections  1  mm  
apart  in  the  D/V  direction.  Serotype  2  AAV  was  also  used  for  delivery  of  NTN  in  the  rat  
striatum, and in the 6-OHDA model an approximately six times smaller titer (as compared 
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to the highest titer used in our study) of this vector was enough to provide significant 
protection  of  the  DAergic  system  (Gasmi  et  al.,  2007a).  A  four-time  higher  titer  of  this  
AAV2-NTN vector led to an approximately ten-fold higher protein expression in the 
striatum,  as  compared  to  titers  and  protein  levels  measured  by  us  (Gasmi  et  al.,  2007b).  
The  serotype  of  our  AAV2-CDNF  vector  is  therefore  probably  not  the  main  cause  of  the  
minor improvements seen in our study, even though there are clear indications that 
alternative serotypes would provide better transduction efficacy and spread than serotype 
2  AAV  (Burger  et  al.,  2004;  McFarland  et  al.,  2009;  Asokan  et  al.,  2012).  The  low  
transduction and expression could also be due to other viral vector properties. One 
potential technical problem is that the estimated titer used may have differed from the 
actual  titer.  The different  titers  were prepared by dilution of  the viral  stock  solution with  
PBS.  Since  AAV  vectors  have  a  tendency  to  aggregate  (Huang  et  al.,  2000;  Wright  et  al.,  
2003), this can result in titers that are not directly related to the dilution coefficient. To 
overcome this problem in the future, the titers of the viral vector solutions should be 
assessed after the dilution. 
 
No  pathology  or  disease  has  been  linked  to  AAV,  and  even  though  a  large  proportion  of  
humans have been naturally infected with AAV, the immunogenicity seems to be rather 
low (Chtarto et al., 2013b). This makes AAV a good candidate for gene delivery in humans. 
In addition to pathogenicity and immunogenicity, one concern regarding all viral vectors is 
the uncontrolled expression of the introduced gene following viral vector transduction. 
Several studies in animals have pointed at potential problems with continuous delivery of 
high  levels  of  NTFs  (Georgievska  et  al.,  2002a;  Zala  et  al.,  2004;  Hovland  et  al.,  2007;  
Denovan-Wright et al., 2008; Kells et al., 2008). One way to try to solve this problem is by 
regulation of transgene expression with inducible (or repressible) promoters together with 
transactivators able to interact with the promoter and an inducer (or repressor) (Chtarto et 
al.,  2013b).  Tetracyclin-responsive  elements  are  the  most  widely  used  system  for  drug-
dependent regulation of viral vectors. However, continuous high doses of antibiotics are 
associated with adverse effects (e.g., phototoxicity, accumulation in bone, disturbances in 
bowel flora) and risk for selection of tetracyclin-resistant bacteria, which limits the clinical 
use of  these vectors.  In  the search for  more clinically  relevant  regulated vectors,  Chtarto 
and  co-workers  (Chtarto  et  al.,  2013a)  reported  the  use  of  a  recombinant  AAV  vector  
regulated by inflammation-induced increase in NF-?B activation in the brain. This type of 
disease-dependent expression opens up an exciting possibility to express the transgene 
specifically in diseased cells. 
 
6.2.5 NOVEL? THERAPEUTIC? STRATEGIES? FOR? NEURODEGENERATIVE?
DISORDERS:?GENERAL?DISCUSSION 
In my thesis I have reviewed novel therapeutic interventions that take advantage of gene 
therapy  in  the  attempt  to  provide  symptomatic  improvements  or  even  a  cure  for  
neurodegenerative diseases such as PD, AD, HD, and ALS. Although not covered here, in 
addition to gene therapy approaches, transplantation of cells in an attempt to replace 
degenerating neuron populations constitutes another exciting and promising novel 
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treatment alternative under development (Lunn et al., 2011). The gene therapy strategies, 
divided in the literature review into symptomatic therapy, elimination of pathogenic 
protein, and addition of therapeutic protein (Figure 7), have all different characteristics and 
are each associated with certain advantages and problems.  
 
The symptomatic gene therapy, e.g., the delivery of enzymes or proteins needed for 
neurotransmitter production and function, is disease-specific and serves to enhance certain 
signaling pathways in the diseased brain. The effect should be seen soon after treatment 
initiation, but as the disease progresses, the effect may diminish. Potential additional 
problems associated with this treatment alternative is the unregulated synthesis, storage 
and release of neurotransmitter due to transduction of cells not involved in the 
endogenous signaling pathway of the transmitter in question.  
 
The second therapeutic strategy, the elimination of pathogenic protein, can be considered 
as a potentially curative treatment alternative. However, even if this strategy may 
theoretically have the ability to halt the progression of the degeneration, it is probably not 
enough alone to reverse the pathology and induce restoration of the impaired neuronal 
signaling pathways. In addition, the excessive reduction of proteins that may be important 
for the normal cell function could be harmful, as seen in the silencing of ?-syn in the rat SN 
(discussed in 2.4.2). This could be avoided by specific silencing of only the mutated allele 
(e.g.,  SOD1 in  ALS)  or  by  targeting of  protein  degradation instead of  expression.  There is  
also an ongoing discussion about the importance of the protein aggregates seen in PD, AD, 
HD, and ALS. It is still debated whether the aggregates cause the cell damage, or if they are 
results of the cells’ attempt to protect themselves from toxic misfolded protein. The 
toxicity  could  also  be  mediated  by  sequestration  of  other  proteins  or  genetic  material  
important to the cell into the aggregates. These issues need to be clarified before this 
treatment strategy can be aimed at the right target in the process. 
 
The third strategy, the use of NTFs, could be considered as an unspecific and indirect 
approach offering in some cases similar survival-promoting and regenerative effects in 
different neurodegenerative disorders (e.g., GDNF in PD, HD, and ALS). Treatment with 
NTFs can be labeled as disease-modifying with the potential to halt or even reverse the 
neurodegeneration. The possible problems with this treatment alternative are, e.g., 
unwanted effects due to off-site administration or abnormal changes in protein expression 
caused by high levels of NTF. In addition, it would be important to re-establish meaningful 
connections instead of just inducing uncontrolled axonal growth/regeneration following 
NTF delivery. NTFs are also subjected to anterograde and/or retrograde transport, bringing 
additional challenges to the delivery of NTFs. 
 
Even if the third strategy hypothetically could by itself be enough to reverse and treat 
neurodegenerative diseases, the subsequent use of all three alternatives appears as the 
optimal way of treating these patients. While giving fast symptomatic relief with an enzyme 
replacement therapy, the underlying pathogenic process of protein misfolding/aggregation 
could be stopped by, e.g., RNA interference, and at the same time the degenerating 
neurons could be stimulated by NTFs to boost survival and restoration of the impaired 
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neuronal circuits. Especially for the two latter strategies, timing is most probably of great 
importance. When does neuronal dysfunction turn into neuronal cell death, and at what 
time  point  is  the  disease  still  reversible?  In  PD,  even  if  70-80%  of  the  striatal  DA  
connections are lost by the time of symptom onset, the actual nigral cell loss is much less 
(30%), providing an opportunity to rescue and revitalize the remaining cells if 
neuroprotective or -restorative treatments were available. With the aim of starting 
treatments as soon as possible, three very exciting ongoing trials are testing the potential 
of anti-amyloid treatments in people that have not yet developed clinical symptoms of AD 
(Miller, 2012). Two of these trials (Alzheimer’s Prevention Initiative (API) and Dominantly 
Inherited Alzheimer Network (DIAN)) focus on patients with mutations associated with 
familial early-onset AD. The third trial (Anti-Amyloid Treatment of Asymptomatic 
Alzheimer’s (A4)) seeks to start anti-amyloid therapy in healthy individuals who show 
developing amyloid plaques in brain scans. The results from these trials will be of great 
importance for determining the future direction of neurodegenerative disease research. 
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7 CONCLUSIONS?
The main objective  for  this  work was the assessment  of  the neuroprotective  potential  of  
long-term delivery  of  CDNF in  the rat  partial  6-OHDA model  of  PD.  Generally,  the results  
show that CDNF, administered as protein infusions or gene therapy, provides protection of 
the nigrostriatal DAergic system both on a functional and a histological level.  
 
The following principle findings have been presented in this thesis: 
1) The partial lesion model used in the neuroprotection studies (2x10 µg 6-OHDA) 
show more beneficial characteristics than injections of 6-OHDA into a single site. 
The cell  loss  was progressive  during the study (eight  weeks)  with  a  magnitude at  
two weeks post-lesion corresponding to the cell loss seen in PD at symptom onset. 
In addition, the 2x10 µg 6-OHDA lesion showed response in the two spontaneous 
motor behavior tests used. Evaluation of the dopaminergic system in partially 6-
OHDA-lesioned  rats  with  [123I]?-CIT SPECT/CT showed high correlation to 
immunohistochemical findings suggesting that the method could reliably be used 
for in vivo detection of lesion progression and treatment effects.  
2) Using  a  restoration  paradigm,  two-week  protein  infusions  of  CDNF  3  µg/24  h  
attenuated the amphetamine-induced ipsilateral rotational behavior. The 
treatment was accompanied with significant protection of the midbrain DAergic 
cells with signs of sprouting of TH-reactive fibers at the site of infusion. Treatment 
with MANF did not provide restoration of the midbrain DAergic system. 
3) While CDNF gene therapy normalized the amphetamine-induced rotational bias in 
6-OHDA-lesioned rats, the effect on DA neuron survival was rather modest. In 
addition, the small and non-significant increase in striatal DA fiber density seen in 
the CDNF-treated striatum was not accompanied with signs of sprouting. Results 
from the CDNF protein infusion and gene therapy studies suggest a retrograde 
transport system for CDNF. Delivery of CDNF did however not induce changes in 
the intact rat DAergic system. 
 
These results  confirm the therapeutic  potential  of  CDNF in  PD.  In  the rat  6-OHDA model,  
the effect of intrastriatal CDNF protein infusion seems to be more beneficial than that of 
CDNF gene therapy. This may be due to differences in extra- versus intracellular effects of 
CDNF, or caused by low expression levels of CDNF following AAV vector-mediated delivery.
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